


**CUMULATIVE
SUPPLEMENT 8**
August 2011



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Cumulative Supplement 8

August 2011

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	vi
1.5 Availability of the Edition	vii
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**CUMULATIVE SUPPLEMENT 8
August 2011**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALCON INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON LABORATORIES INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON RESEARCH LTD (ALCON RES)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
JOHNSON AND JOHNSON PHARMACEUTICAL (JOHNSON AND JOHNSON)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
MCNEIL PEDIATRICS (MCNEIL PED)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
ORTHO BIOTECH PRODUCTS LP (ORTHO BIOTECH)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)

ORTHO MCNEIL JANSSEN
PHARMACEUTICAL INC
(ORTHO MCNEIL JANSSEN)

JANSSEN PHARMACEUTICALS INC
(JANSSEN PHARMS)

ORTHO MCNEIL JANSSEN
PHARMACEUTICAL INC
(ORTHO MCNEIL JANSSEN)

JANSSEN PHARMACEUTICALS INC
(JANSSEN PHARMS)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

JANSSEN PHARMACEUTICALS INC
(JANSSEN PHARMS)

PADDOCK LABORATORIES INC
(PADDOCK LABS)

PADDOCK LABORATORIES LLC
(PADDOCK LLC)

SHIONOGI PHARMA INC
(SHIONOGI PHARMA)

SHIONOGI INC
(SHIONOGI INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001

LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2010</u>	<u>MAR 2011</u>	<u>JUN 2011</u>	<u>SEPT 2011</u>	<u>DEC 2011</u>
DRUG PRODUCTS LISTED	13838	14029	14309		
SINGLE SOURCE	2482 (17.9%)	2477 (17.7%)	2468 (17.2%)		
MULTISOURCE	11267 (81.4%)	11463 (81.7%)	11752 (82.1%)		
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)	11301 (80.6%)	11592 (81.0%)		
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)	162 (1.2%)	160 (1.1%)		
EXCEPTIONS ¹	89 (0.6%)	89 (0.6%)	89 (0.6%)		
NEW MOLECULAR ENTITIES					
APPROVED	8	6	8		
NUMBER OF APPLICANTS	752	768	784		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The

application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 31ST EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

1-1

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

>D>	+	CENTOCOR ORTHO	250MG	N202379	001	Apr 28, 2011	Aug	CAHN
	+		250MG	N202379	001	Apr 28, 2011	Apr	NEWA
>A>	+	JANSSEN BIOTECH	250MG	N202379	001	Apr 28, 2011	Aug	CAHN

ACARBOSE

TABLET; ORAL

ACARBOSE

AB		STRIDES ARCOLAB LTD	25MG	A090912	001	Jul 27, 2011	Jul	NEWA
AB			50MG	A090912	002	Jul 27, 2011	Jul	NEWA
AB			100MG	A090912	003	Jul 27, 2011	Jul	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

>A>		BUTALBITAL AND ACETAMINOPHEN						
>A>		NEXGEN PHARMA	300MG;50MG	A090956	001	Aug 23, 2011	Aug	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		MIRROR PHARMS	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar	CAHN
AA			500MG;50MG;40MG	A040883	001	Dec 23, 2008	Mar	CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA		WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jan	CAHN
----	--	-------------------	-------------------	---------	-----	--------------	-----	------

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

>D>	AA	WEST WARD	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006	Aug	DISC
>A>		@ WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006	Aug	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D>	AA	+	ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001		Aug	DISC
>A>		@		120MG/5ML;12MG/5ML	A085861	001		Aug	DISC

SUSPENSION; ORAL

CAPITAL AND CODEINE

>D>	AA		ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001		Aug	DISC
>A>		@		120MG/5ML;12MG/5ML	A085883	001		Aug	DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D>	AA		WATSON LABS	300MG;15MG	A089997	001	Dec 28, 1994	Aug	DISC
>A>		@		300MG;15MG	A089997	001	Dec 28, 1994	Aug	DISC
>D>	AA			300MG;30MG	A089998	001	Dec 28, 1994	Aug	DISC
>A>		@		300MG;30MG	A089998	001	Dec 28, 1994	Aug	DISC
>D>	AA			300MG;60MG	A089999	001	Dec 28, 1994	Aug	DISC
>A>		@		300MG;60MG	A089999	001	Dec 28, 1994	Aug	DISC
		@	WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003	Jul	DISC
		@		300MG;30MG	A040443	002	Jan 22, 2003	Jul	DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE
@ WATSON LABS FLORIDA 300MG;60MG

A040443 003 Jan 22, 2003 Jul DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA BOCA PHARMA 325MG/15ML;7.5MG/15ML

A040894 001 Jul 19, 2011 Jul NEWA

AA + MIKART 325MG/15ML;7.5MG/15ML

A040482 001 Sep 25, 2003 Jul CTEC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA BOCA PHARMA 300MG;5MG

A090415 001 Jan 24, 2011 Feb CTEC

AB 300MG;5MG

A090415 001 Jan 24, 2011 Jan NEWA

AA 300MG;7.5MG

A090415 002 Jan 24, 2011 Feb CTEC

AB 300MG;7.5MG

A090415 002 Jan 24, 2011 Jan NEWA

AA 300MG;10MG

A090415 003 Jan 24, 2011 Feb CTEC

AB 300MG;10MG

A090415 003 Jan 24, 2011 Jan NEWA

AA + MIKART 300MG;5MG

A040658 001 Jan 19, 2006 Mar CRLD

AA 300MG;5MG

A040658 001 Jan 19, 2006 Feb CTEC

AA + 300MG;7.5MG

A040556 002 Mar 24, 2006 Feb CTEC

AA + 300MG;10MG

A040556 001 Jun 23, 2004 Feb CTEC

@ RANBAXY 500MG;5MG

A040825 001 Aug 16, 2007 May DISC

@ 500MG;10MG

A040824 001 Aug 16, 2007 May DISC

@ RANBAXY LABS LTD 325MG;10MG

A040826 001 Aug 16, 2007 May DISC

@ 750MG;7.5MG

A040822 001 Aug 16, 2007 May DISC

>D> AA WATSON LABS 500MG;2.5MG

A040123 003 Mar 04, 1996 Aug DISC

>A> @ 500MG;2.5MG

A040123 003 Mar 04, 1996 Aug DISC

>D> AA 500MG;7.5MG

A040123 004 Mar 04, 1996 Aug DISC

>A> @ 500MG;7.5MG

A040123 004 Mar 04, 1996 Aug DISC

>D> AA 650MG;7.5MG

A040123 001 Mar 04, 1996 Aug DISC

>A> @ 650MG;7.5MG

A040123 001 Mar 04, 1996 Aug DISC

>D> AA 650MG;10MG

A040123 002 Mar 04, 1996 Aug DISC

>A> @ 650MG;10MG

A040123 002 Mar 04, 1996 Aug DISC

@ WATSON LABS FLORIDA 500MG;5MG

A040493 001 May 28, 2003 Jul DISC

@ 750MG;7.5MG

A040494 001 May 28, 2003 Jul DISC

LORTAB

AA UCB INC 500MG;5MG

A087722 001 Jul 09, 1982 Jan CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

@ ACTAVIS TOTOWA 500MG;5MG

A040199 001 Dec 30, 1998 Jul DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

@ ACTAVIS TOTOWA 325MG;5MG

A040203 001 Mar 15, 1999 Jul DISC

>D> ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

>D> TABLET; ORAL

>D> PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

>D> AA + MYLAN 650MG;65MG

A083978 001 Aug DISC

>A> @ 650MG;65MG

A083978 001 Aug DISC

@ VINTAGE PHARMS 650MG;65MG

A040507 001 Jul 30, 2003 Mar DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

		DARVOCET-N 100							
		@ XANODYNE PHARM	650MG;100MG	N017122	002		Jan	DISC	
		DARVOCET-N 50							
		@ XANODYNE PHARM	325MG;50MG	N017122	001		Jan	DISC	
		PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN							
		@ CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004	Mar	DISC	
		@	500MG;100MG	A076750	001	Jun 28, 2004	Mar	DISC	
		@ MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008	Apr	DISC	
	AB		650MG;100MG	A077821	001	Feb 11, 2008	Mar	CAHN	
>D>	AB	MYLAN	650MG;100MG	A070145	001	Jun 12, 1985	Aug	CRLD	
>A>	+		650MG;100MG	A070145	001	Jun 12, 1985	Aug	CRLD	
		@ TEVA	650MG;100MG	A074119	001	Dec 19, 1994	Mar	DISC	
		@ VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001	Mar	DISC	
		@	650MG;100MG	A074843	001	Feb 12, 1997	Mar	DISC	
>D>	AB	WOCKHARDT	325MG;50MG	A077677	001	Mar 16, 2007	Aug	DISC	
>D>	AB		650MG;100MG	A077677	002	Mar 16, 2007	Aug	DISC	
>A>		@ WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007	Aug	DISC	
>A>		@	650MG;100MG	A077677	002	Mar 16, 2007	Aug	DISC	

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

	AB	INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Jul	NEWA	
--	----	----------------	-------	---------	-----	--------------	-----	------	--

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

>D>	AT	ACTAVIS MID ATLANTIC	2%	A087146	001		Aug	DISC	
>A>		@	2%	A087146	001		Aug	DISC	

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

	+	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993	Jun	CAHN	
--	---	-----------------	-----------	---------	-----	--------------	-----	------	--

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>D>	AB	ACTAVIS ELIZABETH	200MG	A074906	001	Aug 26, 1997	Aug	DISC	
>A>		@	200MG	A074906	001	Aug 26, 1997	Aug	DISC	
	AB	MYLAN	200MG	A074977	001	Apr 13, 1998	Feb	CAHN	

CREAM; TOPICAL

ZOVIRAX

	+	VALEANT INTL	5%	N021478	001	Dec 30, 2002	Jul	CAHN	
--	---	--------------	----	---------	-----	--------------	-----	------	--

OINTMENT; TOPICAL

ZOVIRAX

	+	VALEANT INTL	5%	N018604	001	Mar 29, 1982	Jul	CAHN	
--	---	--------------	----	---------	-----	--------------	-----	------	--

TABLET; ORAL

ACYCLOVIR

>D>	AB	ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997	Aug	DISC	
>A>		@	400MG	A074870	001	Jun 05, 1997	Aug	DISC	
>D>	AB		800MG	A074870	002	Jun 05, 1997	Aug	DISC	
>A>		@	800MG	A074870	002	Jun 05, 1997	Aug	DISC	

TABLET; ORAL

ACYCLOVIR

AB	MYLAN	400MG	A074976 001	Apr 13, 1998	Feb	CAHN
AB		800MG	A074976 002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

>D>	AP	APP PHARMS	EQ 500MG BASE/VIAL	A075015 001	Apr 30, 1998	Aug	CRLD
>A>	AP	+	EQ 500MG BASE/VIAL	A075015 001	Apr 30, 1998	Aug	CRLD
>D>		+	HOSPIRA	A074720 001	Apr 22, 1997	Aug	DISC
>A>		@	EQ 25MG BASE/ML	A074720 001	Apr 22, 1997	Aug	DISC
		@	EQ 50MG BASE/ML	A075065 001	Feb 25, 1999	Feb	DISC
>D>		ZOVIRAX					
>D>	AP	+	GLAXOSMITHKLINE	N018603 001	Oct 22, 1982	Aug	DISC
>A>		@	EQ 500MG BASE/VIAL	N018603 001	Oct 22, 1982	Aug	DISC
>D>	AP	+	EQ 1GM BASE/VIAL	N018603 002	Jun 29, 1989	Aug	DISC
>A>		@	EQ 1GM BASE/VIAL	N018603 002	Jun 29, 1989	Aug	DISC

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

>D>	+	MEDA PHARMS	5%;1%	N022436 001	Jul 31, 2009	Aug	CAHN
	+		5%;1%	N022436 001	Jul 31, 2009	May	CTNA
>A>	+	VALEANT INTL	5%;1%	N022436 001	Jul 31, 2009	Aug	CAHN

ALBENDAZOLE

TABLET; ORAL

ALBENZA

	+	COREPHARMA	200MG	N020666 001	Jun 11, 1996	Jun	CAHN
--	---	------------	-------	-------------	--------------	-----	------

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

>D>	AN	ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533 001	Sep 26, 1995	Aug	DISC
>A>		@	EQ 0.083% BASE	A073533 001	Sep 26, 1995	Aug	DISC
>D>	AN	COBALT LABS INC	EQ 0.083% BASE	A076370 001	Nov 24, 2003	Aug	CAHN
	AN	RTEDOSE CORP	EQ 0.083% BASE	A077839 001	Dec 16, 2008	Jul	CAHN
>A>	AN	WATSON LABS INC	EQ 0.083% BASE	A076370 001	Nov 24, 2003	Aug	CAHN

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

	+	ALLERGAN	0.25%	N022134 001	Jul 28, 2010	Jun	CAHN
--	---	----------	-------	-------------	--------------	-----	------

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL

ACLOVATE

AB	+	NYCOMED US	0.05%	N018702 001	Dec 14, 1982	Mar	CAHN
----	---	------------	-------	-------------	--------------	-----	------

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

>D>		ALCOHOL 5% IN D5-W					
>D>	AP	HOSPIRA	5ML/100ML; 5GM/100ML	A083263 001		Aug	DISC
>A>		@	5ML/100ML; 5GM/100ML	A083263 001		Aug	DISC

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB	MYLAN	EQ 35MG BASE	A078638 001	Aug 04, 2008	Feb	CAHN
AB		EQ 70MG BASE	A078638 002	Aug 04, 2008	Feb	CAHN
	@ SANDOZ	EQ 5MG BASE	A075871 001	Apr 22, 2009	Mar	DISC
	@	EQ 10MG BASE	A075871 002	Apr 22, 2009	Mar	DISC
	@	EQ 35MG BASE	A075871 004	Apr 22, 2009	Mar	DISC
	@	EQ 40MG BASE	A075871 003	Apr 22, 2009	Mar	DISC
	@	EQ 70MG BASE	A075871 005	Apr 22, 2009	Mar	DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	APOTEX INC	10MG	A079013 001	Jul 18, 2011	Jul	NEWA
AB	MYLAN	10MG	A079014 001	Jul 18, 2011	Jul	NEWA
AB	SUN PHARMA GLOBAL	10MG	A079057 001	Jul 18, 2011	Jul	NEWA
AB	TEVA PHARMS	10MG	A079056 001	Jul 18, 2011	Jul	NEWA
AB	TORRENT PHARMS	10MG	A079054 001	Jul 18, 2011	Jul	NEWA
	UROXATRAL					
AB	+ SANOFI AVENTIS US	10MG	N021287 001	Jun 12, 2003	Jul	CFTG

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	IPCA LABS LTD	100MG	A090637 001	Mar 16, 2011	Feb	NEWA
AB		300MG	A090637 002	Mar 16, 2011	Feb	NEWA

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

AP	+ MYLAN INSTITUTIONAL	EQ 500MG BASE/VIAL	N020298 001	May 17, 1996	Jul	CAHN
----	-----------------------	--------------------	-------------	--------------	-----	------

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	AUROBINDO PHARMA USA	0.5MG	A090871 001	Jun 07, 2011	May	NEWA
AB		1MG	A090871 002	Jun 07, 2011	May	NEWA
AB		2MG	A090871 003	Jun 07, 2011	May	NEWA
AB		3MG	A090871 004	Jun 07, 2011	May	NEWA

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

	MEDA PHARMS	0.125MG	N020700 001	Nov 19, 1996	May	CAHN
		0.25MG	N020700 002	Nov 19, 1996	May	CAHN
		0.5MG	N020700 003	Nov 19, 1996	May	CAHN
+		1MG	N020700 004	Nov 19, 1996	May	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

@	ACTAVIS TOTOWA	100MG	A077659 001	Feb 23, 2006	Jul	DISC
---	----------------	-------	-------------	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

>D> AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> HOSPIRA EQ 500MG BASE/100ML A064146 001 Apr 02, 1997 Aug DISC

>A> @ EQ 500MG BASE/100ML A064146 001 Apr 02, 1997 Aug DISC

AMINO ACIDS

INJECTABLE; INJECTION

>D> NOVAMINE 11.4%

>D> + HOSPIRA 11.4% (11.4GM/100ML) N017957 003 Aug 09, 1982 Aug DISC

>A> @ 11.4% (11.4GM/100ML) N017957 003 Aug 09, 1982 Aug DISC

>D> NOVAMINE 15%

>D> + HOSPIRA 15% (15GM/100ML) N017957 004 Nov 28, 1986 Aug DISC

>A> @ 15% (15GM/100ML) N017957 004 Nov 28, 1986 Aug DISC

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

>D> AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

>D> HOSPIRA 3.5%;36.8MG/100ML;25GM/100ML;51MG N019683 001 Nov 07, 1988 Aug DISC
/100ML;22.4MG/100ML;261MG/100ML;2
05MG/100ML>A> @ 3.5%;36.8MG/100ML;25GM/100ML;51MG N019683 001 Nov 07, 1988 Aug DISC
/100ML;22.4MG/100ML;261MG/100ML;2
05MG/100ML

>D> AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

>D> HOSPIRA 4.25%;36.8MG/100ML;20GM/100ML;51M N019683 002 Nov 07, 1988 Aug DISC
G/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML>A> @ 4.25%;36.8MG/100ML;20GM/100ML;51M N019683 002 Nov 07, 1988 Aug DISC
G/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML

>D> AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

>D> HOSPIRA 4.25%;36.8MG/100ML;25GM/100ML;51M N019683 003 Nov 07, 1988 Aug DISC
G/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML>A> @ 4.25%;36.8MG/100ML;25GM/100ML;51M N019683 003 Nov 07, 1988 Aug DISC
G/100ML;22.4MG/100ML;261MG/100ML;
205MG/100MLAMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

>D> AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

>D> HOSPIRA 3.5%;25GM/100ML N019681 001 Nov 01, 1988 Aug DISC

>A> @ 3.5%;25GM/100ML N019681 001 Nov 01, 1988 Aug DISC

>D> AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> HOSPIRA 3.5%;5GM/100ML N019681 002 Nov 01, 1988 Aug DISC

>A> @ 3.5%;5GM/100ML N019681 002 Nov 01, 1988 Aug DISC

>D> AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

>D> HOSPIRA 4.25%;10GM/100ML N019681 004 Nov 01, 1988 Aug DISC

>A> @ 4.25%;10GM/100ML N019681 004 Nov 01, 1988 Aug DISC

>D> AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

>D> HOSPIRA 4.25%;20GM/100ML N019681 005 Nov 01, 1988 Aug DISC

>A> @ 4.25%;20GM/100ML N019681 005 Nov 01, 1988 Aug DISC

>D> AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

>D> HOSPIRA 4.25%;25GM/100ML N019681 003 Nov 01, 1988 Aug DISC

>A> @ 4.25%;25GM/100ML N019681 003 Nov 01, 1988 Aug DISC

>D> AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

>D> HOSPIRA 5%;25GM/100ML N019681 006 Nov 01, 1988 Aug DISC

INJECTABLE; INJECTION

>D> AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
 >A> @ HOSPIRA 5%;25GM/100ML N019681 006 Nov 01, 1988 Aug DISC

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

>D> AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
 >D> HOSPIRA 3.5%;5GM/100ML;30MG/100ML;97MG/10 N019682 001 Nov 01, 1988 Aug DISC
 0ML;120MG/100ML;49.3MG/100ML
 >A> @ 3.5%;5GM/100ML;30MG/100ML;97MG/10 N019682 001 Nov 01, 1988 Aug DISC
 0ML;120MG/100ML;49.3MG/100ML
 >D> AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER
 >D> HOSPIRA 4.25%;5GM/100ML;30MG/100ML;97MG/1 N019682 002 Nov 01, 1988 Aug DISC
 00ML;120MG/100ML;49.3MG/100ML
 >A> @ 4.25%;5GM/100ML;30MG/100ML;97MG/1 N019682 002 Nov 01, 1988 Aug DISC
 00ML;120MG/100ML;49.3MG/100ML

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552 001	Apr 08, 2009	Apr	CAHN
AB		EQ 5MG BASE	A078552 002	Apr 08, 2009	Apr	CAHN
AB		EQ 10MG BASE	A078552 003	Apr 08, 2009	Apr	CAHN
	@ GEDEON RICHTER USA	EQ 2.5MG BASE	A077333 001	Jul 17, 2007	Jul	DISC
	@	EQ 5MG BASE	A077333 002	Jul 17, 2007	Jul	DISC
	@	EQ 10MG BASE	A077333 003	Jul 17, 2007	Jul	DISC
AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771 001	Apr 12, 2011	Mar	NEWA
AB		EQ 5MG BASE	A077771 002	Apr 12, 2011	Mar	NEWA
AB		EQ 10MG BASE	A077771 003	Apr 12, 2011	Mar	NEWA
AB	PURACAP PHARM	EQ 2.5MG BASE	A078131 001	Sep 04, 2007	May	CAHN
AB		EQ 5MG BASE	A078131 002	Sep 04, 2007	May	CAHN
AB		EQ 10MG BASE	A078131 003	Sep 04, 2007	May	CAHN
AB	SECAN PHARMS	EQ 5MG BASE	A090752 001	Apr 15, 2011	Apr	NEWA
AB		EQ 10MG BASE	A090752 002	Apr 15, 2011	Apr	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	DR REDDYS LABS INC	EQ 5MG BASE;40MG	A090149 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A090149 002	Jul 05, 2011	Jun	NEWA
AB	LUPIN PHARMS	EQ 5MG BASE;40MG	A078466 005	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A078466 006	Jul 05, 2011	Jun	NEWA
AB	MYLAN	EQ 5MG BASE;40MG	A079047 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A079047 002	Jul 05, 2011	Jun	NEWA
AB	TEVA PHARMS	EQ 5MG BASE;40MG	A077179 005	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A077179 006	Jul 05, 2011	Jun	NEWA
AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A090364 002	Jul 05, 2011	Jun	NEWA
	LOTREL					
AB	NOVARTIS	EQ 5MG BASE;40MG	N020364 007	Apr 11, 2006	Jan	CFTG
AB	+	EQ 10MG BASE;40MG	N020364 006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	A062058 001		Feb	CDFR
AB		500MG	A062058 002		Feb	CDFR

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

>A>	+	SHIONOGI INC	775MG	N050813	001	Jan 23, 2008	Aug	CAHN
>D>	+	VICTORY PHARMA	775MG	N050813	001	Jan 23, 2008	Aug	CAHN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

>D>	AB	RANBAXY	200MG	A065080	002	Aug 11, 2003	Aug	DISC
>D>	AB	+	400MG	A065080	001	Aug 11, 2003	Aug	DISC
>A>		@ RANBAXY LABS LTD	200MG	A065080	002	Aug 11, 2003	Aug	DISC
>A>		@	400MG	A065080	001	Aug 11, 2003	Aug	DISC

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N	N050824	001	Feb 08, 2011	Feb	NEWA
---	-----------------	-----------------------------------	---------	-----	--------------	-----	------

/A,20MG

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

AP	+	X GEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Jun	CRLD
----	---	--------------	-----------	---------	-----	--------------	-----	------

FUNGIZONE

@ APOTHECON

50MG/VIAL

A060517	001		Jun	DISC
---------	-----	--	-----	------

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+	ALDOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Jul	CAHN
---	----------------	-----------	---------	-----	--------------	-----	------

+		100MG/VIAL	N050729	002	Nov 22, 1996	Jul	CAHN
---	--	------------	---------	-----	--------------	-----	------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP		AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG	A090340	001	Sep 20, 2010	Apr	CAIN
----	--	------------------	---------------------------	---------	-----	--------------	-----	------

BASE/VIAL

AP			EQ 1GM BASE/VIAL;EQ 500MG	A090349	001	Sep 20, 2010	Apr	CAIN
----	--	--	---------------------------	---------	-----	--------------	-----	------

BASE/VIAL

AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349	002	Sep 20, 2010	Apr	CAIN
----	--	--	-----------------------------------	---------	-----	--------------	-----	------

AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010	Apr	CAIN
----	--	--	-----------------------------------	---------	-----	--------------	-----	------

AP			EQ 10GM BASE/VIAL;EQ 5GM	A090339	001	Sep 20, 2010	Apr	CAIN
----	--	--	--------------------------	---------	-----	--------------	-----	------

BASE/VIAL

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

DAVA PHARMS INC

EQ 125MG BASE/5ML

A062982	001	Feb 10, 1989	Jul	CTEC
---------	-----	--------------	-----	------

PRINCIPEN

@ APOTHECON

EQ 125MG BASE/5ML

A061394	002		Jul	DISC
---------	-----	--	-----	------

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB		SANTOS BIOTECH	1MG	A078944	001	Jun 28, 2010	Feb	CAHN
----	--	----------------	-----	---------	-----	--------------	-----	------

AB		SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011	Jul	NEWA
----	--	--------------------	-----	---------	-----	--------------	-----	------

@ SYNTHON PHARMS

1MG

A078322	001	Jun 28, 2010	Jul	DISC
---------	-----	--------------	-----	------

ARGATROBAN

INJECTABLE; IV (INFUSION)

ARGATROBAN IN SODIUM CHLORIDE

+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	Jun	NEWA
+	SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May	NEWA

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

@	SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011	May	DISC
---	--------	----------------------	---------	-----	--------------	-----	------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

>A>	+	MERCK SHARP DOHME	EQ 10MG BASE	N022117	002	Aug 13, 2009	Aug	CAHN
>D>	+	ORGANON USA INC	EQ 10MG BASE	N022117	002	Aug 13, 2009	Aug	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

>D>	AA	ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710	002	Aug 23, 1983	Aug	DISC
>A>	@		325MG;50MG;40MG	A086710	002	Aug 23, 1983	Aug	DISC
	@	PURACAP PHARM	325MG;50MG;40MG	A087048	002	Dec 09, 1983	Jun	CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	MIRROR PHARMS	325MG;200MG	A040832	001	Jan 07, 2010	Mar	CAHN
AB	PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	MIRROR PHARMS	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	CAHN
AB	PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	COASTAL PHARMS	325MG;4.8355MG	A091670	001	Mar 16, 2011	Feb	NEWA	
AA	WATSON LABS	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	NEWA	
	PERCODAN							
AA	+	ENDO PHARMS	325MG;4.8355MG	N007337	007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MYLAN	25MG	A074126	003	Aug 26, 1998	Feb	CAHN
AB		50MG	A074126	001	Mar 23, 1994	Feb	CAHN
AB		100MG	A074126	002	Mar 23, 1994	Feb	CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	10MG	A078940	001	Aug 30, 2010	Aug	DISC
>A>	@		10MG	A078940	001	Aug 30, 2010	Aug	DISC
>D>	AB		18MG	A078940	002	Aug 30, 2010	Aug	DISC

CAPSULE; ORALATOMOXETINE HYDROCHLORIDE

>A>	@ ACTAVIS ELIZABETH	18MG	A078940 002	Aug 30, 2010	Aug	DISC
>D>	AB	25MG	A078940 003	Aug 30, 2010	Aug	DISC
>A>	@	25MG	A078940 003	Aug 30, 2010	Aug	DISC
>D>	AB	40MG	A078940 004	Aug 30, 2010	Aug	DISC
>A>	@	40MG	A078940 004	Aug 30, 2010	Aug	DISC
>D>	AB	60MG	A078940 005	Aug 30, 2010	Aug	DISC
>A>	@	60MG	A078940 005	Aug 30, 2010	Aug	DISC
>D>	AB	80MG	A078940 006	Aug 30, 2010	Aug	DISC
>A>	@	80MG	A078940 006	Aug 30, 2010	Aug	DISC
>D>	AB	100MG	A078940 007	Aug 30, 2010	Aug	DISC
>A>	@	100MG	A078940 007	Aug 30, 2010	Aug	DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDETABLET; ORALATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	250MG;100MG	A091211 001	Jan 12, 2011	Jan	NEWA
	MALARONE					
AB	+ GLAXOSMITHKLINE	250MG;100MG	N021078 001	Jul 14, 2000	Jan	CFTG

ATROPINEINJECTABLE; INJECTIONATROPINE

@ SOLVAY	EQ 2MG SULFATE/0.7ML	A071295 001	Jan 30, 1987	Jul	CAHN
----------	----------------------	-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDESPRAY, METERED; NASAL

>D>	ASTEPRO					
>D>	+ MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N022203 001	Oct 15, 2008	Aug	DISC
>A>	@	EQ 0.125MG BASE/SPRAY	N022203 001	Oct 15, 2008	Aug	DISC

AZILSARTAN MEDOXOMILTABLET; ORALEDARBI

TAKEDA PHARMS	40MG	N200796 001	Feb 25, 2011	Feb	NEWA
+	80MG	N200796 002	Feb 25, 2011	Feb	NEWA

AZITHROMYCINTABLET; ORALAZITHROMYCIN

AB	APOTEX CORP	EQ 250MG BASE	A065507 001	Jul 13, 2011	Jul	NEWA
AB		EQ 500MG BASE	A065509 001	Jul 13, 2011	Jul	NEWA
AB		EQ 600MG BASE	A065508 001	Jul 13, 2011	Jul	NEWA

AZTREONAMINJECTABLE; INJECTIONAZTREONAM

AP	BEDFORD	1GM/VIAL	A065286 001	Mar 23, 2011	Mar	NEWA
AP		2GM/VIAL	A065286 002	Mar 23, 2011	Mar	NEWA

BACITRACINOINTMENT; OPHTHALMICBACITRACIN

+	FERA PHARMS	500 UNITS/GM	A061212 001		Feb	CAHN
+	NYCOMED US	500 UNITS/GM	A061212 001		Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764 002	Feb	CAHN
AT	NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764 002	Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Feb	CAHN
AT	NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002	Feb	CAHN
+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002	Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	CNS THERAPS INC	0.05MG/ML	N022462 001	Nov 19, 2010	Feb	CTEC
AP		0.5MG/ML	N022462 002	Nov 19, 2010	Feb	CTEC
AP		2MG/ML	N022462 003	Nov 19, 2010	Feb	CTEC

LIORESAL

AP	+	MEDTRONIC	0.05MG/ML	N020075 003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075 001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075 002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

>A>	AB	PRINSTON INC	5MG	A076118 001	Feb 11, 2004	Aug	CAHN
>A>	AB		10MG	A076118 002	Feb 11, 2004	Aug	CAHN
>A>	AB		20MG	A076118 003	Feb 11, 2004	Aug	CAHN
>A>	AB		40MG	A076118 004	Feb 11, 2004	Aug	CAHN
>D>	AB	PRINSTON PHARM LLC	5MG	A076118 001	Feb 11, 2004	Aug	CAHN
	AB		5MG	A076118 001	Feb 11, 2004	May	CAHN
>D>	AB		10MG	A076118 002	Feb 11, 2004	Aug	CAHN
	AB		10MG	A076118 002	Feb 11, 2004	May	CAHN
>D>	AB		20MG	A076118 003	Feb 11, 2004	Aug	CAHN
	AB		20MG	A076118 003	Feb 11, 2004	May	CAHN
>D>	AB		40MG	A076118 004	Feb 11, 2004	Aug	CAHN
	AB		40MG	A076118 004	Feb 11, 2004	May	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	5MG;6.25MG	A076612 001	Feb 11, 2004	Feb	CAHN
AB		10MG;12.5MG	A076612 002	Feb 11, 2004	Feb	CAHN
AB		20MG;12.5MG	A076612 003	Feb 11, 2004	Feb	CAHN
AB		20MG;25MG	A076612 004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP	LUITPOLD	1MG/ML	A091152 001	Mar 29, 2010	Feb	CAHN
----	----------	--------	-------------	--------------	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

@ ACTAVIS TOTOWA

0.5MG

A040699 001 Feb 14, 2008 Jul DISC

@

1MG

A040705 001 Feb 14, 2008 Jul DISC

@

2MG

A040706 001 Feb 14, 2008 Jul DISC

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB	STI PHARMA LLC	EQ 0.1% BASE	A070052 001	Jul 31, 1985	Apr	CAHN
----	----------------	--------------	-------------	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

@ ACTAVIS TOTOWA

5MG

A040552 001 Oct 28, 2004 Jul DISC

@

10MG

A040553 001 Oct 28, 2004 Jul DISC

@

25MG

A040554 001 Oct 28, 2004 Jul DISC

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	ROXANE	50MG	A078285 001	Mar 24, 2011	Mar	NEWA
----	--------	------	-------------	--------------	-----	------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+ AXCAN 140MG;125MG;125MG

N050786 001 Sep 28, 2006 Jun CAHN

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

+ SCHERING 200MG

N202258 001 May 13, 2011 May NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

@ HOSPIRA

50MG/ML

N019030 001 Apr 29, 1986 Jun DISC

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	+	B BRAUN	200MG/100ML	N019121 002	Apr 29, 1986	Aug	CTEC
>A>		+		200MG/100ML	N019121 002	Apr 29, 1986	Aug	CTEC
>D>	AP	+		400MG/100ML	N019121 003	Apr 29, 1986	Aug	CTEC
>A>		+		400MG/100ML	N019121 003	Apr 29, 1986	Aug	CTEC
>D>	AP	+	HOSPIRA	200MG/100ML	N019008 002	Apr 29, 1986	Aug	DISC

INJECTABLE; INJECTIONBRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>	@	HOSPIRA	200MG/100ML	N019008	002	Apr 29, 1986	Aug	DISC
>D>	AP	+	400MG/100ML	N019008	003	Apr 29, 1986	Aug	DISC
>A>	@		400MG/100ML	N019008	003	Apr 29, 1986	Aug	DISC

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMICBROMDAY

+	ISTA PHARMS INC	0.09%	N021664	002	Oct 16, 2010	Mar	CRLD
	BROMFENAC SODIUM						
	COASTAL PHARMS	0.09%	A201211	001	May 11, 2011	Apr	NEWA
	XIBROM						
	@ ISTA PHARMS INC	0.09%	N021664	001	Mar 24, 2005	Mar	DISC

BUDESONIDECAPSULE; ORALBUDESONIDE

AB	MYLAN	3MG	A090410	001	May 16, 2011	May	NEWA	
	ENTOCORT EC							
AB	+	ASTRAZENECA	3MG	N021324	001	Oct 02, 2001	May	CFTG

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTIONDUOCAINE

@	AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003	Jun	CAHN
---	----------------------	--	---------	-----	--------------	-----	------

BUPROPION HYDROBROMIDETABLET, EXTENDED RELEASE; ORALAPLENZIN

	VALEANT INTL	174MG	N022108	001	Apr 23, 2008	Jun	CAHN
+		348MG	N022108	002	Apr 23, 2008	Jun	CAHN
		522MG	N022108	003	Apr 23, 2008	Jun	CAHN

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE; ORALBUPROPION HYDROCHLORIDE

AB1	ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	May	NEWA	
AB2		150MG	A091520	001	Jun 09, 2011	May	NEWA	
AB1		150MG	A091459	002	Jun 09, 2011	May	NEWA	
AB1		200MG	A091459	003	Jun 09, 2011	May	NEWA	
AB1	WATSON LABS FLORIDA	100MG	A079095	001	Mar 24, 2009	May	CAHN	
AB1		150MG	A079095	002	Mar 24, 2009	May	CAHN	
AB2		150MG	A079094	001	Mar 24, 2009	May	CAHN	
AB1		200MG	A079095	003	Mar 24, 2009	May	CAHN	
	WELLBUTRIN XL							
AB3	+	VALEANT INTL	150MG	N021515	001	Aug 28, 2003	Jul	CAHN
AB3		300MG	N021515	002	Aug 28, 2003	Jul	CAHN	

BUSPIRONE HYDROCHLORIDETABLET; ORALBUSPAR

>D>								
>D>	AB	BRISTOL MYERS SQUIBB	5MG	N018731	001	Sep 29, 1986	Aug	DISC
>A>	@		5MG	N018731	001	Sep 29, 1986	Aug	DISC

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

@	ACTAVIS TOTOWA	5MG	A075388	001	May 09, 2002	Jul	DISC
@		10MG	A075388	002	May 09, 2002	Jul	DISC
@		15MG	A075388	003	May 09, 2002	Jul	DISC
@		30MG	A078302	001	Dec 17, 2007	Jul	DISC

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	G AND W LABS INC	0.005%	A078468	001	Mar 24, 2011	Mar	NEWA
----	------------------	--------	---------	-----	--------------	-----	------

CALCIUM ACETATE

SOLUTION; ORAL

PHOSLYRA

+	FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N022581	001	Apr 18, 2011	Apr	NEWA
---	-----------------	----------------------	---------	-----	--------------	-----	------

TABLET; ORAL

CALCIUM ACETATE

AB	PADDOCK LABS	EQ 169MG CALCIUM	A091561	001	Apr 13, 2011	Mar	NEWA
----	--------------	------------------	---------	-----	--------------	-----	------

ELIPHOS

AB	+	CYPRESS PHARM	EQ 169MG CALCIUM	A078502	001	Nov 25, 2008	Mar	CTEC
----	---	---------------	------------------	---------	-----	--------------	-----	------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

>A>	AB	PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Aug	CAHN
>A>	AB		25MG	A074477	002	Feb 13, 1996	Aug	CAHN
>A>	AB		50MG	A074477	003	Feb 13, 1996	Aug	CAHN
>A>	AB		100MG	A074477	004	Feb 13, 1996	Aug	CAHN
>D>	AB	PRINSTON PHARM LLC	12.5MG	A074477	001	Feb 13, 1996	Aug	CAHN
	AB		12.5MG	A074477	001	Feb 13, 1996	May	CAHN
>D>	AB		25MG	A074477	002	Feb 13, 1996	Aug	CAHN
	AB		25MG	A074477	002	Feb 13, 1996	May	CAHN
>D>	AB		50MG	A074477	003	Feb 13, 1996	Aug	CAHN
	AB		50MG	A074477	003	Feb 13, 1996	May	CAHN
>D>	AB		100MG	A074477	004	Feb 13, 1996	Aug	CAHN
	AB		100MG	A074477	004	Feb 13, 1996	May	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	NOSTRUM	100MG	A076697	001	May 20, 2011	May	NEWA
AB		200MG	A076697	002	May 20, 2011	May	NEWA
AB		300MG	A076697	003	May 20, 2011	May	NEWA

CARBATROL

AB	SHIRE	100MG	N020712	003	Sep 30, 1997	May	CFTG
AB		200MG	N020712	001	Sep 30, 1997	May	CFTG
AB	+	300MG	N020712	002	Sep 30, 1997	May	CFTG

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

@	JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988	Jan	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB	MERCK SHARP DOHME	10MG;100MG	N017555	001		Jan	CAHN
----	-------------------	------------	---------	-----	--	-----	------

TABLET; ORAL

SINEMET

AB	MERCK SHARP DOHME	25MG;100MG	N017555 003		Jan	CAHN
AB	+	25MG;250MG	N017555 002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

AB	MERCK SHARP DOHME	25MG;100MG	N019856 002	Dec 24, 1992	Jan	CAHN
AB	+	50MG;200MG	N019856 001	May 30, 1991	Jan	CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

AA	RIVERS EDGE PHARMS	4MG	A090756 001	May 27, 2011	May	NEWA
----	--------------------	-----	-------------	--------------	-----	------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	MIRROR PHARMS	350MG	A040823 001	Oct 22, 2008	Mar	CAHN
AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN

CEFACLOR

FOR SUSPENSION; ORAL

CEFACLOR

>D>	@ ACS DOBFAR INFO SA	EQ 125MG BASE/5ML	A062206 001		Aug	CAHN
>D>	@	EQ 187MG BASE/5ML	A062206 003	Apr 20, 1988	Aug	CAHN
>D>	@	EQ 250MG BASE/5ML	A062206 002		Aug	CAHN
>D>	@	EQ 375MG BASE/5ML	A062206 004	Apr 20, 1988	Aug	CAHN
>A>	@ FACTA FARMA	EQ 125MG BASE/5ML	A062206 001		Aug	CAHN
>A>	@	EQ 187MG BASE/5ML	A062206 003	Apr 20, 1988	Aug	CAHN
>A>	@	EQ 250MG BASE/5ML	A062206 002		Aug	CAHN
>A>	@	EQ 375MG BASE/5ML	A062206 004	Apr 20, 1988	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

+	TEVA	EQ 500MG BASE	A065058 002	Sep 04, 2002	Jul	CRLD
	@ WORLD GEN	EQ 500MG BASE	A065057 001	Jan 05, 2001	Jul	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005	Jan	CAHN
AP	STERI PHARMA	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991	Jul	CMFD
AP		EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991	Jul	CMFD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065369 001	Jun 18, 2007	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065369 002	Jun 18, 2007	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065369 003	Jun 18, 2007	Jan	CAHN

MAXIPIME

>D>	AP	+	BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N050679 001	Jan 18, 1996	Aug	CAHN
>D>	AP	+		EQ 1GM BASE/VIAL	N050679 002	Jan 18, 1996	Aug	CAHN
>D>	AP	+		EQ 2GM BASE/VIAL	N050679 003	Jan 18, 1996	Aug	CAHN

INJECTABLE; INJECTION

MAXIPIME

>A>	AP	+	HOSPIRA INC	EQ 500MG BASE/VIAL	N050679 001	Jan 18, 1996	Aug	CAHN
>A>	AP	+		EQ 1GM BASE/VIAL	N050679 002	Jan 18, 1996	Aug	CAHN
>A>	AP	+		EQ 2GM BASE/VIAL	N050679 003	Jan 18, 1996	Aug	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP			HOSPIRA INC	EQ 500MG BASE/VIAL	A065290 001	Aug 11, 2006	Jan	CAHN
AP				EQ 1GM BASE/VIAL	A065293 001	Aug 10, 2006	Jan	CAHN
AP				EQ 1GM BASE/VIAL	A065290 002	Aug 11, 2006	Jan	CAHN
AP				EQ 2GM BASE/VIAL	A065293 002	Aug 10, 2006	Jan	CAHN
AP				EQ 2GM BASE/VIAL	A065290 003	Aug 11, 2006	Jan	CAHN
AP				EQ 10GM BASE/VIAL	A065292 001	Aug 10, 2006	Jan	CAHN

CEFOXITIN

INJECTABLE; INJECTION

CEFOXITIN

>A>	AP		ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Aug	NEWA
>A>	AP			EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Aug	NEWA
>A>	AP			EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Aug	NEWA

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP			HOSPIRA INC	EQ 1GM BASE/VIAL	A065313 001	Jan 23, 2006	Jan	CAHN
AP				EQ 2GM BASE/VIAL	A065313 002	Jan 23, 2006	Jan	CAHN
AP				EQ 10GM BASE/VIAL	A065312 001	Feb 13, 2006	Jan	CAHN

MEFOXIN

>D>		@	MERCK	EQ 1GM BASE/VIAL	N050517 001		Aug	CAHN
>D>		@		EQ 2GM BASE/VIAL	N050517 002		Aug	CAHN
>D>		@		EQ 10GM BASE/VIAL	N050517 003		Aug	CAHN
>A>		@	MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	N050517 001		Aug	CAHN
>A>		@		EQ 2GM BASE/VIAL	N050517 002		Aug	CAHN
>A>		@		EQ 10GM BASE/VIAL	N050517 003		Aug	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	+		SANDOZ	EQ 200MG BASE	A065462 002	May 28, 2008	Jan	CRLD
			VANTIN					
		@	PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674 001	Aug 07, 1992	Jan	DISC
		@		EQ 200MG BASE	N050674 002	Aug 07, 1992	Jan	DISC

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME IN DEXTROSE CONTAINER

B BRAUN

+

EQ 1GM BASE	N050823 001	Jun 13, 2011	Jun	NEWA
EQ 2GM BASE	N050823 002	Jun 13, 2011	Jun	NEWA

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AP			HOSPIRA INC	EQ 250MG BASE/VIAL	A065230 001	Aug 02, 2005	Jan	CAHN
AP				EQ 500MG BASE/VIAL	A065230 002	Aug 02, 2005	Jan	CAHN

INJECTABLE; IM-IV

CEFTRIAXONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065230 003	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065230 004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTION

CEFTRIAXONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065232 001	Aug 02, 2005	Jan	CAHN
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A065168 001	May 17, 2005	Jan	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	ALKEM LABS LTD	EQ 250MG BASE	A065496 001	Jun 07, 2010	May	CAHN
AB		EQ 500MG BASE	A065496 002	Jun 07, 2010	May	CAHN
AB	APOTEX	EQ 250MG BASE	A065069 001	Oct 02, 2002	Jun	CAHN
AB		EQ 500MG BASE	A065069 002	Oct 02, 2002	Jun	CAHN

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048 001	Jan 09, 2004	Mar	CTEC
AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

>D>	AB	ACS DOBFAR INFO SA	EQ 250MG BASE	A062118 001	Aug	CAHN
>D>	AB		EQ 500MG BASE	A062118 002	Aug	CAHN
>A>	AB	FACTA FARMA	EQ 250MG BASE	A062118 001	Aug	CAHN
>A>	AB		EQ 500MG BASE	A062118 002	Aug	CAHN

KEFLEX

>A>	AB	SHIONOGI INC	EQ 250MG BASE	N050405 002	Aug	CAHN
>A>		@	EQ 333MG BASE	N050405 004	May 12, 2006	Aug
>A>	AB		EQ 500MG BASE	N050405 003	Aug	CAHN
>A>		+	EQ 750MG BASE	N050405 005	May 12, 2006	Aug
>D>	AB	VICTORY PHARMA	EQ 250MG BASE	N050405 002	Aug	CAHN
>D>		@	EQ 333MG BASE	N050405 004	May 12, 2006	Aug
>D>	AB		EQ 500MG BASE	N050405 003	Aug	CAHN
>D>		+	EQ 750MG BASE	N050405 005	May 12, 2006	Aug

FOR SUSPENSION; ORAL

CEPHALEXIN

>D>		@ ACS DOBFAR	EQ 100MG BASE/ML	A062117 001	Aug	CAHN
		@	EQ 100MG BASE/ML	A062117 001	Jan	CAHN
>D>	AB		EQ 125MG BASE/5ML	A062117 002	Aug	CAHN
	AB		EQ 125MG BASE/5ML	A062117 002	Jan	CAHN
>D>	AB	+	EQ 250MG BASE/5ML	A062117 003	Aug	CAHN
	AB	+	EQ 250MG BASE/5ML	A062117 003	Jan	CAHN
>A>		@ FACTA FARMA	EQ 100MG BASE/ML	A062117 001	Aug	CAHN
>A>	AB		EQ 125MG BASE/5ML	A062117 002	Aug	CAHN

FOR SUSPENSION; ORAL

CEPHALEXIN

>A>	AB	+	FACTA FARMA	EQ 250MG BASE/5ML	A062117 003		Aug	CAHN
TABLET, FOR SUSPENSION; ORAL								
>D>			PANIXINE DISPERDOSE					
>D>			RANBAXY	EQ 125MG BASE	A065100 002	Sep 11, 2003	Aug	DISC
>D>		+		EQ 250MG BASE	A065100 001	Sep 11, 2003	Aug	DISC
>A>		@	RANBAXY LABS LTD	EQ 125MG BASE	A065100 002	Sep 11, 2003	Aug	DISC
>A>		@		EQ 250MG BASE	A065100 001	Sep 11, 2003	Aug	DISC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>D>	AA		ACTAVIS MID ATLANTIC	5MG/5ML	A078617 001	Feb 02, 2010	Aug	DISC
>A>		@		5MG/5ML	A078617 001	Feb 02, 2010	Aug	DISC
>D>	AA		PERRIGO ISRAEL	5MG/5ML	A078398 001	Jun 17, 2008	Aug	CAHN
>A>	AA		PERRIGO R AND D	5MG/5ML	A078398 001	Jun 17, 2008	Aug	CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE

>A>	AB		APOTEX INC	30MG	A091260 001	Aug 25, 2011	Aug	NEWA
EVOXAC								
>D>		+	DAIICHI SANKYO CO	30MG	N020989 002	Jan 11, 2000	Aug	CFTG
>A>	AB	+		30MG	N020989 002	Jan 11, 2000	Aug	CFTG

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT			LYNE	0.12%	A074291 001	Dec 28, 1995	Feb	CAHN
----	--	--	------	-------	-------------	--------------	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA			NATCO PHARMA LTD	EQ 150MG BASE	A091621 001	Jan 21, 2011	Jan	NEWA
AA				EQ 300MG BASE	A090612 001	Jan 21, 2011	Jan	NEWA

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP			SUN PHARMA GLOBAL	EQ 500MG BASE/VIAL	A091546 001	Jul 26, 2011	Jul	NEWA
----	--	--	-------------------	--------------------	-------------	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

ZUTRIPRO

		+	CYPRESS PHARM	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439 001	Jun 08, 2011	Jun	NEWA
--	--	---	---------------	----------------------------	-------------	--------------	-----	------

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

		@	ACTAVIS TOTOWA	250MG	A088928 001	May 08, 1987	Jul	DISC
		@		500MG	A040113 001	Sep 29, 1995	Jul	DISC
>D>	AA		OHM LABS	250MG	A081298 001	Dec 29, 1993	Aug	DISC
>A>		@		250MG	A081298 001	Dec 29, 1993	Aug	DISC
>D>	AA			500MG	A081299 001	Dec 29, 1993	Aug	DISC
>A>		@		500MG	A081299 001	Dec 29, 1993	Aug	DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074557	001	Aug 15, 1996	Apr	CRLD
CHOLESTYRAMINE LIGHT								
AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074558	001	Aug 15, 1996	Apr	CRLD
QUESTRAN								
		@ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N016640	001		Apr	DISC
		@	EQ 4GM RESIN/SCOOPFUL	N016640	003		Apr	DISC
QUESTRAN LIGHT								
		@ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Apr	DISC
		@	EQ 4GM RESIN/SCOOPFUL	N019669	003	Dec 05, 1988	Apr	DISC
AB	+		EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Mar	CRLD

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT		TARO	1%	A090269	001	Feb 23, 2011	Feb	NEWA
----	--	------	----	---------	-----	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

		@ ACTAVIS TOTOWA	100MG	A077028	002	Nov 26, 2004	Jul	DISC
--	--	------------------	-------	---------	-----	--------------	-----	------

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

>D> CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> + HOSPIRA EQ 6MG BASE/ML A074269 001 Dec 27, 1994 Aug DISC

>A> @ EQ 6MG BASE/ML A074269 001 Dec 27, 1994 Aug DISC

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP TEVA PARENTERAL 200MG/100ML A077138 001 Mar 18, 2008 Aug DISC

>D> AP 400MG/200ML A077138 002 Mar 18, 2008 Aug DISC

>A> @ TEVA PHARMS 200MG/100ML A077138 001 Mar 18, 2008 Aug DISC

>A> @ 400MG/200ML A077138 002 Mar 18, 2008 Aug DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

@ DEPOMED INC EQ 500MG BASE N021744 001 May 19, 2005 May DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB ANCHEN PHARMS 212.6MG;EQ 287.5MG BASE A078166 002 Nov 27, 2007 Jun CMFD

AB 425.2MG;EQ 574.9MG BASE A078166 001 Nov 27, 2007 Jun CMFD

CISPLATIN

INJECTABLE; INJECTION

PLATINOL

@ BRISTOL MYERS 50MG/VIAL N018057 002 Jun DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	MYLAN	EQ 10MG BASE	A077042 001	Nov 05, 2004	Apr	CAHN
AB		EQ 20MG BASE	A077042 002	Nov 05, 2004	Apr	CAHN
AB		EQ 40MG BASE	A077042 003	Nov 05, 2004	Apr	CAHN

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

>D>	AA	ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075 001	Oct 31, 1993	Aug	DISC
>A>		@	EQ 0.5MG BASE/5ML	A074075 001	Oct 31, 1993	Aug	DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	MATRIX LABS LTD	EQ 75MG BASE	A091225 001	May 31, 2011	May	NEWA
AB		EQ 150MG BASE	A091225 002	May 31, 2011	May	NEWA
AB		EQ 300MG BASE	A091225 003	May 31, 2011	May	NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAGEL

BT	+	GALDERMA LABS LP	EQ 1% BASE	N050782 001	Nov 27, 2000	Mar	CRLD
----	---	------------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>D>	AT	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811 001	Sep 01, 1988	Aug	DISC
>A>		@	EQ 1% BASE	A062811 001	Sep 01, 1988	Aug	DISC
		@ COREPHARMA	EQ 1% BASE	A064108 001	Sep 27, 1996	Apr	CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

OLUX

AB	+	STIEFEL LABS INC	0.05%	N021142 001	May 26, 2000	May	CAHN
----	---	------------------	-------	-------------	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

>D>	AB1	ACTAVIS MID ATLANTIC	0.05%	A074139 001	Aug 03, 1994	Aug	DISC
>A>		@	0.05%	A074139 001	Aug 03, 1994	Aug	DISC
		@ COREPHARMA	0.05%	A075338 001	Feb 09, 2001	Apr	CAHN
		CLOBETASOL PROPIONATE (EMOLLIENT)					
		@ COREPHARMA	0.05%	A075733 001	Aug 22, 2001	Apr	CAHN

TEMOVATE

>D>	AB1	+	ALTANA	0.05%	N019322 001	Dec 27, 1985	Aug	CAHN
>A>	AB1	+	NYCOMED US	0.05%	N019322 001	Dec 27, 1985	Aug	CAHN

GEL; TOPICAL

TEMOVATE

>D>	AB	+	ALTANA	0.05%	N020337 001	Apr 29, 1994	Aug	CAHN
>A>	AB	+	NYCOMED US	0.05%	N020337 001	Apr 29, 1994	Aug	CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

>D>	AB	ACTAVIS MID ATLANTIC	0.05%	A074128 001	Aug 03, 1994	Aug	DISC
>A>		@	0.05%	A074128 001	Aug 03, 1994	Aug	DISC
		@ COREPHARMA	0.05%	A075057 001	Aug 12, 1998	Apr	CAHN

TEMOVATE

>D>	AB	+	ALTANA	0.05%	N019323 001	Dec 27, 1985	Aug	CAHN
-----	----	---	--------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

TEMOVATE

>A>	AB	+	NYCOMED US	0.05%	N019323	001	Dec 27, 1985	Aug	CAHN
-----	----	---	------------	-------	---------	-----	--------------	-----	------

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

	AB		ACTAVIS MID ATLANTIC	0.05%	A078854	001	Jun 07, 2011	May	NEWA
--	----	--	----------------------	-------	---------	-----	--------------	-----	------

CLOBEX

	AB	+	GALDERMA LABS	0.05%	N021644	001	Feb 05, 2004	May	CFTG
--	----	---	---------------	-------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

>D>	AT		ACTAVIS MID ATLANTIC	0.05%	A074331	001	Dec 15, 1995	Aug	DISC
-----	----	--	----------------------	-------	---------	-----	--------------	-----	------

>A>			@	0.05%	A074331	001	Dec 15, 1995	Aug	DISC
-----	--	--	---	-------	---------	-----	--------------	-----	------

	AT		NYCOMED US	0.05%	A075391	001	Feb 08, 1999	Apr	CAHN
--	----	--	------------	-------	---------	-----	--------------	-----	------

TEMOVATE

>D>	AT	+	ALTANA	0.05%	N019966	001	Feb 22, 1990	Aug	CAHN
-----	----	---	--------	-------	---------	-----	--------------	-----	------

>A>	AT	+	NYCOMED US	0.05%	N019966	001	Feb 22, 1990	Aug	CAHN
-----	----	---	------------	-------	---------	-----	--------------	-----	------

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

	AT		PADDOCK LABS	0.05%	A090898	001	Jun 16, 2011	May	NEWA
--	----	--	--------------	-------	---------	-----	--------------	-----	------

CLOBEX

	AT	+	GALDERMA LABS LP	0.05%	N021835	001	Oct 27, 2005	Jun	CTEC
--	----	---	------------------	-------	---------	-----	--------------	-----	------

		+		0.05%	N021835	001	Oct 27, 2005	May	CFTG
--	--	---	--	-------	---------	-----	--------------	-----	------

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

		+	PROMIUS PHARMA LLC	0.1%	N017765	001		Jun	CAHN
--	--	---	--------------------	------	---------	-----	--	-----	------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

>A>	AB		MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Aug	CAHN
-----	----	--	------------------	------	---------	-----	--------------	-----	------

>A>	AB	+		50MG	N019906	002	Dec 29, 1989	Aug	CAHN
-----	----	---	--	------	---------	-----	--------------	-----	------

>A>	AB			75MG	N019906	003	Dec 29, 1989	Aug	CAHN
-----	----	--	--	------	---------	-----	--------------	-----	------

>D>	AB		TYCO HLTHCARE	25MG	N019906	001	Dec 29, 1989	Aug	CAHN
-----	----	--	---------------	------	---------	-----	--------------	-----	------

>D>	AB	+		50MG	N019906	002	Dec 29, 1989	Aug	CAHN
-----	----	---	--	------	---------	-----	--------------	-----	------

>D>	AB			75MG	N019906	003	Dec 29, 1989	Aug	CAHN
-----	----	--	--	------	---------	-----	--------------	-----	------

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP			APP PHARMS	1MG/10ML (0.1MG/ML)	A200673	001	Jul 08, 2011	Jun	NEWA
----	--	--	------------	---------------------	---------	-----	--------------	-----	------

AP				5MG/10ML (0.5MG/ML)	A200673	002	Jul 08, 2011	Jun	NEWA
----	--	--	--	---------------------	---------	-----	--------------	-----	------

AP			HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jul	CAHN
----	--	--	--------------------	---------------------	---------	-----	--------------	-----	------

AP				5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jul	CAHN
----	--	--	--	---------------------	---------	-----	--------------	-----	------

AP			WEST WARD	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jan	NEWA
----	--	--	-----------	---------------------	---------	-----	--------------	-----	------

AP				5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jan	NEWA
----	--	--	--	---------------------	---------	-----	--------------	-----	------

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

		+	ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jun	NEWA
--	--	---	--------	----------	---------	-----	--------------	-----	------

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

AB	MIRROR PHARMS	0.5MG;500MG	A040618	001	May 13, 2008	Mar	CAHN
----	---------------	-------------	---------	-----	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

AP	+	AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750	001		Jun	CAHN
----	---	----------------------	-------------	---------	-----	--	-----	------

>A> CRIZOTINIB

>A> CAPSULE; ORAL

>A> XALKORI

>A>	PFIZER	200MG	N202570	001	Aug 26, 2011	Aug	NEWA
-----	--------	-------	---------	-----	--------------	-----	------

>A>	+	250MG	N202570	002	Aug 26, 2011	Aug	NEWA
-----	---	-------	---------	-----	--------------	-----	------

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

>D>	AN	ACTAVIS MID ATLANTIC	10MG/ML	A075067	001	Jul 19, 1999	Aug	DISC
-----	----	----------------------	---------	---------	-----	--------------	-----	------

>A>	@	10MG/ML	A075067	001	Jul 19, 1999	Aug	DISC
-----	---	---------	---------	-----	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB	ANESTA AG	15MG	N021777	001	Feb 01, 2007	Apr	CFTG
----	-----------	------	---------	-----	--------------	-----	------

AB	+	30MG	N021777	002	Feb 01, 2007	Apr	CFTG
----	---	------	---------	-----	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN	15MG	A090738	001	Apr 18, 2011	Apr	NEWA
----	-------	------	---------	-----	--------------	-----	------

AB		30MG	A090738	002	Apr 18, 2011	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006	Jan	CAHN
----	------------------	-----	---------	-----	--------------	-----	------

AB		10MG	A077563	002	Apr 19, 2006	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

AB	KVK TECH	5MG	A078048	001	Feb 28, 2011	Feb	NEWA
----	----------	-----	---------	-----	--------------	-----	------

AB		10MG	A078048	002	Feb 28, 2011	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
----	-------------	-----	---------	-----	--------------	-----	------

AB		10MG	A077209	001	Oct 04, 2005	Feb	CAHN
----	--	------	---------	-----	--------------	-----	------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

>D>	AP	BAXTER HLTHCARE	500MG/VIAL	A040745	001	May 21, 2008	Aug	CRLD
-----	----	-----------------	------------	---------	-----	--------------	-----	------

>A>	AP	+	500MG/VIAL	A040745	001	May 21, 2008	Aug	CRLD
-----	----	---	------------	---------	-----	--------------	-----	------

>D>	AP		1GM/VIAL	A040745	002	May 21, 2008	Aug	CRLD
-----	----	--	----------	---------	-----	--------------	-----	------

>A>	AP	+	1GM/VIAL	A040745	002	May 21, 2008	Aug	CRLD
-----	----	---	----------	---------	-----	--------------	-----	------

>D>	AP		2GM/VIAL	A040745	003	May 21, 2008	Aug	CRLD
-----	----	--	----------	---------	-----	--------------	-----	------

>A>	AP	+	2GM/VIAL	A040745	003	May 21, 2008	Aug	CRLD
-----	----	---	----------	---------	-----	--------------	-----	------

CYTOXAN

>D>	AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142	003	Aug	CRLD
-----	----	---	-----------------	------------	---------	-----	-----	------

>A>	AP		500MG/VIAL	N012142	003		Aug	CRLD
-----	----	--	------------	---------	-----	--	-----	------

>D>	AP	+	1GM/VIAL	N012142	004	Aug 30, 1982	Aug	CRLD
-----	----	---	----------	---------	-----	--------------	-----	------

>A>	AP		1GM/VIAL	N012142	004	Aug 30, 1982	Aug	CRLD
-----	----	--	----------	---------	-----	--------------	-----	------

>D>	AP	+	2GM/VIAL	N012142	005	Aug 30, 1982	Aug	CRLD
-----	----	---	----------	---------	-----	--------------	-----	------

>A>	AP		2GM/VIAL	N012142	005	Aug 30, 1982	Aug	CRLD
-----	----	--	----------	---------	-----	--------------	-----	------

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

@ ACTAVIS TOTOWA	25MG	A076686 001	Oct 24, 2005	Jul	DISC
@	50MG	A076686 002	Oct 24, 2005	Jul	DISC
@	100MG	A076686 003	Oct 24, 2005	Jul	DISC

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513 001	Dec 22, 2004	May	CAHN
+	EQ 15MG BASE	N021513 002	Dec 22, 2004	May	CAHN

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

@ TIBOTEC	EQ 300MG BASE	N021976 001	Jun 23, 2006	May	DISC
-----------	---------------	-------------	--------------	-----	------

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

+	GALEN (UK)	EQ 2MG BASE/ML	N050704 002	Apr 08, 1996	Jun	CAHN
---	------------	----------------	-------------	--------------	-----	------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

@ COREPHARMA	75MG	N050261 001		May	CAHN
AB	150MG	N050261 002		May	CAHN
AB +	300MG	N050261 003		May	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

AB	VERSAPHARM	150MG	A065389 001	Dec 01, 2008	May	CAHN
AB		300MG	A065389 002	Dec 01, 2008	May	CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

>A>	AB	ACTAVIS TOTOWA	50MG	A071588 001	Jun 05, 1987	Aug	CAHN
>D>	AB	AMIDE PHARM	50MG	A071588 001	Jun 05, 1987	Aug	CAHN

DESLORATADINE

TABLET; ORAL

DESLORATADINE

AB	DR REDDYS LABS LTD	5MG	A078365 001	Mar 08, 2011	Feb	NEWA
----	--------------------	-----	-------------	--------------	-----	------

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

AB	+	SCHERING	5MG;240MG	N021605 001	Mar 03, 2005	Apr	CFTG
----	---	----------	-----------	-------------	--------------	-----	------

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

AB		DR REDDYS LABS LTD	5MG;240MG	A078366 001	Apr 26, 2011	Apr	NEWA
----	--	--------------------	-----------	-------------	--------------	-----	------

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

STIMATE

@ CSL BEHRING	0.15MG/SPRAY	N020355 001	Mar 07, 1994	May	DISC
---------------	--------------	-------------	--------------	-----	------

DESGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

AB	VINTAGE	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Feb	NEWA
----	---------	---------------	---------	-----	--------------	-----	------

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB	VERSAPHARM	0.05%	A090727	001	Mar 10, 2011	Feb	NEWA
----	------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

TOPICORT

+	TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985	May	CMFD
---	-------------------	-------	---------	-----	--------------	-----	------

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	LYNE	0.5MG/5ML	A090891	001	Jul 12, 2011	Jun	NEWA
----	------	-----------	---------	-----	--------------	-----	------

AA	VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011	Apr	NEWA
----	----------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

DEXAMETHASONE

>D>	@ PAR PHARM	0.5MG	A088148	001	Apr 28, 1983	Aug	CMFD
-----	-------------	-------	---------	-----	--------------	-----	------

>A>	BP	0.5MG	A088148	001	Apr 28, 1983	Aug	CMFD
-----	----	-------	---------	-----	--------------	-----	------

>D>	@	0.75MG	A088160	001	Apr 28, 1983	Aug	CMFD
-----	---	--------	---------	-----	--------------	-----	------

>A>	BP	0.75MG	A088160	001	Apr 28, 1983	Aug	CMFD
-----	----	--------	---------	-----	--------------	-----	------

>D>	@	1.5MG	A088237	001	Apr 28, 1983	Aug	CMFD
-----	---	-------	---------	-----	--------------	-----	------

>A>	BP	1.5MG	A088237	001	Apr 28, 1983	Aug	CMFD
-----	----	-------	---------	-----	--------------	-----	------

>D>	@	4MG	A088238	001	Apr 28, 1983	Aug	CMFD
-----	---	-----	---------	-----	--------------	-----	------

>A>	BP	4MG	A088238	001	Apr 28, 1983	Aug	CMFD
-----	----	-----	---------	-----	--------------	-----	------

>D>	@	6MG	A088481	001	Nov 28, 1983	Aug	CMFD
-----	---	-----	---------	-----	--------------	-----	------

>A>	BP	6MG	A088481	001	Nov 28, 1983	Aug	CMFD
-----	----	-----	---------	-----	--------------	-----	------

>D>	ROXANE	0.5MG	A084611	001		Aug	CTEC
-----	--------	-------	---------	-----	--	-----	------

>A>	BP	0.5MG	A084611	001		Aug	CTEC
-----	----	-------	---------	-----	--	-----	------

>D>		0.75MG	A084613	001		Aug	CTEC
-----	--	--------	---------	-----	--	-----	------

>A>	BP	0.75MG	A084613	001		Aug	CTEC
-----	----	--------	---------	-----	--	-----	------

>D>		1MG	A088306	001	Sep 15, 1983	Aug	CTEC
-----	--	-----	---------	-----	--------------	-----	------

>A>	BP	1MG	A088306	001	Sep 15, 1983	Aug	CTEC
-----	----	-----	---------	-----	--------------	-----	------

>D>		2MG	A087916	001	Aug 26, 1982	Aug	CTEC
-----	--	-----	---------	-----	--------------	-----	------

>A>	BP	2MG	A087916	001	Aug 26, 1982	Aug	CTEC
-----	----	-----	---------	-----	--------------	-----	------

>D>		4MG	A084612	001		Aug	CTEC
-----	--	-----	---------	-----	--	-----	------

>A>	BP	4MG	A084612	001		Aug	CTEC
-----	----	-----	---------	-----	--	-----	------

>D>	+	6MG	A088316	001	Sep 15, 1983	Aug	CTEC
-----	---	-----	---------	-----	--------------	-----	------

>A>	BP +	6MG	A088316	001	Sep 15, 1983	Aug	CTEC
-----	------	-----	---------	-----	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	PFIZER	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	May	CAHN
----	--------	---------------------	---------	-----	--------------	-----	------

AP		EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	May	CAHN
----	--	----------------------	---------	-----	--------------	-----	------

>D>	AP +	TEVA PARENTERAL	EQ 10MG PHOSPHATE/ML	A081126	001	Aug 31, 1990	Aug	DISC
-----	------	-----------------	----------------------	---------	-----	--------------	-----	------

>A>	@	EQ 10MG PHOSPHATE/ML	A081126	001	Aug 31, 1990	Aug	DISC
-----	---	----------------------	---------	-----	--------------	-----	------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938 001	Jul 31, 1989	Feb	CAHN
AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938 001	Jul 31, 1989	Jan	CAHN

DEXTMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

	NOVARTIS	25MG	N021802 008	Apr 21, 2011	May	NEWA
		35MG	N021802 007	Apr 21, 2011	May	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	COREPHARMA	5MG	N017078 001		Jun	CAHN
AB		10MG	N017078 002		Jun	CAHN
AB	+	15MG	N017078 003		Jun	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575 001	Feb 08, 2011	Jan	NEWA
----	---------------	---------------------	-------------	--------------	-----	------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634 004		Jun	CAHN
----	-----------------	----------------------	-------------	--	-----	------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634 001		Jun	CAHN
----	-----------------	-----------------------	-------------	--	-----	------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634 003		Jun	CAHN
----	-----------------	-----------------------	-------------	--	-----	------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634 002		Jun	CAHN
----	-----------------	-----------------------	-------------	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>	HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML	N019514 001	May 08, 1986	Aug	DISC
>D>		;146MG/100ML;207MG/100ML				
>A>	@	5GM/100ML;111MG/100ML;256MG/100ML	N019514 001	May 08, 1986	Aug	DISC
>A>		;146MG/100ML;207MG/100ML				

DIAZEPAM

TABLET; ORAL

DIAZEPAM

>D>	AB	ACTAVIS ELIZABETH	2MG	A070781 001	Mar 19, 1986	Aug	DISC
>A>		@	2MG	A070781 001	Mar 19, 1986	Aug	DISC
>D>	AB		5MG	A070706 001	Mar 19, 1986	Aug	DISC
>A>		@	5MG	A070706 001	Mar 19, 1986	Aug	DISC
>D>	AB		10MG	A070707 001	Mar 19, 1986	Aug	DISC
>A>		@	10MG	A070707 001	Mar 19, 1986	Aug	DISC

DICLOFENAC SODIUM

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB	VALEANT INTL	100MG	A075492	001	Feb 11, 2000	Apr	CAHN
----	--------------	-------	---------	-----	--------------	-----	------

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

AA	LANNETT HOLDINGS INC	25MG	A200177	001	Jul 18, 2011	Jul	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

+	ALCON PHARMS LTD	0.05%	N022212	001	Jun 23, 2008	May	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

DIGOXIN

TABLET; ORAL

DIGOXIN

@ ACTAVIS TOTOWA 0.125MG

A040282	001	Dec 23, 1999	Jul	DISC
---------	-----	--------------	-----	------

@ 0.25MG

A040282	002	Dec 23, 1999	Jul	DISC
---------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

AB3	VALEANT INTL	120MG	N020062	001	Aug 10, 1992	Jun	CAHN
AB3		180MG	N020062	002	Dec 27, 1991	Jun	CAHN
AB3		240MG	N020062	003	Dec 27, 1991	Jun	CAHN
AB3	+	300MG	N020062	004	Dec 27, 1991	Jun	CAHN
BC	+	360MG	N020062	005	Aug 24, 1999	Jun	CAHN

DILTIAZEM HYDROCHLORIDE

AB3	VALEANT INTL	120MG	A075116	001	Dec 23, 1999	Apr	CAHN
AB3		180MG	A075116	002	Dec 23, 1999	Apr	CAHN
AB3		240MG	A075116	003	Dec 23, 1999	Apr	CAHN
AB3		300MG	A075116	004	Dec 23, 1999	Apr	CAHN

TIAZAC

AB4	VALEANT INTL	120MG	N020401	001	Sep 11, 1995	Jun	CAHN
AB4		180MG	N020401	002	Sep 11, 1995	Jun	CAHN
AB4		240MG	N020401	003	Sep 11, 1995	Jun	CAHN
AB4		300MG	N020401	004	Sep 11, 1995	Jun	CAHN
AB4		360MG	N020401	005	Sep 11, 1995	Jun	CAHN
AB4	+	420MG	N020401	006	Oct 16, 1998	Jun	CAHN

TABLET; ORAL

CARDIZEM

AB	VALEANT INTL	30MG	N018602	001	Nov 05, 1982	Jun	CAHN
AB		60MG	N018602	002	Nov 05, 1982	Jun	CAHN
AB		90MG	N018602	003	Dec 08, 1986	Jun	CAHN
AB	+	120MG	N018602	004	Dec 08, 1986	Jun	CAHN

DILTIAZEM HYDROCHLORIDE

>D>	AB	MYLAN	30MG	A073185	001	Nov 05, 1992	Aug	CMS2
>A>	AB		30MG	A072838	004	Nov 05, 1992	Aug	CMS1
>A>		@	30MG	A073185	001	Nov 05, 1992	Aug	CMS2
>D>	AB		60MG	A073186	001	Nov 05, 1992	Aug	CMS2
>A>	AB		60MG	A072838	003	Nov 05, 1992	Aug	CMS1
>A>		@	60MG	A073186	001	Nov 05, 1992	Aug	CMS2
>D>	AB		90MG	A072837	001	Nov 05, 1992	Aug	CMS2

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

>A>		@ MYLAN	90MG	A072837	001	Nov 05, 1992	Aug	CMS2
>A>	AB		90MG	A072838	002	Nov 05, 1992	Aug	CMS1

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

AB	VALEANT INTL	120MG	N021392	001	Feb 06, 2003	Jun	CAHN
AB		180MG	N021392	002	Feb 06, 2003	Jun	CAHN
AB		240MG	N021392	003	Feb 06, 2003	Jun	CAHN
AB		300MG	N021392	004	Feb 06, 2003	Jun	CAHN
AB		360MG	N021392	005	Feb 06, 2003	Jun	CAHN
AB	+	420MG	N021392	006	Feb 06, 2003	Jun	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

>D>								
>D>	AP	HOSPIRA	5MG/ML	A074601	001	Dec 19, 1997	Aug	DISC
>A>		@	5MG/ML	A074601	001	Dec 19, 1997	Aug	DISC

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542	002	Apr 21, 2006	Feb	CAHN
AB		75MG	A040542	003	Apr 21, 2006	Feb	CAHN

DISULFIRAM

TABLET; ORAL

ANTABUSE

AB	ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983	Mar	CTEC
AB	+	500MG	A088483	001	Dec 08, 1983	Mar	CTEC

DISULFIRAM

AB	SIGMAPHARM LABS LLC	250MG	A091619	001	Mar 28, 2011	Mar	NEWA
AB		500MG	A091619	002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DIVALPROEX SODIUM

AB	MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Mar	NEWA
----	-------	------------------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB	AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554	001	Apr 21, 2011	Apr	NEWA
AB		EQ 250MG VALPROIC ACID	A090554	002	Apr 21, 2011	Apr	NEWA
AB		EQ 500MG VALPROIC ACID	A090554	003	Apr 21, 2011	Apr	NEWA
AB	UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163	001	Apr 05, 2011	Mar	NEWA
AB		EQ 250MG VALPROIC ACID	A079163	002	Apr 05, 2011	Mar	NEWA
AB		EQ 500MG VALPROIC ACID	A079163	003	Apr 05, 2011	Mar	NEWA
AB	WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080	001	Feb 25, 2011	Feb	NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995	Aug	CRLD
>A>	AP	+	EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995	Aug	CRLD
>D>	AP	TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993	Aug	DISC
>A>		@	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993	Aug	DISC

DOCETAXEL

INJECTABLE; INJECTION

DOCEFREZ

+	SUN PHARMA GLOBAL	20MG/VIAL	N022534 001	May 03, 2011	May	NEWA
+		80MG/VIAL	N022534 002	May 03, 2011	May	NEWA

DOCETAXEL

	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jun	NEWA	
		80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jun	NEWA	
AP	+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234 001	Mar 08, 2011	Jun	CTEC
	+		20MG/2ML (10MG/ML)	N022234 001	Mar 08, 2011	Mar	NEWA
AP	+		80MG/8ML (10MG/ML)	N022234 002	Mar 08, 2011	Jun	CTEC
	+		80MG/8ML (10MG/ML)	N022234 002	Mar 08, 2011	Mar	NEWA
AP	+		160MG/16ML (10MG/ML)	N022234 003	Mar 08, 2011	Jun	CTEC
	+		160MG/16ML (10MG/ML)	N022234 003	Mar 08, 2011	Mar	NEWA
AP		SANDOZ	20MG/2ML (10MG/ML)	N201525 001	Jun 29, 2011	Jun	NEWA
AP			80MG/8ML (10MG/ML)	N201525 002	Jun 29, 2011	Jun	NEWA
AP			160MG/16ML (10MG/ML)	N201525 003	Jun 29, 2011	Jun	NEWA

TAXOTERE

@	SANOFI AVENTIS US	40MG/ML	N020449 001	May 14, 1996	Mar	DISC
---	-------------------	---------	-------------	--------------	-----	------

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	ACCORD HLTHCARE	5MG	A201335 001	Aug 29, 2011	Aug	NEWA
>A>	AB		10MG	A201335 002	Aug 29, 2011	Aug	NEWA
	AB	ACTAVIS PHARMA	5MG	A090551 001	May 31, 2011	May	NEWA
	AB		10MG	A090551 002	May 31, 2011	May	NEWA
	AB	APOTEX	5MG	A078841 001	Jun 02, 2011	May	NEWA
	AB		10MG	A078841 002	Jun 02, 2011	May	NEWA
	AB	AUROBINDO	5MG	A090056 001	May 31, 2011	May	NEWA
	AB		10MG	A090056 002	May 31, 2011	May	NEWA
	AB	CIPLA LTD	5MG	A077518 001	May 31, 2011	May	NEWA
	AB		10MG	A077518 002	May 31, 2011	May	NEWA
	AB	DR REDDYS LABS LTD	5MG	A201001 001	May 31, 2011	May	NEWA
	AB		10MG	A201001 002	May 31, 2011	May	NEWA
	AB	HIKMA PHARMS	5MG	A090247 001	May 31, 2011	May	NEWA
	AB		10MG	A090247 002	May 31, 2011	May	NEWA
	AB	HUAHAI US INC	5MG	A200292 001	May 31, 2011	May	NEWA
	AB		10MG	A200292 002	May 31, 2011	May	NEWA
	AB	JUBILANT LIFE	5MG	A090768 001	May 31, 2011	May	NEWA
	AB		10MG	A090768 002	May 31, 2011	May	NEWA
	AB	MATRIX LABS LTD	5MG	A090521 001	May 31, 2011	May	NEWA
	AB		10MG	A090521 002	May 31, 2011	May	NEWA
	AB	PLIVA HRVATSKA DOO	5MG	A090425 001	May 31, 2011	May	NEWA
	AB		10MG	A090425 002	May 31, 2011	May	NEWA
	AB	ROXANE	5MG	A078662 001	May 31, 2011	May	NEWA
	AB		10MG	A078662 002	May 31, 2011	May	NEWA
	AB	SANDOZ	5MG	A090290 001	May 31, 2011	May	NEWA
	AB		10MG	A090290 002	May 31, 2011	May	NEWA
	AB	SUN PHARM INDS	5MG	A090493 001	May 31, 2011	May	NEWA
	AB		10MG	A090493 002	May 31, 2011	May	NEWA
	AB	TEVA	5MG	A077344 001	May 31, 2011	May	NEWA
	AB		10MG	A077344 002	May 31, 2011	May	NEWA
	AB	TORRENT PHARMS	5MG	A090686 001	May 31, 2011	May	NEWA
	AB		10MG	A090686 002	May 31, 2011	May	NEWA

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	WOCKHARDT	5MG	A091267	001	May 31, 2011	May	NEWA
AB		10MG	A091267	002	May 31, 2011	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

AB	SANDOZ	5MG	A091198	001	May 10, 2011	Apr	NEWA
AB		10MG	A091198	002	May 10, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011	Apr	NEWA
AB		10MG	A090175	002	May 10, 2011	Apr	NEWA

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

>D>	AB	ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000	Aug	DISC
>A>		@	EQ 1MG BASE	A075574	001	Oct 18, 2000	Aug	DISC
>D>	AB		EQ 2MG BASE	A075574	002	Oct 18, 2000	Aug	DISC
>A>		@	EQ 2MG BASE	A075574	002	Oct 18, 2000	Aug	DISC
>D>	AB		EQ 4MG BASE	A075574	003	Oct 18, 2000	Aug	DISC
>A>		@	EQ 4MG BASE	A075574	003	Oct 18, 2000	Aug	DISC
>D>	AB		EQ 8MG BASE	A075574	004	Oct 18, 2000	Aug	DISC
>A>		@	EQ 8MG BASE	A075574	004	Oct 18, 2000	Aug	DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Jan	NEWA
AB	MYLAN	40MG	A090855	001	Jul 01, 2010	Jan	CDFR
AB	+ PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005	Feb	CTEC
AB	+	EQ 150MG BASE	A065055	003	Jul 15, 2005	Jan	CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB	WATSON LABS FLORIDA	EQ 50MG BASE	A062031	002	Oct 13, 1982	May	CAHN
AB		EQ 100MG BASE	A062031	001		May	CAHN

DRONABINOL

CAPSULE; ORAL

DRONABINOL

>A>	AB	INSYS THERAP	2.5MG	A078501	001	Aug 19, 2011	Aug	NEWA
>A>	AB		5MG	A078501	002	Aug 19, 2011	Aug	NEWA
>A>	AB		10MG	A078501	003	Aug 19, 2011	Aug	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

LORYNA

AB	SANDOZ	3MG;0.02MG	A079221	001	Mar 28, 2011	Mar	NEWA
----	--------	------------	---------	-----	--------------	-----	------

TABLET; ORAL-28

SYEDA

AB	SANDOZ	3MG;0.03MG	A090114	001	Mar 28, 2011	Mar	NEWA
----	--------	------------	---------	-----	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

SPECTAZOLE

@ ORTHO JANSSEN

1%

N018751	001	Dec 23, 1982	Jul	CAHN
---------	-----	--------------	-----	------

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

>D> EDROPHONIUM CHLORIDE

>D> AP HOSPIRA 10MG/ML A040131 001 Feb 24, 1998 Aug DISC

>A> @ 10MG/ML A040131 001 Feb 24, 1998 Aug DISC

>A> EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE

>A> TABLET; ORAL

>A> COMPLERA

>A> + GILEAD SCIENCES INC 200MG;25MG;300MG N202123 001 Aug 10, 2011 Aug NEWA

ENALAPRIL MALEATE

TABLET; ORAL

VASOTEC

AB VALEANT INTL 2.5MG N018998 005 Jul 26, 1988 Jun CAHN

AB 5MG N018998 001 Dec 24, 1985 Jun CAHN

AB 10MG N018998 002 Dec 24, 1985 Jun CAHN

AB + 20MG N018998 003 Dec 24, 1985 Jun CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB VALEANT INTL 5MG;12.5MG N019221 003 Jul 12, 1995 Jun CAHN

AB + 10MG;25MG N019221 001 Oct 31, 1986 Jun CAHN

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

LOVENOX

SANOFI AVENTIS US 300MG/3ML (100MG/ML) N020164 009 Jan 23, 2003 Feb CDFR

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT + ALLERGAN 0.05% N021565 001 Oct 16, 2003 Feb CFTG

EPINASTINE HYDROCHLORIDE

AT CYPRESS PHARM 0.05% A090870 001 Mar 14, 2011 Feb NEWA

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

>D> + DENTSPLY PHARM 0.005MG/ML;4% N021383 001 Aug CFTG

>A> AP + 0.005MG/ML;4% N021383 001 Aug CFTG

>A> PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

>A> AP SEPTODONT INC 0.005MG/ML;4% A078959 001 Aug 30, 2011 Aug NEWA

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP MUSTAFA NEVSAT 200MG/100ML (2MG/ML) A090266 002 Apr 15, 2011 Apr NEWA

AP 50MG/25ML (2MG/ML) A090266 001 Apr 15, 2011 Apr NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

>D> EPOPROSTENOL SODIUM

>D> + ACTELION EQ 1.5MG BASE/VIAL N022260 001 Jun 27, 2008 Aug CTNA

INJECTABLE; INJECTION

>A> VELETRI
 >A> + ACTELION EQ 1.5MG BASE/VIAL N022260 001 Jun 27, 2008 Aug CTNA

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB ARBOR PHARMS INC 250MG A062746 001 Dec 22, 1986 Jan CAHN

GEL; TOPICAL

E-GLADES

AT COREPHARMA 2% A065009 001 Mar 18, 2002 Apr CAHN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT + FERA PHARMS 0.5% A062447 001 Sep 26, 1983 Feb CAHN

AT + NYCOMED US 0.5% A062447 001 Sep 26, 1983 Jan CAHN

SOLUTION; TOPICAL

ERYDERM

@ ARBOR PHARMS INC

2%

A062290 001 Jan CAHN

ERYTHROMYCIN

@ COREPHARMA

2%

A064127 001 Feb 14, 1997 Apr CAHN

SWAB; TOPICAL

ERYCETTE

@ ORTHO JANSSEN

2%

N050594 001 Feb 15, 1985 Jul CAHN

ERYTHROMYCIN

@ COREPHARMA

2%

A064128 001 Jul 03, 1996 Apr CAHN

TABLET; ORAL

ERYTHROMYCIN

ARBOR PHARMS INC

250MG

A061621 001 Jan CAHN

+

500MG

A061621 002 Jan CAHN

TABLET, COATED PARTICLES; ORAL

PCE

ARBOR PHARMS INC

333MG

N050611 001 Sep 09, 1986 Jan CAHN

+

500MG

N050611 002 Aug 22, 1990 Jan CAHN

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

@ ARBOR PHARMS INC

250MG

A060272 001 Jan CAHN

@

333MG

A060272 002 Jan CAHN

ERY-TAB

+ ARBOR PHARMS INC

250MG

A062298 001 Jan CAHN

+

333MG

A062298 003 Mar 29, 1982 Jan CAHN

+

500MG

A062298 002 Jan CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB ARBOR PHARMS INC EQ 200MG BASE/5ML N050207 001 Jan CAHN

ERYPED

AB ARBOR PHARMS INC EQ 200MG BASE/5ML N050207 003 Mar 30, 1987 Jan CAHN

+

EQ 400MG BASE/5ML

N050207 002 Jan CAHN

SUSPENSION; ORAL

E.E.S. 200

AB ARBOR PHARMS INC EQ 200MG BASE/5ML A061639 001 Jan CAHN

E.E.S. 400

AB + ARBOR PHARMS INC EQ 400MG BASE/5ML A061639 002 Jan CAHN

PEDIAMYCIN

AB ARBOR PHARMS INC EQ 200MG BASE/5ML A062304 001 Jan CAHN

SUSPENSION; ORAL

PEDIAMYCIN 400

AB	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304 002	Jan	CAHN
----	------------------	-------------------	-------------	-----	------

TABLET; ORAL

E.E.S. 400

	@ ARBOR PHARMS INC	EQ 400MG BASE	A061905 001	Jan	CAHN
--	--------------------	---------------	-------------	-----	------

BX	+	EQ 400MG BASE	A061905 002	Aug 12, 1982	Jan CAHN
----	---	---------------	-------------	--------------	----------

ERYTHROMYCIN ETHYLSUCCINATE

BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061904 001	Jan CAHN
----	---	------------------	---------------	-------------	----------

TABLET, CHEWABLE; ORAL

E.E.S.

	@ ARBOR PHARMS INC	EQ 200MG BASE	N050297 002	Jan	CAHN
--	--------------------	---------------	-------------	-----	------

ERYPED

	@ ARBOR PHARMS INC	EQ 200MG BASE	N050297 003	Jul 05, 1988	Jan CAHN
--	--------------------	---------------	-------------	--------------	----------

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

	@ ARBOR PHARMS INC	EQ 125MG BASE	A060359 002	Jan	CAHN
--	--------------------	---------------	-------------	-----	------

>D>		EQ 250MG BASE	A060359 001	Aug	CRLD
-----	--	---------------	-------------	-----	------

>A>	+	EQ 250MG BASE	A060359 001	Aug	CRLD
-----	---	---------------	-------------	-----	------

		EQ 250MG BASE	A060359 001	Jan	CAHN
--	--	---------------	-------------	-----	------

>D>	+	EQ 500MG BASE	A060359 003	Aug	DISC
-----	---	---------------	-------------	-----	------

>A>	@	EQ 500MG BASE	A060359 003	Aug	DISC
-----	---	---------------	-------------	-----	------

	+	EQ 500MG BASE	A060359 003	Jan	CAHN
--	---	---------------	-------------	-----	------

ESTRADIOL

TABLET; ORAL

ESTRACE

>D>	AB	BRISTOL MYERS SQUIBB	0.5MG	A081295 001	Jun 30, 1993 Aug DISC
-----	----	----------------------	-------	-------------	-----------------------

>A>	@	0.5MG	A081295 001	Jun 30, 1993 Aug	DISC
-----	---	-------	-------------	------------------	------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

AB	NOVO NORDISK INC	0.5MG;0.1MG	N020907 002	Dec 28, 2006	Mar CTEC
----	------------------	-------------	-------------	--------------	----------

ESTRADIOL AND NORETHINDRONE ACETATE

AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324 002	Jun 09, 2011	May NEWA
----	--------------------	-------------	-------------	--------------	----------

ESTROPIPATE

CREAM; VAGINAL

OGEN

	@ PHARMACIA AND UPJOHN	1.5MG/GM	A084710 001	Apr	DISC
--	------------------------	----------	-------------	-----	------

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

>A>	AB	LUPIN LTD	1MG	A091124 001	Sep 13, 2011 Aug NEWA
-----	----	-----------	-----	-------------	-----------------------

>A>	AB		2MG	A091124 002	Sep 13, 2011 Aug NEWA
-----	----	--	-----	-------------	-----------------------

>A>	AB		3MG	A091124 003	Sep 13, 2011 Aug NEWA
-----	----	--	-----	-------------	-----------------------

	@ TEVA	1MG	A091169 001	May 23, 2011	Jun DISC
--	--------	-----	-------------	--------------	----------

AB		1MG	A091169 001	May 23, 2011	May NEWA
----	--	-----	-------------	--------------	----------

	@	2MG	A091169 002	May 23, 2011	Jun DISC
--	---	-----	-------------	--------------	----------

AB		2MG	A091169 002	May 23, 2011	May NEWA
----	--	-----	-------------	--------------	----------

	@	3MG	A091169 003	May 23, 2011	Jun DISC
--	---	-----	-------------	--------------	----------

AB		3MG	A091169 003	May 23, 2011	May NEWA
----	--	-----	-------------	--------------	----------

TABLET; ORAL

ESZOPICLONE

@ WOCKHARDT LTD

1MG

A091165 001 Jul 14, 2011 Jul NEWA

@

2MG

A091165 002 Jul 14, 2011 Jul NEWA

@

3MG

A091165 003 Jul 14, 2011 Jul NEWA

LUNESTA

>D> SUNOVION PHARMS INC

1MG

N021476 001 Dec 15, 2004 Aug CTEC

>A> AB

1MG

N021476 001 Dec 15, 2004 Aug CTEC

1MG

N021476 001 Dec 15, 2004 Jun CTEC

AB

1MG

N021476 001 Dec 15, 2004 May CFTG

>D>

2MG

N021476 002 Dec 15, 2004 Aug CTEC

>A> AB

2MG

N021476 002 Dec 15, 2004 Aug CTEC

2MG

N021476 002 Dec 15, 2004 Jun CTEC

AB

2MG

N021476 002 Dec 15, 2004 May CFTG

>D>

+

3MG

N021476 003 Dec 15, 2004 Aug CTEC

>A> AB

+

3MG

N021476 003 Dec 15, 2004 Aug CTEC

+

3MG

N021476 003 Dec 15, 2004 Jun CTEC

AB

+

3MG

N021476 003 Dec 15, 2004 May CFTG

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB WATSON LABS

0.02MG;0.09MG

A079218 001 Jun 06, 2011 May NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB WATSON LABS

0.03MG,0.01MG;0.15MG,N/A

A078834 001 May 31, 2011 May NEWA

LOSEASONIQUE

>D> DURAMED

0.02MG,0.01MG;0.1MG,N/A

N022262 001 Oct 24, 2008 Aug CAHN

>A> TEVA WOMENS

0.02MG,0.01MG;0.1MG,N/A

N022262 001 Oct 24, 2008 Aug CAHN

LYBREL

AB + WYETH PHARMS INC

0.02MG;0.09MG

N021864 001 May 22, 2007 May CFTG

SEASONIQUE

AB + TEVA WOMENS

0.03MG,0.01MG;0.15MG,N/A

N021840 001 May 25, 2006 May CFTG

TABLET; ORAL-21

ALESSE

>D> @ AKRIMAX PHARMS

0.02MG;0.1MG

N020683 001 Mar 27, 1997 Aug CAHN

@

0.02MG;0.1MG

N020683 001 Mar 27, 1997 Jul CAHN

>A> @ WYETH PHARMS

0.02MG;0.1MG

N020683 001 Mar 27, 1997 Aug CAHN

TRIPHASIL-21

>D> @ AKRIMAX PHARMS

0.03MG,0.04MG,0.03MG;0.05MG,0.075
MG,0.125MG

N019192 001 Nov 01, 1984 Aug CAHN

>A> @ WYETH PHARMS

0.03MG,0.04MG,0.03MG;0.05MG,0.075
MG,0.125MG

N019192 001 Nov 01, 1984 Aug CAHN

TABLET; ORAL-28

ALESSE

>D> @ AKRIMAX PHARMS

0.02MG;0.1MG

N020683 002 Mar 27, 1997 Aug CAHN

@

0.02MG;0.1MG

N020683 002 Mar 27, 1997 Jul CAHN

>A> @ WYETH PHARMS

0.02MG;0.1MG

N020683 002 Mar 27, 1997 Aug CAHN

ORSYTHIA

AB1 VINTAGE PHARMS

0.02MG;0.1MG

A077099 001 May 11, 2011 Apr NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

BRIELLYN

AB GLENMARK GENERICS

0.035MG;0.4MG

A090538 001 Mar 22, 2011 Mar NEWA

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

+ WARNER CHILCOTT

0.025MG;0.8MG

N022573 001 Dec 22, 2010 Jan CRLD

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

+	WATSON LABS INC	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jun	CAHN
---	-----------------	---------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

LO LOESTRIN FE

+	WARNER CHILCOTT CO	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May	CRLD
---	--------------------	-----------------------	---------	-----	--------------	-----	------

TABLET; ORAL-28

GILDESS FE 1.5/30

AB	VINTAGE	0.03MG;1.5MG	A077075	001	Apr 28, 2005	Jan	CTNA
----	---------	--------------	---------	-----	--------------	-----	------

GILDESS FE 1/20

AB	VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005	Jan	CTNA
----	---------	------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494	001	Jun 17, 2011	Jun	NEWA
----	-------------------	---	---------	-----	--------------	-----	------

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011	Feb	NEWA
----	-------------	---	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

OVRAL

>D>	@ AKRIMAX PHARMS	0.05MG;0.5MG	N016672	001		Aug	CAHN
-----	------------------	--------------	---------	-----	--	-----	------

>A>	@ WYETH PHARMS	0.05MG;0.5MG	N016672	001		Aug	CAHN
-----	----------------	--------------	---------	-----	--	-----	------

TABLET; ORAL-28

LO/OVRAL-28

>D>	AB	AKRIMAX PHARMS	0.03MG;0.3MG	N017802	001	Aug	CAHN
-----	----	----------------	--------------	---------	-----	-----	------

>A>	AB	WYETH PHARMS	0.03MG;0.3MG	N017802	001	Aug	CAHN
-----	----	--------------	--------------	---------	-----	-----	------

OVRAL-28

>A>	@ WYETH PHARMS	0.05MG;0.5MG	N016806	001		Aug	CAHN
-----	----------------	--------------	---------	-----	--	-----	------

>D>	@ WYETH PHARMS INC	0.05MG;0.5MG	N016806	001		Aug	CAHN
-----	--------------------	--------------	---------	-----	--	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	VERSAPHARM	250MG	A040686	001	May 28, 2008	May	CAHN
----	------------	-------	---------	-----	--------------	-----	------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

@ MYLAN

200MG

A075071	001	Sep 30, 1998	Feb	CAHN
---------	-----	--------------	-----	------

@

300MG

A075071	002	Sep 30, 1998	Feb	CAHN
---------	-----	--------------	-----	------

TABLET; ORAL

ETODOLAC

>D>	AB	ACTAVIS ELIZABETH	400MG	A074819	001	Feb 28, 1997	Aug	DISC
-----	----	-------------------	-------	---------	-----	--------------	-----	------

>A>	@		400MG	A074819	001	Feb 28, 1997	Aug	DISC
-----	---	--	-------	---------	-----	--------------	-----	------

@ MYLAN

400MG

A075012	001	Sep 30, 1998	Feb	CAHN
---------	-----	--------------	-----	------

@

500MG

A075012	002	Sep 30, 1998	Feb	CAHN
---------	-----	--------------	-----	------

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011	May	NEWA
---	-----------------	--------------	---------	-----	--------------	-----	------

ETRAVIRINE

TABLET; ORAL

INTELENCE

	TIBOTEC	100MG	N022187	001	Jan 18, 2008	Jan	CRLD
--	---------	-------	---------	-----	--------------	-----	------

+		200MG	N022187	002	Dec 22, 2010	Jan	NEWA
---	--	-------	---------	-----	--------------	-----	------

EXEMESTANE

TABLET; ORAL

AROMASIN

AB	+	PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999	Mar	CFTG
----	---	----------------------	------	---------	-----	--------------	-----	------

EXEMESTANE

AB		ROXANE	25MG	A077431	001	Apr 01, 2011	Mar	NEWA
----	--	--------	------	---------	-----	--------------	-----	------

EZOGABINE

TABLET; ORAL

POTIGA

	VALEANT PHARMS	50MG	N022345	001	Jun 10, 2011	Jun	NEWA
--	----------------	------	---------	-----	--------------	-----	------

		200MG	N022345	002	Jun 10, 2011	Jun	NEWA
--	--	-------	---------	-----	--------------	-----	------

		300MG	N022345	003	Jun 10, 2011	Jun	NEWA
--	--	-------	---------	-----	--------------	-----	------

+		400MG	N022345	004	Jun 10, 2011	Jun	NEWA
---	--	-------	---------	-----	--------------	-----	------

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB		APOTEX	125MG	A091480	001	Jul 22, 2011	Jul	NEWA
----	--	--------	-------	---------	-----	--------------	-----	------

AB			250MG	A091480	002	Jul 22, 2011	Jul	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			500MG	A091480	003	Jul 22, 2011	Jul	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB		AUROBINDO PHARMA LTD	125MG	A091114	001	Mar 21, 2011	Mar	NEWA
----	--	----------------------	-------	---------	-----	--------------	-----	------

AB			250MG	A091114	002	Mar 21, 2011	Mar	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			500MG	A091114	003	Mar 21, 2011	Mar	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB		MYLAN	125MG	A201333	001	Mar 24, 2011	Mar	NEWA
----	--	-------	-------	---------	-----	--------------	-----	------

AB			250MG	A201333	002	Mar 24, 2011	Mar	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			500MG	A201333	003	Mar 24, 2011	Mar	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB		ROXANE	125MG	A090128	001	Mar 21, 2011	Mar	NEWA
----	--	--------	-------	---------	-----	--------------	-----	------

AB			250MG	A090128	002	Mar 21, 2011	Mar	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			500MG	A090128	003	Mar 21, 2011	Mar	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB		WATSON LABS	125MG	A078278	001	Mar 21, 2011	Mar	NEWA
----	--	-------------	-------	---------	-----	--------------	-----	------

AB			250MG	A078278	002	Mar 21, 2011	Mar	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			500MG	A078278	003	Mar 21, 2011	Mar	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

>D>	AP	HOSPIRA	10MG/ML	A075870	001	Nov 23, 2001	Aug	DISC
-----	----	---------	---------	---------	-----	--------------	-----	------

>A>		@	10MG/ML	A075870	001	Nov 23, 2001	Aug	DISC
-----	--	---	---------	---------	-----	--------------	-----	------

	AP	PFIZER	10MG/ML	A078641	001	Jun 25, 2008	May	CAHN
--	----	--------	---------	---------	-----	--------------	-----	------

FAMOTIDINE PRESERVATIVE FREE

	AP	PFIZER	10MG/ML	A078642	001	Jun 25, 2008	May	CAHN
--	----	--------	---------	---------	-----	--------------	-----	------

PEPCID

		@ MERCK	10MG/ML	N019510	001	Nov 04, 1986	Jan	DISC
--	--	---------	---------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

PEPCID PRESERVATIVE FREE

@ MERCK 10MG/ML

N019510 004 Nov 04, 1986 Jan DISC

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

@ MERCK 0.4MG/ML

N020249 001 Feb 18, 1994 Jan DISC

TABLET; ORAL

FAMOTIDINE

>D> AB ACTAVIS ELIZABETH 20MG

A075650 001 Sep 14, 2001 Aug DISC

>A> @ 20MG

A075650 001 Sep 14, 2001 Aug DISC

>D> AB 40MG

A075650 002 Sep 14, 2001 Aug DISC

>A> @ 40MG

A075650 002 Sep 14, 2001 Aug DISC

AB ALEMBIC PHARMS LTD 20MG

A078916 001 May 22, 2009 Jul CAHN

AB 40MG

A078916 002 May 22, 2009 Jul CAHN

AB MYLAN 20MG

A075457 001 Apr 18, 2001 Feb CAHN

AB 40MG

A075457 002 Apr 18, 2001 Feb CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+ HORIZON PHARMA 26.6MG;800MG

N022519 001 Apr 23, 2011 Apr NEWA

FELBAMATE

TABLET; ORAL

FELBAMATE

>A> AB AMNEAL PHARMS 400MG

A201680 001 Sep 13, 2011 Aug NEWA

>A> AB 600MG

A201680 002 Sep 13, 2011 Aug NEWA

FELBATOL

>D> MEDA PHARMS 400MG

N020189 001 Jul 29, 1993 Aug CFTG

>A> AB 400MG

N020189 001 Jul 29, 1993 Aug CFTG

>D> + 600MG

N020189 002 Jul 29, 1993 Aug CFTG

>A> AB + 600MG

N020189 002 Jul 29, 1993 Aug CFTG

FENOFIBRATE

TABLET; ORAL

FENOGLIDE

SHORE THERAP 40MG

N022118 001 Aug 10, 2007 Feb CAHN

+ 120MG

N022118 002 Aug 10, 2007 Feb CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB MALLINCKRODT INC 100MCG/HR

A077154 004 Feb 09, 2011 Jan NEWA

FENTANYL-25

AB MALLINCKRODT INC 25MCG/HR

A077154 001 Feb 09, 2011 Jan NEWA

FENTANYL-50

AB MALLINCKRODT INC 50MCG/HR

A077154 002 Feb 09, 2011 Jan NEWA

FENTANYL-75

AB MALLINCKRODT INC 75MCG/HR

A077154 003 Feb 09, 2011 Jan NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

ARCHIMEDES 100MCG

N022569 001 Jun 30, 2011 Jun NEWA

+ 400MCG

N022569 002 Jun 30, 2011 Jun NEWA

TABLET; SUBLINGUAL

ABSTRAL

	PROSTRAKAN INC	EQ 0.1MG BASE	N022510 001	Jan 07, 2011	Jan	NEWA
		EQ 0.2MG BASE	N022510 002	Jan 07, 2011	Jan	NEWA
		EQ 0.3MG BASE	N022510 003	Jan 07, 2011	Jan	NEWA
+		EQ 0.4MG BASE	N022510 004	Jan 07, 2011	Jan	NEWA
		EQ 0.6MG BASE	N022510 005	Jan 07, 2011	Jan	NEWA
		EQ 0.8MG BASE	N022510 006	Jan 07, 2011	Jan	NEWA

FIDAXOMICIN

TABLET; ORAL

DIFICID

+	OPTIMER PHARMS	200MG	N201699 001	May 27, 2011	May	NEWA
---	----------------	-------	-------------	--------------	-----	------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

>A>	AB	SUN PHARMA GLOBAL	5MG	A090507 001	Aug 16, 2011	Aug	NEWA
-----	----	-------------------	-----	-------------	--------------	-----	------

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB		AMNEAL PHARM	50MG	A078423 001	Mar 07, 2011	Feb	NEWA
AB			100MG	A078423 002	Mar 07, 2011	Feb	NEWA
AB			150MG	A078423 003	Mar 07, 2011	Feb	NEWA
AB			200MG	A078423 004	Mar 07, 2011	Feb	NEWA
AB		MYLAN	50MG	A076042 001	Jul 29, 2004	Feb	CAHN
AB			100MG	A076042 002	Jul 29, 2004	Feb	CAHN
AB			150MG	A076042 003	Jul 29, 2004	Feb	CAHN
AB			200MG	A076042 004	Jul 29, 2004	Feb	CAHN

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

AB		VALEANT	250MG	N017001 001		Jun	CFTG
AB	+		500MG	N017001 002		Jun	CFTG

FLUCYTOSINE

AB		SIGMAPHARM LABS LLC	250MG	A201566 001	Jun 28, 2011	Jun	NEWA
AB			500MG	A201566 002	Jun 28, 2011	Jun	NEWA

FLUDARABINE PHOSPHATE

TABLET; ORAL

OFORTA

+	SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008	Apr	CMFD
	@	10MG	N022273 001	Dec 18, 2008	Jan	DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	+	FEINSTEIN	20-200mCi/ML	N021870 001	Aug 19, 2005	Feb	CTEC
AP		PETNET	20-200mCi/ML	A079086 001	Feb 25, 2011	Feb	NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB		WEST-WARD PHARM CORP	0.1MG	A091302 001	Jul 22, 2011	Jul	NEWA
----	--	----------------------	-------	-------------	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	PFIZER	0.5MG/5ML (0.1MG/ML)	A078595 001	May 13, 2008	May	CAHN
AP		1MG/10ML (0.1MG/ML)	A078595 002	May 13, 2008	May	CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.01%	N012787 004		Jun	CAHN
AT	+		0.025%	N012787 005		Jun	CAHN
AT	+		0.025%	N012787 002		Jun	CAHN

SYNALAR-HP

@ MEDIMETRIKS PHARMS

0.2%

N016161 002

Jun CAHN

OINTMENT; TOPICAL

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.025%	N013960 001		Jun	CAHN
----	---	--------------------	--------	-------------	--	-----	------

SOLUTION; TOPICAL

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.01%	N015296 001		Jun	CAHN
----	---	--------------------	-------	-------------	--	-----	------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

>D>	@	MEDICIS	0.025%;EQ 3.5MG BASE/GM	A060700 001		Aug	CAHN
>A>	@	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700 001		Aug	CAHN

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	SANDOZ	5GM/100ML (50MG/ML)	A091299 002	May 02, 2011	Apr	NEWA
AP		2.5GM/50ML (50MG/ML)	A091299 001	May 02, 2011	Apr	NEWA
	@ VALEANT	500MG/10ML (50MG/ML)	N012209 001		Mar	DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223 001	Mar 19, 2009	Apr	CAHN
AB1		EQ 20MG BASE	A090223 002	Mar 19, 2009	Apr	CAHN
AB		EQ 40MG BASE	A090223 003	Mar 19, 2009	Apr	CAHN

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

@ WATSON PHARMS

0.025%

N012806 003

Jul DISC

@

0.05%

N012806 002

Jul DISC

OINTMENT; TOPICAL

CORDRAN

@ WATSON PHARMS

0.025%

N012806 004

Jun DISC

@

0.05%

N012806 001

Jun DISC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	MYLAN	125MG	A076224 001	May 09, 2003	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

LOTION; TOPICAL

CUTIVATE

AB	+	NYCOMED US	0.05%	N021152	001	Mar 31, 2005	Apr	CFTG
----	---	------------	-------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

AB		GLENMARK GENERICS	0.05%	A090759	001	May 02, 2011	Apr	NEWA
----	--	-------------------	-------	---------	-----	--------------	-----	------

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@	MYLAN	50MG	A075950	001	Oct 15, 2001	Feb	CAHN
---	-------	------	---------	-----	--------------	-----	------

@		100MG	A075950	002	Oct 15, 2001	Feb	CAHN
---	--	-------	---------	-----	--------------	-----	------

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	+	AMNEAL PHARM	1MG	A040625	001	Jul 21, 2005	Apr	CAHN
----	---	--------------	-----	---------	-----	--------------	-----	------

AA		JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005	Jan	CAHN
----	--	------------------	-----	---------	-----	--------------	-----	------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

AP	+	GLAXOSMITHKLINE	2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jun	CFTG
----	---	-----------------	-------------	---------	-----	--------------	-----	------

AP	+		5MG/0.4ML	N021345	002	May 28, 2004	Jun	CFTG
----	---	--	-----------	---------	-----	--------------	-----	------

AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	Jun	CFTG
----	---	--	-------------	---------	-----	--------------	-----	------

AP	+		10MG/0.8ML	N021345	004	May 28, 2004	Jun	CFTG
----	---	--	------------	---------	-----	--------------	-----	------

FONDAPARINUX SODIUM

AP		DR REDDYS LABS LTD	2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jun	NEWA
----	--	--------------------	-------------	---------	-----	--------------	-----	------

AP			5MG/0.4ML	A091316	002	Jul 11, 2011	Jun	NEWA
----	--	--	-----------	---------	-----	--------------	-----	------

AP			7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jun	NEWA
----	--	--	-------------	---------	-----	--------------	-----	------

AP			10MG/0.8ML	A091316	004	Jul 11, 2011	Jun	NEWA
----	--	--	------------	---------	-----	--------------	-----	------

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

@	NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006	Jun	DISC
---	----------	--------------	---------	-----	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB		AUROBINDO PHARMA LTD	10MG	A091163	001	Mar 30, 2011	Mar	NEWA
----	--	----------------------	------	---------	-----	--------------	-----	------

AB			20MG	A091163	002	Mar 30, 2011	Mar	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			40MG	A091163	003	Mar 30, 2011	Mar	NEWA
----	--	--	------	---------	-----	--------------	-----	------

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		EMCURE PHARMS USA	10MG;12.5MG	A079025	001	Sep 17, 2010	Jul	CAHN
----	--	-------------------	-------------	---------	-----	--------------	-----	------

AB			20MG;12.5MG	A079025	002	Sep 17, 2010	Jul	CAHN
----	--	--	-------------	---------	-----	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	+	APP PHARMS	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Apr	CRLD
----	---	------------	-------------------------	---------	-----	--------------	-----	------

AP		PFIZER	EQ 50MG PNENYTOIN NA/ML	A078476	001	Mar 18, 2008	May	CAHN
----	--	--------	-------------------------	---------	-----	--------------	-----	------

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	MARKSANS PHARMA	100MG	A090007 001	Jul 21, 2011	Jul	NEWA
AB		300MG	A090007 002	Jul 21, 2011	Jul	NEWA
AB		400MG	A090007 003	Jul 21, 2011	Jul	NEWA
AB	MATRIX LABS LTD	100MG	A090158 001	Feb 14, 2011	Jan	NEWA
AB		300MG	A090158 002	Feb 14, 2011	Jan	NEWA
AB		400MG	A090158 003	Feb 14, 2011	Jan	NEWA
AB	MYLAN	100MG	A090158 001	Feb 14, 2011	May	CAHN
AB		300MG	A090158 002	Feb 14, 2011	May	CAHN
AB		400MG	A090158 003	Feb 14, 2011	May	CAHN

SOLUTION; ORAL

GABAPENTIN

AA	HI TECH PHARMA	250MG/5ML	A078974 001	Feb 18, 2011	Feb	NEWA
AA	+ PARKE DAVIS	250MG/5ML	N021129 001	Mar 02, 2000	Feb	CFTG

TABLET; ORAL

GABAPENTIN

AB	HIKMA PHARMS	600MG	A078782 001	Jul 21, 2011	Jul	NEWA
AB		800MG	A078782 002	Jul 21, 2011	Jul	NEWA
AB	ZYDUS PHARMS USA INC	600MG	A078926 001	Feb 11, 2011	Jan	NEWA
AB		800MG	A078926 002	Feb 11, 2011	Jan	NEWA

GRALISE

BX	+ ABBOTT PRODS	300MG	N022544 001	Jan 28, 2011	Jan	NEWA
BX	+	600MG	N022544 002	Jan 28, 2011	Jan	NEWA
BX	+ DEPOMED INC	300MG	N022544 001	Jan 28, 2011	Jul	CAHN
BX	+	600MG	N022544 002	Jan 28, 2011	Jul	CAHN

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

+	GLAXO GRP LTD	600MG	N022399 001	Apr 06, 2011	Apr	NEWA
---	---------------	-------	-------------	--------------	-----	------

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277 001	Mar 14, 2011	Mar	NEWA
+		6.0472GM/10ML (604.72MG/ML)	N201277 002	Mar 14, 2011	Mar	NEWA
+		9.0708GM/15ML (604.72MG/ML)	N201277 003	Mar 14, 2011	Mar	NEWA
+		18.1416GM/30ML (604.72MG/ML)	N201277 004	Mar 14, 2011	Mar	NEWA
+		39.3068GM/65ML (604.72MG/ML)	N201277 005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB	MYLAN	EQ 8MG BASE	A090900 001	Jan 24, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090900 002	Jan 24, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090900 003	Jan 24, 2011	Jan	NEWA
AB	SUN PHARMA GLOBAL	EQ 8MG BASE	A090178 001	Feb 02, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090178 002	Feb 02, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090178 003	Feb 02, 2011	Jan	NEWA
	RAZADYNE ER					
AB	+ JANSSEN PHARMS	EQ 8MG BASE	N021615 001	Apr 01, 2005	Jul	CAHN
AB		EQ 16MG BASE	N021615 002	Apr 01, 2005	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

RAZADYNE ER

AB	JANSSEN PHARMS	EQ 24MG BASE	N021615 003	Apr 01, 2005	Jul	CAHN
----	----------------	--------------	-------------	--------------	-----	------

SOLUTION; ORAL

RAZADYNE

AA	+ JANSSEN PHARMS	4MG/ML	N021224 001	Jun 22, 2001	Jul	CAHN
----	------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

>D>	AB	ACTAVIS ELIZABETH	EQ 4MG BASE	A077585 001	Sep 15, 2009	Aug	DISC
>A>		@	EQ 4MG BASE	A077585 001	Sep 15, 2009	Aug	DISC
>D>	AB		EQ 8MG BASE	A077585 002	Sep 15, 2009	Aug	DISC
>A>		@	EQ 8MG BASE	A077585 002	Sep 15, 2009	Aug	DISC
>D>	AB		EQ 12MG BASE	A077585 003	Sep 15, 2009	Aug	DISC
>A>		@	EQ 12MG BASE	A077585 003	Sep 15, 2009	Aug	DISC
	AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957 001	Mar 29, 2011	Mar	NEWA
	AB		EQ 8MG BASE	A090957 002	Mar 29, 2011	Mar	NEWA
	AB		EQ 12MG BASE	A090957 003	Mar 29, 2011	Mar	NEWA
	AB	ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898 001	Feb 17, 2011	Jan	NEWA
	AB		EQ 8MG BASE	A078898 002	Feb 17, 2011	Jan	NEWA
	AB		EQ 12MG BASE	A078898 003	Feb 17, 2011	Jan	NEWA
		RAZADYNE					
	AB	+ JANSSEN PHARMS	EQ 4MG BASE	N021169 001	Feb 28, 2001	Jul	CAHN
	AB		EQ 8MG BASE	N021169 002	Feb 28, 2001	Jul	CAHN
	AB		EQ 12MG BASE	N021169 003	Feb 28, 2001	Jul	CAHN

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

>A>		GATIFLOXACIN					
>A>	AT	APOTEX CORP	0.3%	A079084 001	Aug 19, 2011	Aug	NEWA
		ZYMAR					
>D>	+	ALLERGAN	0.3%	N021493 001	Mar 28, 2003	Aug	CFTG
>A>	AT	+	0.3%	N021493 001	Mar 28, 2003	Aug	CFTG

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

>A>		GEMCITABINE					
>A>	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795 001	Aug 04, 2011	Aug	NEWA
>A>	+		1GM/26.3ML (38MG/ML)	N200795 002	Aug 04, 2011	Aug	NEWA
>A>	+		2GM/52.6ML (38MG/ML)	N200795 003	Aug 04, 2011	Aug	NEWA
	+		EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	Feb	CRLD

GEMCITABINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594 001	Jul 25, 2011	Jul	NEWA	
AP		EQ 1GM BASE/VIAL	A091594 002	Jul 25, 2011	Jul	NEWA	
AP		EQ 2GM BASE/VIAL	A091594 003	Jul 25, 2011	Jul	NEWA	
AP	ACTAVIS TOTOWA	EQ 200MG BASE/VIAL	A079160 001	Jul 25, 2011	Jul	NEWA	
AP		EQ 1GM BASE/VIAL	A079160 002	Jul 25, 2011	Jul	NEWA	
AP	APP PHARMS	EQ 2GM BASE/VIAL	A090242 003	May 16, 2011	May	NEWA	
AP	DR REDDYS LABS LTD	EQ 200MG BASE/VIAL	A091365 001	Jul 25, 2011	Jul	NEWA	
AP		EQ 1GM BASE/VIAL	A091365 002	Jul 25, 2011	Jul	NEWA	
AP	FRESENIUS KABI ONCOL	EQ 200MG BASE/VIAL	A090799 001	Jul 25, 2011	Jul	NEWA	
AP		EQ 1GM BASE/VIAL	A090799 002	Jul 25, 2011	Jul	NEWA	
AP		EQ 2GM BASE/VIAL	A090799 003	May 16, 2011	May	NEWA	
AP	HOSPIRA	EQ 200MG BASE/VIAL	A078339 001	Jul 25, 2011	Jul	NEWA	
AP		EQ 1GM BASE/VIAL	A078339 002	Jul 25, 2011	Jul	NEWA	
AP	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	Jul	CTEC
	+		EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	May	CTNA

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP	ONCO THERAPIES LTD	EQ 200MG BASE/VIAL	A200145 001	Jul 25, 2011	Jul	NEWA
AP		EQ 1GM BASE/VIAL	A200145 002	Jul 25, 2011	Jul	NEWA
AP		EQ 2GM BASE/VIAL	A200145 003	Jul 25, 2011	Jul	NEWA
AP	SUN PHARMA GLOBAL	EQ 200MG BASE/VIAL	A078433 001	Jul 25, 2011	Jul	NEWA
AP		EQ 1GM BASE/VIAL	A078433 002	Jul 25, 2011	Jul	NEWA
AP	TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983 002	Jan 25, 2011	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A077983 001	Jan 25, 2011	Jan	NEWA
AP	WATSON LABS	EQ 200MG BASE/VIAL	A078759 001	Jul 25, 2011	Jul	NEWA
AP		EQ 1GM BASE/VIAL	A078759 002	Jul 25, 2011	Jul	NEWA
GEMZAR						
AP	+ LILLY	EQ 200MG BASE/VIAL	N020509 001	May 15, 1996	Jan	CFTG
AP	+	EQ 1GM BASE/VIAL	N020509 002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB	BLU CARIBE	600MG	A078012 001	Mar 26, 2007	Feb	CAHN
----	------------	-------	-------------	--------------	-----	------

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	FERA PHARMS	EQ 0.3% BASE	A065024 001	Jul 30, 2004	Feb	CAHN
AT	NYCOMED US	EQ 0.3% BASE	A065024 001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

AT	FERA PHARMS	EQ 0.3% BASE	A065121 001	Jan 30, 2004	Feb	CAHN
----	-------------	--------------	-------------	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	MYLAN	1MG	A077486 001	Feb 10, 2006	Feb	CAHN
AB		2MG	A077486 002	Feb 10, 2006	Feb	CAHN
AB		4MG	A077486 003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

>D>	AB	ALPHAPHARM	5MG	A074438 001	Jun 20, 1995	Aug	CAHN
>D>	AB		10MG	A074438 002	Jun 20, 1995	Aug	CAHN
>A>	AB	MYLAN	5MG	A074438 001	Jun 20, 1995	Aug	CAHN
>A>	AB		10MG	A074438 002	Jun 20, 1995	Aug	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

>D>	AB	TEVA PHARMS	5MG;500MG	A077270 003	Oct 28, 2005	Aug	CRLD
>A>	AB	+	5MG;500MG	A077270 003	Oct 28, 2005	Aug	CRLD
	AB	ZYDUS PHARMS USA INC	2.5MG;250MG	A078905 001	Jan 31, 2011	Jan	NEWA
	AB		2.5MG;500MG	A078905 002	Jan 31, 2011	Jan	NEWA
	AB		5MG;500MG	A078905 003	Jan 31, 2011	Jan	NEWA
>D>		METAGLIP					
>D>	AB	BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460 001	Oct 21, 2002	Aug	DISC
>A>		@	2.5MG;250MG	N021460 001	Oct 21, 2002	Aug	DISC
>D>	AB		2.5MG;500MG	N021460 002	Oct 21, 2002	Aug	DISC

TABLET; ORAL

>D>	METAGLIP								
>A>	@ BRISTOL MYERS SQUIBB	2.5MG;500MG	N021460	002	Oct 21, 2002	Aug	DISC		
>D>	AB +	5MG;500MG	N021460	003	Oct 21, 2002	Aug	DISC		
>A>	@	5MG;500MG	N021460	003	Oct 21, 2002	Aug	DISC		

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	May	CAHN		
---	--------------	------------	---------	-----	--------------	-----	------	--	--

GLYBURIDE

TABLET; ORAL

GLYBURIDE

	@ ACTAVIS TOTOWA	1.5MG	A075947	001	Nov 14, 2002	Jul	DISC		
	@	3MG	A075947	002	Nov 14, 2002	Jul	DISC		
	@	6MG	A075947	003	Nov 14, 2002	Jul	DISC		
AB	HERITAGE PHARMS INC	1.25MG	A090937	001	Feb 28, 2011	May	CAHN		
AB		2.5MG	A090937	002	Feb 28, 2011	May	CAHN		
AB		5MG	A090937	003	Feb 28, 2011	May	CAHN		
AB	INDICUS PHARMA	1.25MG	A090937	001	Feb 28, 2011	Feb	NEWA		
AB		2.5MG	A090937	002	Feb 28, 2011	Feb	NEWA		
AB		5MG	A090937	003	Feb 28, 2011	Feb	NEWA		

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

+	PROSTRAKAN INC	3.1MG/24HR	N022198	001	Sep 12, 2008	Jun	CAHN		
---	----------------	------------	---------	-----	--------------	-----	------	--	--

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@	ELORAC	125MG	A061996	001		Jan	CAHN		
@		250MG	A061996	002		Jan	CAHN		
	FULVICIN P/G 165								
@	ELORAC	165MG	A061996	003	Apr 06, 1982	Jan	CAHN		
	FULVICIN P/G 330								
@	ELORAC	330MG	A061996	004	Apr 06, 1982	Jan	CAHN		

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

>D>	AB	ACTAVIS MID ATLANTIC	0.05%	A077109	001	Jun 14, 2005	Aug	DISC	
>A>		@	0.05%	A077109	001	Jun 14, 2005	Aug	DISC	

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	PFIZER	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	May	CAHN		
>A>	AP	SAGENT PHARMS	EQ 5MG BASE/ML	A091637	001	Sep 02, 2011	Aug	NEWA	
>A>	AP		EQ 5MG BASE/ML	A200742	001	Sep 02, 2011	Aug	NEWA	

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Jul	NEWA		
--	--------	----------------	---------	-----	--------------	-----	------	--	--

INJECTABLE; INJECTION

HEPARIN SODIUM

	PFIZER	5,000 UNITS/ML	N201370 002	Jul 21, 2011	Jul	NEWA
		10,000 UNITS/ML	N201370 003	Jul 21, 2011	Jul	NEWA
AP	SANDOZ	1,000 UNITS/ML	A091682 001	Jun 08, 2011	May	NEWA
AP		5,000 UNITS/ML	A091659 001	Jun 08, 2011	May	NEWA
AP		5,000 UNITS/ML	A091682 002	Jun 08, 2011	May	NEWA
AP		10,000 UNITS/ML	A201002 001	Jun 08, 2011	May	NEWA
	HEPARIN SODIUM PRESERVATIVE FREE					
	PFIZER	1,000 UNITS/ML	N201370 004	Jul 21, 2011	Jul	NEWA

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+	GE HEALTHCARE	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
---	---------------	------------	-------------	--------------	-----	------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AB	NOVEL LABS INC	1.5MG;5MG	A091528 001	Apr 20, 2011	Apr	NEWA
	TUSSIGON					
AB	+ KING PHARMS	1.5MG;5MG	A088508 001	Jul 30, 1985	Apr	CTEC

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

+	AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005	Jul	CAHN
---	-----------	--------------	-------------	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA	HETERO LABS UNIT III	10MG	A040901 001	Sep 12, 2008	Jul	CAHN
AA		25MG	A040901 002	Sep 12, 2008	Jul	CAHN
AA		50MG	A040901 003	Sep 12, 2008	Jul	CAHN
AA		100MG	A040901 004	Sep 12, 2008	Jul	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG	A200645 001	Nov 30, 2010	Apr	CAHN
AB	JUBILANT CADISTA	12.5MG	A078391 001	Feb 11, 2008	Jan	CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>D>	AB	ACTAVIS ELIZABETH	25MG	A085054 002	Aug	DISC
>A>	@		25MG	A085054 002	Aug	DISC
>D>	AB		50MG	A085208 001	Aug	DISC
>A>	@		50MG	A085208 001	Aug	DISC
	AB	JUBILANT CADISTA	25MG	A040809 001	Sep 04, 2007	Jan CAHN
	AB		50MG	A040809 002	Sep 04, 2007	Jan CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

	@ SANOFI AVENTIS	12.5MG;75MG	N020758 001	Sep 30, 1997	Jun	CAHN
		12.5MG;150MG	N020758 002	Sep 30, 1997	Jun	CAHN
>D>		12.5MG;300MG	N020758 003	Aug 31, 1998	Aug	CRLD

TABLET; ORAL

AVALIDE

>A>	+	SANOFI AVENTIS	12.5MG;300MG	N020758 003	Aug 31, 1998	Aug	CRLD
			12.5MG;300MG	N020758 003	Aug 31, 1998	Jun	CAHN
>D>	+		25MG;300MG	N020758 004	Mar 15, 2005	Aug	DISC
>A>	@		25MG;300MG	N020758 004	Mar 15, 2005	Aug	DISC
	+		25MG;300MG	N020758 004	Mar 15, 2005	Jun	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

>A>	AB	PRINSTON INC	12.5MG;10MG	A076230 001	Jul 01, 2002	Aug	CAHN
>A>	AB		12.5MG;20MG	A076230 002	Jul 01, 2002	Aug	CAHN
>A>	AB		25MG;20MG	A076230 003	Jul 01, 2002	Aug	CAHN
>D>	AB	PRINSTON PHARM LLC	12.5MG;10MG	A076230 001	Jul 01, 2002	Aug	CAHN
	AB		12.5MG;10MG	A076230 001	Jul 01, 2002	May	CAHN
>D>	AB		12.5MG;20MG	A076230 002	Jul 01, 2002	Aug	CAHN
	AB		12.5MG;20MG	A076230 002	Jul 01, 2002	May	CAHN
>D>	AB		25MG;20MG	A076230 003	Jul 01, 2002	Aug	CAHN
	AB		25MG;20MG	A076230 003	Jul 01, 2002	May	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;50MG	A200180 001	Jan 12, 2011	Jan	NEWA
AB		12.5MG;100MG	A200180 002	Jan 12, 2011	Jan	NEWA
AB		25MG;100MG	A200180 003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A201356 001	Apr 20, 2011	Apr	NEWA
AB		12.5MG;20MG	A201356 002	Apr 20, 2011	Apr	NEWA
AB		25MG;20MG	A201356 003	Apr 20, 2011	Apr	NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

REZIRA

+	CYPRESS PHARM	5MG/5ML; 60MG/5ML	N022442 001	Jun 08, 2011	Jun	NEWA
---	---------------	-------------------	-------------	--------------	-----	------

HYDROCORTISONE

SOLUTION; TOPICAL

TEXACORT

>A>	+	STAYMA	2.5%	A081271 001	Apr 17, 1992	Aug	CAHN
>D>	+	TIBER LABS	2.5%	A081271 001	Apr 17, 1992	Aug	CAHN
	+		2.5%	A081271 001	Apr 17, 1992	May	CAHN

TABLET; ORAL

HYDROCORTISONE

AB	COREPHARMA	5MG	A040646 001	Mar 30, 2007	Apr	CAHN
AB		10MG	A040646 002	Mar 30, 2007	Apr	CAHN
AB		20MG	A040646 003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

@	FERA PHARMS	0.5%	A080828 001		Mar	CAHN
---	-------------	------	-------------	--	-----	------

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

>D>	A-HYDROCORT					
>D>	AP	HOSPIRA	EQ 250MG BASE/VIAL	A085930 001	Aug	DISC
>A>		@	EQ 250MG BASE/VIAL	A085930 001	Aug	DISC
>D>	AP		EQ 500MG BASE/VIAL	A085931 001	Aug	DISC
>A>		@	EQ 500MG BASE/VIAL	A085931 001	Aug	DISC
>D>	AP		EQ 1GM BASE/VIAL	A085932 001	Aug	DISC
>A>		@	EQ 1GM BASE/VIAL	A085932 001	Aug	DISC

HYDROFLUMETHIAZIDE

TABLET; ORAL

HYDROFLUMETHIAZIDE

@	PAR PHARM	50MG	A088850 001	May 31, 1985	May	DISC
---	-----------	------	-------------	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	ELITE LABS	8MG	A076723 001	Oct 18, 2005	Feb	CAHN
----	------------	-----	-------------	--------------	-----	------

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

@	MERCK SANTE SAS	5GM/VIAL (5GM/KIT)	N022041 001	Apr 08, 2011	Apr	DISC
---	-----------------	--------------------	-------------	--------------	-----	------

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRINE

@	PHARMICS	1%	N000004 004		Jan	CAHN
---	----------	----	-------------	--	-----	------

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+	KV PHARM	1250MG/5ML (250MG/ML)	N021945 001	Feb 03, 2011	Feb	NEWA
---	----------	-----------------------	-------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@	ACTAVIS TOTOWA	10MG	A040600 001	Dec 28, 2004	Jul	DISC
@		25MG	A040602 001	Dec 28, 2004	Jul	DISC
@		50MG	A040604 001	Dec 28, 2004	Jul	DISC
AB	HETERO LABS UNIT III	10MG	A040805 001	May 29, 2008	Jul	CAHN
AB		25MG	A040805 002	May 29, 2008	Jul	CAHN
AB		50MG	A040805 003	May 29, 2008	Jul	CAHN

IBUPROFEN

TABLET; ORAL

IBUPROHM

>D>	AB	OHM LABS	400MG	A070469 001	Aug 29, 1985	Aug	DISC
>A>		@	400MG	A070469 001	Aug 29, 1985	Aug	DISC

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

>D> COMBUNOX

>D> AB + FOREST LABS 400MG;5MG N021378 001 Nov 26, 2004 Aug DISC

>A> @ 400MG;5MG N021378 001 Nov 26, 2004 Aug DISC

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

>D> AB ACTAVIS ELIZABETH 400MG;5MG A078769 001 Jan 04, 2008 Aug CRLD

>A> AB + 400MG;5MG A078769 001 Jan 04, 2008 Aug CRLD

>A> ICATIBANT ACETATE

>A> INJECTABLE; SUBCUTANEOUS

>A> FIRAZYR

>A> + SHIRE ORPHAN THERAP EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N022150 001 Aug 25, 2011 Aug NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP SANDOZ 1MG/ML A091293 001 Mar 29, 2011 Mar NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP BEDFORD LABS 1GM/20ML(50MG/ML) A076619 001 Jun 29, 2011 Jun NEWA

AP 3GM/60ML(50MG/ML) A076619 002 Jun 29, 2011 Jun NEWA

ILOPERIDONE

TABLET; ORAL

FANAPT

NOVARTIS

2MG

N022192 002 May 06, 2009 Jan CAHN

4MG

N022192 003 May 06, 2009 Jan CAHN

6MG

N022192 004 May 06, 2009 Jan CAHN

8MG

N022192 005 May 06, 2009 Jan CAHN

10MG

N022192 006 May 06, 2009 Jan CAHN

ILOPROST

SOLUTION; INHALATION

VENTAVIS

@ ACTELION PHARMS LTD 20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004 Jun DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ ACTAVIS TOTOWA 10MG

A040753 001 Feb 28, 2008 Jul DISC

@ 25MG

A040752 001 Feb 28, 2008 Jul DISC

@ 50MG

A040751 001 Feb 28, 2008 Jul DISC

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB TARO 5%

A200173 001 Apr 15, 2011 Apr NEWA

AB TEVA PHARMS USA 5%

A200481 001 Apr 18, 2011 Apr NEWA

AB TOLMAR 5%

A091044 001 Feb 28, 2011 Feb NEWA

ZYCLARA

+ GRACEWAY 2.5%

N022483 002 Jul 15, 2011 Jul NEWA

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+	NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Jul	NEWA
---	----------	---------------	---------	-----	--------------	-----	------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB	HETERO DRUGS LTD	25MG	A091240	001	Apr 12, 2011	Mar	NEWA
AB		50MG	A091240	002	Apr 12, 2011	Mar	NEWA
AB	HETERO LABS UNIT III	25MG	A091240	001	Apr 12, 2011	Jul	CAHN
AB		50MG	A091240	002	Apr 12, 2011	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	+	SANDOZ	75MG	A074464	001	May 28, 1998	Jan	CTNA
----	---	--------	------	---------	-----	--------------	-----	------

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+	GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454	001	Jan 14, 2011	Jan	NEWA
---	-----------------	----------------------	---------	-----	--------------	-----	------

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

	@	HOSPIRA	41%	A074898	001	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-200 IN PLASTIC CONTAINER

	@	HOSPIRA	41%	A074636	001	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-250

>D>	AP	HOSPIRA	51%	A075005	001	Feb 24, 1998	Aug	DISC
-----	----	---------	-----	---------	-----	--------------	-----	------

>A>		@	51%	A075005	001	Feb 24, 1998	Aug	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

		@	51%	A074898	002	Dec 30, 1997	Feb	DISC
--	--	---	-----	---------	-----	--------------	-----	------

IOPAMIDOL-250 IN PLASTIC CONTAINER

	@	HOSPIRA	51%	A074636	002	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300

>D>	AP	HOSPIRA	61%	A075005	002	Feb 24, 1998	Aug	DISC
-----	----	---------	-----	---------	-----	--------------	-----	------

>A>		@	61%	A075005	002	Feb 24, 1998	Aug	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

		@	61%	A074898	003	Dec 30, 1997	Feb	DISC
--	--	---	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300 IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	61%	A074637	001	Apr 03, 1997	Aug	DISC
-----	----	---------	-----	---------	-----	--------------	-----	------

>A>		@	61%	A074637	001	Apr 03, 1997	Aug	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

		@	61%	A074636	003	Dec 30, 1997	Feb	DISC
--	--	---	-----	---------	-----	--------------	-----	------

IOPAMIDOL-370

>D>	AP	HOSPIRA	76%	A075005	003	Feb 24, 1998	Aug	DISC
-----	----	---------	-----	---------	-----	--------------	-----	------

>A>		@	76%	A075005	003	Feb 24, 1998	Aug	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

		@	76%	A074898	004	Dec 30, 1997	Feb	DISC
--	--	---	-----	---------	-----	--------------	-----	------

IOPAMIDOL-370 IN PLASTIC CONTAINER

	@	HOSPIRA	76%	A074636	004	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D>	AN	ACTAVIS MID ATLANTIC	0.02%	A075111	001	Apr 22, 1999	Aug	DISC
-----	----	----------------------	-------	---------	-----	--------------	-----	------

>A>		@	0.02%	A075111	001	Apr 22, 1999	Aug	DISC
-----	--	---	-------	---------	-----	--------------	-----	------

	AN	RITEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul	CAHN
--	----	---------------	-------	---------	-----	--------------	-----	------

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	BIONICHE PHARMA	40MG/2ML (20MG/ML)	A090393 002	May 13, 2011	May	NEWA
AP		100MG/5ML (20MG/ML)	A090393 003	May 13, 2011	May	NEWA
AP	X-GEN PHARMS	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Jul	CAHN
AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Jul	CAHN

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

EQ 50MG BASE/2.5ML (EQ 20MG
BASE/ML)

N021135 002 Mar 20, 2005 Apr CMFD

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB	VALEANT INTL	5MG	N012093 007	Jul 29, 1988	Jun	CAHN
AB		10MG	N012093 002	Jul 29, 1988	Jun	CAHN
AB		20MG	N012093 006	Jul 29, 1988	Jun	CAHN
AB	+	30MG	N012093 005	Jul 29, 1988	Jun	CAHN
	+	40MG	N012093 001	Jul 29, 1988	Jun	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB	TORRENT PHARMS	30MG	A200270 001	Jun 03, 2011	May	NEWA
AB		60MG	A200495 001	Jun 03, 2011	May	NEWA
AB		120MG	A200495 002	Jun 03, 2011	May	NEWA

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB	MIKAH PHARMA	2.5MG	A077169 001	Apr 24, 2006	Feb	CAHN
AB		5MG	A077169 002	Apr 24, 2006	Feb	CAHN

ITRACONAZOLE

INJECTABLE; INJECTION

SPORANOX

@ ORTHO MCNEIL JANSSEN 10MG/ML

N020966 001 Mar 30, 1999 May DISC

TABLET; ORAL

ONMEL

+ STIEFEL LABS INC 200MG

N022484 001 Apr 29, 2010 May CTNA

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA

>D>	+	STIEFEL LABS INC	2%	N021738 001	Jun 12, 2007	Aug	CFTG
>A>	AT	+	2%	N021738 001	Jun 12, 2007	Aug	CFTG

>A>		KETOCONAZOLE					
>A>	AT	PERRIGO ISRAEL	2%	A091550 001	Aug 25, 2011	Aug	NEWA

GEL; TOPICAL

XOLEGEL

	+	AQUA PHARMS	2%	N021946 001	Jul 28, 2006	May	CAHN
--	---	-------------	----	-------------	--------------	-----	------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	PFIZER	15MG/ML	A078299 001	Jul 16, 2007	May	CAHN
AP		30MG/ML	A078299 002	Jul 16, 2007	May	CAHN

SPRAY, METERED; NASAL

SPRIX

+	LUITPOLD	15.75MG/SPRAY	N022382 001	May 14, 2010	May	CAHN
---	----------	---------------	-------------	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

AB	+	VIIIV HLTHCARE	150MG;300MG	N020857 001	Sep 26, 1997	May	CFTG
----	---	----------------	-------------	-------------	--------------	-----	------

LAMIVUDINE AND ZIDOVUDINE

AB		TEVA PHARMS	150MG;300MG	A079081 001	May 25, 2011	May	NEWA
----	--	-------------	-------------	-------------	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB		ACTAVIS TOTOWA	25MG	A078669 001	Apr 08, 2011	Mar	NEWA
AB			100MG	A078669 002	Apr 08, 2011	Mar	NEWA
AB			150MG	A078669 003	Apr 08, 2011	Mar	NEWA
AB			200MG	A078669 004	Apr 08, 2011	Mar	NEWA
AB		ALEMBIC LTD	25MG	A090607 001	Jan 13, 2011	Jan	NEWA
AB			100MG	A090607 002	Jan 13, 2011	Jan	NEWA
AB			150MG	A090607 003	Jan 13, 2011	Jan	NEWA
AB			200MG	A090607 004	Jan 13, 2011	Jan	NEWA
AB		ALEMBIC PHARMS LTD	25MG	A090607 001	Jan 13, 2011	Apr	CAHN
AB			100MG	A090607 002	Jan 13, 2011	Apr	CAHN
AB			150MG	A090607 003	Jan 13, 2011	Apr	CAHN
AB			200MG	A090607 004	Jan 13, 2011	Apr	CAHN
AB		HIKMA PHARMS	25MG	A078134 001	Apr 19, 2011	Apr	NEWA
AB			100MG	A078134 002	Apr 19, 2011	Apr	NEWA
AB			150MG	A078134 003	Apr 19, 2011	Apr	NEWA
AB			200MG	A078134 004	Apr 19, 2011	Apr	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB		JUBILANT LIFE	5MG	A200220 001	Feb 28, 2011	Feb	NEWA
AB			25MG	A200220 002	Feb 28, 2011	Feb	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT		ALCON RES	0.005%	A091449 001	Mar 22, 2011	Mar	NEWA
AT		APOTEX	0.005%	A077697 001	Mar 22, 2011	Mar	NEWA
AT		BAUSCH AND LOMB	0.005%	A201006 001	Mar 22, 2011	Mar	NEWA
AT		LUITPOLD	0.005%	A200925 001	Mar 22, 2011	May	CAHN
AT		MYLAN	0.005%	A201786 001	Mar 22, 2011	Mar	NEWA
AT		PADDOCK LABS	0.005%	A090887 001	Jul 19, 2011	Jul	NEWA
AT		PHARMAFORCE	0.005%	A200925 001	Mar 22, 2011	Mar	NEWA

XALATAN

AT	+	PHARMACIA AND UPJOHN	0.005%	N020597 001	Jun 05, 1996	Mar	CFTG
----	---	----------------------	--------	-------------	--------------	-----	------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	ACCORD HLTHCARE	2.5MG	A090934	001	Jun 03, 2011	May	NEWA
>A>	AB	ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011	Aug CAHN
>D>	AB	AMIDE PHARM	2.5MG	A090292	001	Jul 13, 2011	Aug CAHN
AB		2.5MG	A090292	001	Jul 13, 2011	Jul	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A091191	001	Jun 03, 2011	May	NEWA
AB	ENDO PHARMS	2.5MG	A090789	001	Jun 03, 2011	May	NEWA
AB	FRESENIUS KABI ONCOL	2.5MG	A090491	001	Jun 03, 2011	May	NEWA
AB	IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011	May	NEWA
AB	INDICUS PHARMA	2.5MG	A201804	001	Jun 03, 2011	May	NEWA
AB	KUDCO IRELAND	2.5MG	A091098	001	Jun 03, 2011	May	NEWA
AB	NATCO PHARMA LTD	2.5MG	A200161	001	Jun 03, 2011	May	NEWA
AB	ROXANE	2.5MG	A090838	001	Jun 03, 2011	May	NEWA
AB	SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011	May	NEWA
	@ SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011	Jun	DISC
AB		2.5MG	A090196	001	Jun 03, 2011	May	NEWA
AB	TEVA PHARMS	2.5MG	A090289	001	Jun 03, 2011	May	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

	@ GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Apr	DISC
	LUPRON DEPOT						
+	ABBOTT ENDOCRINE	22.5MG/VIAL	N020517	001	Dec 22, 1995	Jun	CAHN
+		30MG/VIAL	N020517	002	May 30, 1997	Jun	CAHN
		45MG/VIAL	N020517	003	Jun 17, 2011	Jun	NEWA
	LUPRON DEPOT-PED						
>A>	+	ABBOTT ENDOCRINE	11.25MG/VIAL	N020263	007	Aug 15, 2011	Aug NEWA
>A>	+	30MG/VIAL	N020263	008	Aug 15, 2011	Aug	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>D>	AN	BREATH LTD	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug CAHN
>D>	AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug CAHN
>D>	AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug CAHN
>A>	AN	WATSON LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug CAHN
>A>	AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug CAHN
>A>	AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	INNOPHARMA LLC	500MG/ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	NEWA
----	----------------	---------------------	---------	-----	--------------	-----	------

SOLUTION; ORAL

LEVETIRACETAM

AA	APOTEX	100MG/ML	A090187	001	Aug 05, 2011	Jul	NEWA
----	--------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

LEVETIRACETAM

AB	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	Jan	NEWA
AB		500MG	A090843	002	Feb 14, 2011	Jan	NEWA
AB		750MG	A090843	003	Feb 14, 2011	Jan	NEWA
AB		1GM	A090843	004	Feb 14, 2011	Jan	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	AJANTA PHARMA	250MG	A201293 001	Jun 14, 2011	May	NEWA
AB		500MG	A201293 002	Jun 14, 2011	May	NEWA
AB		750MG	A201293 003	Jun 14, 2011	May	NEWA
AB		1GM	A201293 004	Jun 14, 2011	May	NEWA
>A>	AB	BRECKENRIDGE PHARM	250MG	A090511 001	Aug 18, 2011	Aug
>A>	AB		500MG	A090511 002	Aug 18, 2011	Aug
>A>	AB		750MG	A090511 003	Aug 18, 2011	Aug
>A>	AB		1GM	A090511 004	Aug 18, 2011	Aug

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

>D>		UCB INC	500MG	N022285 001	Sep 12, 2008	Aug
>A>	AB		500MG	N022285 001	Sep 12, 2008	Aug
>D>	+		750MG	N022285 002	Feb 12, 2009	Aug
>A>	AB	+	750MG	N022285 002	Feb 12, 2009	Aug

LEVETIRACETAM

>A>	AB	ACTAVIS ELIZABETH	500MG	A091557 001	Sep 12, 2011	Aug
>A>	AB		750MG	A091557 002	Sep 12, 2011	Aug
>A>	AB	APOTEX INC	500MG	A091261 001	Sep 12, 2011	Aug
>A>	AB		750MG	A091261 002	Sep 12, 2011	Aug
>A>	AB	LUPIN LTD	500MG	A091399 001	Sep 12, 2011	Aug
>A>	AB		750MG	A091399 002	Sep 12, 2011	Aug
>A>	AB	MUTUAL PHARM CO INC	500MG	A091285 001	Sep 12, 2011	Aug
>A>	AB		750MG	A091285 002	Sep 12, 2011	Aug
>A>	AB	PAR PHARM	500MG	A091291 001	Sep 12, 2011	Aug
>A>	AB		750MG	A091291 002	Sep 12, 2011	Aug
>A>	AB	TEVA PHARMS	500MG	A091430 001	Sep 12, 2011	Aug
>A>	AB		750MG	A091430 002	Sep 12, 2011	Aug
>A>	AB	WATSON LABS FLORIDA	500MG	A091093 001	Sep 12, 2011	Aug
>A>	AB		750MG	A091093 002	Sep 12, 2011	Aug

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	DR REDDYS LABS LTD	5MG	A090392 001	Feb 24, 2011	Feb	NEWA
AB	GLENMARK GENERICS	5MG	A090385 001	Feb 24, 2011	Feb	NEWA
>A>	AB	TEVA PHARMS	5MG	A090199 001	Aug 22, 2011	Aug

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

AP	+	ORTHO MCNEIL PHARM	EQ 500MG/20ML (EQ 25MG/ML)	N020635 001	Dec 20, 1996	Jun
AP	+		EQ 750MG/30ML (EQ 25MG/ML)	N020635 004	Dec 20, 1996	Jun
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+	ORTHO MCNEIL PHARM	EQ 250MG/50ML (EQ 5MG/ML)	N020635 002	Dec 20, 1996	Jun
AP	+		EQ 500MG/100ML (EQ 5MG/ML)	N020635 003	Dec 20, 1996	Jun
AP	+		EQ 750MG/150ML (EQ 5MG/ML)	N020635 005	Dec 20, 1996	Jun

LEVOFLOXACIN

AP		AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644 001	Jun 20, 2011	Jun
AP			EQ 750MG/30ML (EQ 25MG/ML)	A091644 002	Jun 20, 2011	Jun
AP		SAGENT PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A200560 001	Jun 20, 2011	Jun
AP			EQ 750MG/30ML (EQ 25MG/ML)	A200560 002	Jun 20, 2011	Jun
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		ACS DOBFAR INFO SA	EQ 250MG/50ML (EQ 5MG/ML)	A090343 001	Jul 07, 2011	Jun
AP			EQ 500MG/100ML (EQ 5MG/ML)	A090343 002	Jul 07, 2011	Jun

INJECTABLE; INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ACS DOBFAR INFO SA	EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jun	NEWA
----	--------------------	----------------------------	---------	-----	--------------	-----	------

SOLUTION; ORAL

LEVAQUIN

AA	+ ORTHO MCNEIL JANSSEN	250MG/10ML	N021721	001	Oct 21, 2004	Jun	CFTG
----	------------------------	------------	---------	-----	--------------	-----	------

LEVOFLOXACIN

AA	HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Jun	NEWA
----	----------------	------------	---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT	HI TECH PHARMA	0.5%	A076826	001	Feb 10, 2011	Jan	NEWA
----	----------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

LEVAQUIN

AB	ORTHO MCNEIL JANSSEN	250MG	N020634	001	Dec 20, 1996	Jun	CFTG
----	----------------------	-------	---------	-----	--------------	-----	------

AB		500MG	N020634	002	Dec 20, 1996	Jun	CFTG
----	--	-------	---------	-----	--------------	-----	------

AB	+	750MG	N020634	003	Sep 08, 2000	Jun	CFTG
----	---	-------	---------	-----	--------------	-----	------

LEVOFLOXACIN

AB	AUROBINDO PHARMA LTD	250MG	A201043	001	Jun 20, 2011	Jun	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

AB		500MG	A201043	002	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		750MG	A201043	003	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	DR REDDYS LABS INC	250MG	A076710	001	Jun 20, 2011	Jun	NEWA
----	--------------------	-------	---------	-----	--------------	-----	------

AB		500MG	A076710	002	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		750MG	A076710	003	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	GLENMARK GENERICS	250MG	A200250	001	Jun 20, 2011	Jun	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

AB		500MG	A200250	002	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		750MG	A200250	003	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	LUPIN	250MG	A078424	001	Jun 20, 2011	Jun	NEWA
----	-------	-------	---------	-----	--------------	-----	------

AB		500MG	A078424	002	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		750MG	A078424	003	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	MYLAN	250MG	A076276	001	Jun 20, 2011	Jun	NEWA
----	-------	-------	---------	-----	--------------	-----	------

AB		500MG	A076276	002	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		750MG	A077097	001	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	SANDOZ	250MG	A077438	001	Jun 20, 2011	Jun	NEWA
----	--------	-------	---------	-----	--------------	-----	------

AB		500MG	A077438	002	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		750MG	A077438	003	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	TEVA	250MG	A076361	001	Jun 20, 2011	Jun	NEWA
----	------	-------	---------	-----	--------------	-----	------

AB		500MG	A076361	002	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		750MG	A076361	003	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	TORRENT PHARMS	250MG	A090722	001	Jun 20, 2011	Jun	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

AB		500MG	A090722	002	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		750MG	A090722	003	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	WOCKHARDT	250MG	A090367	001	Jun 20, 2011	Jun	NEWA
----	-----------	-------	---------	-----	--------------	-----	------

AB		500MG	A090367	002	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		750MG	A090367	003	Jun 20, 2011	Jun	NEWA
----	--	-------	---------	-----	--------------	-----	------

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	Apr	NEWA
---	-----------------	--	---------	-----	--------------	-----	------

+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	Apr	NEWA
---	--	--------------------------------------	---------	-----	--------------	-----	------

SOLUTION; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	May	CDFR
---	-----------------	--	---------	-----	--------------	-----	------

SOLUTION; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	May	CDFR
---	-----------------	--------------------------------------	---------	-----	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

@ TEVA WOMENS

		0.75MG	N021045	001	Jul 28, 1999	Feb	CAHN
AB	+	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ VALEANT PHARM INTL

LEVORPHANOL TARTRATE

ROXANE

		2MG	N008720	001	Dec 19, 1991	Mar	DISC
		2MG	A074278	001	Mar 31, 2000	Mar	CTEC

LEVOTHYROXINE SODIUM

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

+ APP PHARMS

+

+

		100MCG/VIAL	N202231	001	Jun 24, 2011	Jun	NEWA
		200MCG/VIAL	N202231	002	Jun 24, 2011	Jun	NEWA
		500MCG/VIAL	N202231	003	Jun 24, 2011	Jun	NEWA

TABLET; ORAL

LEVO-T

ALARA PHARM

AB1, AB2, AB3		0.025MG	N021342	001	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.05MG	N021342	002	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.075MG	N021342	003	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.088MG	N021342	004	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.1MG	N021342	005	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.112MG	N021342	006	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.125MG	N021342	007	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.137MG	N021342	012	Dec 08, 2003	Feb	CTEC
AB1, AB2, AB3		0.15MG	N021342	008	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.175MG	N021342	009	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.2MG	N021342	010	Mar 01, 2002	Feb	CTEC
AB1, + AB2, AB3		0.3MG	N021342	011	Mar 01, 2002	Feb	CTEC

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT	NOVOCOL INC	5%	A040911 001	May 23, 2011	May	NEWA
----	-------------	----	-------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	HI TECH PHARMA	2%	A040837 001	Mar 23, 2011	Mar	NEWA
----	----------------	----	-------------	--------------	-----	------

XYLOCAINE

>D>	AT	+	APP PHARMS	2%	N008816 001	Aug	CAHN
-----	----	---	------------	----	-------------	-----	------

>A>	AT	+	OAK PHARMS	2%	N008816 001	Aug	CAHN
-----	----	---	------------	----	-------------	-----	------

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

>D>	AT		ACTAVIS MID ATLANTIC	2%	A086578 001	Aug	DISC
-----	----	--	----------------------	----	-------------	-----	------

>A>			@	2%	A086578 001	Aug	DISC
-----	--	--	---	----	-------------	-----	------

SOLUTION; TOPICAL

PEDIATRIC LTA KIT

>D>			HOSPIRA	2%	A085995 001	Aug	DISC
-----	--	--	---------	----	-------------	-----	------

>A>			@	2%	A085995 001	Aug	DISC
-----	--	--	---	----	-------------	-----	------

SYSTEM; INTRADERMAL

ZINGO

	@	POWDER PHARMS	0.5MG	N022114 001	Aug 16, 2007	Jun	CAHN
--	---	---------------	-------	-------------	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

>D>	AB	+	APP PHARMS	2.5%;2.5%	N019941 001	Dec 30, 1992	Aug	CAHN
-----	----	---	------------	-----------	-------------	--------------	-----	------

>A>	AB	+	OAK PHARMS	2.5%;2.5%	N019941 001	Dec 30, 1992	Aug	CAHN
-----	----	---	------------	-----------	-------------	--------------	-----	------

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

	+	BOEHRINGER INGELHEIM	5MG	N201280 001	May 02, 2011	May	NEWA
--	---	----------------------	-----	-------------	--------------	-----	------

LISINOPRIL

TABLET; ORAL

LISINOPRIL

>A>	AB		PRINSTON INC	2.5MG	A076180 001	Jul 01, 2002	Aug	CAHN
-----	----	--	--------------	-------	-------------	--------------	-----	------

>A>	AB			5MG	A076180 002	Jul 01, 2002	Aug	CAHN
-----	----	--	--	-----	-------------	--------------	-----	------

>A>	AB			10MG	A076180 003	Jul 01, 2002	Aug	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

>A>	AB			20MG	A076164 001	Jul 01, 2002	Aug	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

>A>	AB			30MG	A076164 002	Jul 01, 2002	Aug	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

>A>	AB			40MG	A076164 003	Jul 01, 2002	Aug	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

>D>	AB		PRINSTON PHARM LLC	2.5MG	A076180 001	Jul 01, 2002	Aug	CAHN
-----	----	--	--------------------	-------	-------------	--------------	-----	------

	AB			2.5MG	A076180 001	Jul 01, 2002	May	CAHN
--	----	--	--	-------	-------------	--------------	-----	------

>D>	AB			5MG	A076180 002	Jul 01, 2002	Aug	CAHN
-----	----	--	--	-----	-------------	--------------	-----	------

	AB			5MG	A076180 002	Jul 01, 2002	May	CAHN
--	----	--	--	-----	-------------	--------------	-----	------

>D>	AB			10MG	A076180 003	Jul 01, 2002	Aug	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

	AB			10MG	A076180 003	Jul 01, 2002	May	CAHN
--	----	--	--	------	-------------	--------------	-----	------

>D>	AB			20MG	A076164 001	Jul 01, 2002	Aug	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

	AB			20MG	A076164 001	Jul 01, 2002	May	CAHN
--	----	--	--	------	-------------	--------------	-----	------

>D>	AB			30MG	A076164 002	Jul 01, 2002	Aug	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

	AB			30MG	A076164 002	Jul 01, 2002	May	CAHN
--	----	--	--	------	-------------	--------------	-----	------

>D>	AB			40MG	A076164 003	Jul 01, 2002	Aug	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

TABLET; ORAL

LISINOPRIL

AB	PRINSTON PHARM LLC	40MG	A076164 003	Jul 01, 2002	May	CAHN
----	--------------------	------	-------------	--------------	-----	------

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	GLENMARK GENERICS	450MG	A091616 001	Feb 14, 2011	Jan	NEWA
----	-------------------	-------	-------------	--------------	-----	------

LORAZEPAM

TABLET; ORAL

ATIVAN

AB	VALEANT INTL	0.5MG	N017794 001		Jul	CAHN
AB		1MG	N017794 002		Jul	CAHN
AB	+	2MG	N017794 003		Jul	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	ALEMBIC PHARMS LTD	25MG	A090428 001	Oct 06, 2010	Apr	CAHN	
AB		50MG	A090428 002	Oct 06, 2010	Apr	NEWA	
AB		100MG	A090428 003	Oct 06, 2010	Apr	CAHN	
>D>	AB	HUAHAI US INC	25MG	A091497 001	Jun 06, 2011	Aug	CAHN
	AB		25MG	A091497 001	Jun 06, 2011	May	NEWA
>D>	AB		50MG	A091497 002	Jun 06, 2011	Aug	CAHN
	AB		50MG	A091497 002	Jun 06, 2011	May	NEWA
>D>	AB		100MG	A091497 003	Jun 06, 2011	Aug	CAHN
	AB		100MG	A091497 003	Jun 06, 2011	May	NEWA
	AB	MYLAN	25MG	A091590 001	Oct 06, 2010	Jan	NEWA
	AB		50MG	A091590 002	Oct 06, 2010	Jan	NEWA
	AB		100MG	A091590 003	Oct 06, 2010	Jan	NEWA
>A>	AB	PRINSTON INC	25MG	A091497 001	Jun 06, 2011	Aug	CAHN
>A>	AB		50MG	A091497 002	Jun 06, 2011	Aug	CAHN
>A>	AB		100MG	A091497 003	Jun 06, 2011	Aug	CAHN

LOTEPREDNOL ETABONATE

OINTMENT; OPHTHALMIC

LOTEMAX

+	BAUSCH AND LOMB	0.5%	N200738 001	Apr 15, 2011	Apr	NEWA
---	-----------------	------	-------------	--------------	-----	------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

>D>	PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER					
>D>	HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML	N018406 002	Jul 08, 1982	Aug	DISC
		; 526MG/100ML; 502MG/100ML				
>A>	@	30MG/100ML; 37MG/100ML; 222MG/100ML	N018406 002	Jul 08, 1982	Aug	DISC
		; 526MG/100ML; 502MG/100ML				

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451 001	Feb 23, 2011	Feb	NEWA
AA		25MG	A201451 002	Feb 23, 2011	Feb	NEWA
AA		50MG	A201451 003	Feb 23, 2011	Feb	NEWA
AA	JUBILANT CADISTA	12.5MG	A040659 001	Jun 04, 2010	Jan	CAHN
AA		25MG	A040659 002	Jun 04, 2010	Jan	CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	LUPIN LTD	250MG	A091322 001	Jul 22, 2011	Jul	NEWA
----	-----------	-------	-------------	--------------	-----	------

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	MYLAN	7.5MG	A077934 001	Jul 20, 2006	Feb	CAHN
AB		15MG	A077934 002	Jul 20, 2006	Feb	CAHN
AB	PURACAP PHARM	7.5MG	A077938 001	Jul 19, 2006	Jun	CAHN
AB		15MG	A077938 002	Jul 19, 2006	Jun	CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE

@ SUN PHARMA GLOBAL

5MG

A090058 001 May 05, 2010 May CAHN

@

10MG

A090058 002 May 05, 2010 May CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP	BAXTER HLTHCARE CORP	10MG/ML	A081002 001	Jul 30, 1993	May	CAHN
----	----------------------	---------	-------------	--------------	-----	------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA	ALEMBIC PHARMS LTD	200MG	A090122 001	Feb 18, 2009	May	CAHN
AA		400MG	A090122 002	Feb 18, 2009	May	CAHN
AA	TARO	200MG	A200998 001	May 23, 2011	May	NEWA
AA		400MG	A200998 002	May 23, 2011	May	NEWA

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+ AQUA PHARMS 2%;0.01%

N020922 001 Dec 10, 1999 May CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	SANDOZ	500MG/VIAL	A091201 001	Mar 29, 2011	Mar	NEWA
AP		1GM/VIAL	A091201 002	Mar 29, 2011	Mar	NEWA
	MERREM					
AP	+ ASTRAZENECA	500MG/VIAL	N050706 003	Jun 21, 1996	Mar	CTNA
AP	+	1GM/VIAL	N050706 001	Jun 21, 1996	Mar	CTNA

MESALAMINE

ENEMA; RECTAL

ROWASA

AB	+ MEDA PHARMS	4GM/60ML	N019618 001	Dec 24, 1987	Jun	CAHN
----	---------------	----------	-------------	--------------	-----	------

SFROWASA

AB	MEDA PHARMS	4GM/60ML	N019618 002	Jun 20, 2008	Jun	CAHN
----	-------------	----------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

ASACOL

+ WARNER CHILCOTT LLC 400MG

N019651 001 Jan 31, 1992 Jun CAHN

TABLET, DELAYED RELEASE; ORAL

ASACOL HD

+ WARNER CHILCOTT LLC 800MG

N021830 001 May 29, 2008 Jun CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB MYLAN 500MG

A075973 001 Jan 25, 2002 Feb CAHN

AB 850MG

A075973 002 Jan 25, 2002 Feb CAHN

AB 1GM

A075973 003 Jan 25, 2002 Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

AB2 ANDRX LABS LLC 500MG

N021574 001 Apr 27, 2004 Jun CTEC

AB + 1GM

N021574 002 Apr 27, 2004 Jun CTEC

GLUCOPHAGE XR

AB1 BRISTOL MYERS SQUIBB 500MG

N021202 001 Oct 13, 2000 Jun CTEC

METFORMIN HYDROCHLORIDE

>D> AB1 ACTAVIS ELIZABETH 500MG

A076450 001 Oct 01, 2004 Aug DISC

>A> @ 500MG

A076450 001 Oct 01, 2004 Aug DISC

AB1 500MG

A076450 001 Oct 01, 2004 Jun CTEC

>D> AB 750MG

A076878 001 Apr 13, 2005 Aug DISC

>A> @ 750MG

A076878 001 Apr 13, 2005 Aug DISC

>A> AB1 ALVOGEN 500MG

A078321 001 Apr 17, 2008 Aug CAHN

>A> AB 750MG

A078321 002 Apr 17, 2008 Aug CAHN

AB1 AMNEAL PHARMS NY 500MG

A078596 001 Jan 03, 2008 Jun CTEC

AB1 APOTEX 500MG

A076706 001 Dec 14, 2004 Jun CTEC

AB 750MG

A076706 002 Dec 29, 2005 Jun CAHN

AB1 IMPAX LABS 500MG

A076249 001 Jul 30, 2004 Jun CTEC

>D> AB2 LUPIN LTD 500MG

A090692 001 Jun 29, 2011 Aug CAHN

>A> AB2 500MG

A090692 001 Jun 29, 2011 Aug CAHN

AB2 500MG

A090692 001 Jun 29, 2011 Jun NEWA

>D> AB 1GM

A090692 002 Jun 29, 2011 Aug CAHN

>A> AB 1GM

A090692 002 Jun 29, 2011 Aug CAHN

AB 1GM

A090692 002 Jun 29, 2011 Jun NEWA

AB1 MYLAN 500MG

A076650 001 Sep 13, 2005 Jun CTEC

>D> AB1 NEUROSCI INC 500MG

A078321 001 Apr 17, 2008 Aug CAHN

AB1 500MG

A078321 001 Apr 17, 2008 Jun CTEC

>D> AB 750MG

A078321 002 Apr 17, 2008 Aug CAHN

AB1 NOSTRUM 500MG

A076756 001 Jul 26, 2006 Jun CTEC

AB1 RANBAXY LABS LTD 500MG

A076413 001 Jun 18, 2004 Jun CTEC

AB1 SANDOZ 500MG

A076873 001 Dec 14, 2004 Jun CTEC

AB1 SUN PHARM INDS (IN) 500MG

A077336 001 Feb 09, 2006 Jun CTEC

AB1 TEVA 500MG

A076269 001 Jun 18, 2004 Jun CTEC

AB1 TORRENT PHARM 500MG

A090014 001 Dec 30, 2009 Jun CTEC

AB1 WATSON LABS FLORIDA 500MG

A076172 001 Jun 16, 2004 Jun CTEC

AB1 WATSON LABS INC 500MG

A076818 001 Dec 14, 2004 Jun CTEC

AB1 ZYDUS PHARMS USA 500MG

A077060 001 Apr 20, 2005 Jun CTEC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB TAKEDA GLOBAL 500MG;EQ 15MG BASE

N021842 001 Aug 29, 2005 Feb CFTG

AB + 850MG;EQ 15MG BASE

N021842 002 Aug 29, 2005 Feb CFTG

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB MYLAN 500MG;EQ 15MG BASE

A090406 001 Feb 25, 2011 Feb NEWA

AB 850MG;EQ 15MG BASE

A090406 002 Feb 25, 2011 Feb NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	EMCURE PHARMS USA	5MG	A040734 001	Dec 14, 2007	Jul	CAHN
AB		10MG	A040734 002	Dec 14, 2007	Jul	CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	LANNETT HOLDINGS INC	500MG	A084756 002	Mar 31, 2003	Jun	CAHN
AA		750MG	A084756 001		Jun	CAHN
	@ PURACAP PHARM	500MG	A084231 002		Jun	CAHN
	@	750MG	A084471 001		Jun	CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

AB	+ NOVARTIS	0.2MG	N006035 003		Apr	CTEC
	METHYLERGONOVINE MALEATE					
AB	NOVEL LABS INC	0.2MG	A091577 001	May 02, 2011	Apr	NEWA

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	5MG	A040321 001	Feb 05, 2002	Aug	DISC
>A>		@	5MG	A040321 001	Feb 05, 2002	Aug	DISC
>D>	AB		10MG	A040321 002	Feb 05, 2002	Aug	DISC
>A>		@	10MG	A040321 002	Feb 05, 2002	Aug	DISC
>D>	AB		20MG	A040321 003	Feb 05, 2002	Aug	DISC
>A>		@	20MG	A040321 003	Feb 05, 2002	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	20MG	A075450 001	Dec 21, 2001	Aug	DISC
>A>		@	20MG	A075450 001	Dec 21, 2001	Aug	DISC

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB	JUBILANT CADISTA	4MG	A040189 001	Oct 31, 1997	Jan	CAHN
AB		8MG	A040189 002	Oct 31, 1997	Jan	CAHN
AB		16MG	A040189 003	Jul 20, 2007	Jan	CAHN
AB		32MG	A040189 004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HEMOPARM	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Apr	CAHN
AP		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Apr	CAHN
	@ HOSPIRA	EQ 500MG BASE/VIAL	A089173 001	Aug 18, 1987	Feb	DISC
	@	EQ 1GM BASE/VIAL	A089174 001	Aug 18, 1987	Feb	DISC

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	MUSTAFA NEVSAT	EQ 40MG BASE/VIAL	A040888 001	Jul 18, 2011	Jul	NEWA
AP		EQ 125MG BASE/VIAL	A040888 002	Jul 18, 2011	Jul	NEWA
AP		EQ 500MG BASE/VIAL	A040888 003	Jul 18, 2011	Jul	NEWA
AP		EQ 1GM BASE/VIAL	A040888 004	Jul 18, 2011	Jul	NEWA

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	MUSTAFA NEVSAT	EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jul	NEWA
SOLU-MEDROL							
AP	+ PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N011856	007	Feb 27, 1985	Jul	CTEC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991	Aug	DISC
>A>		@	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991	Aug	DISC

TABLET; ORAL

REGLAN

>D>	AB	ALAVEN PHARM	EQ 5MG BASE	N017854	002	May 05, 1987	Aug	CAHN
>D>	AB	+	EQ 10MG BASE	N017854	001		Aug	CAHN
>A>	AB	ANI PHARMS	EQ 5MG BASE	N017854	002	May 05, 1987	Aug	CAHN
>A>	AB	+	EQ 10MG BASE	N017854	001		Aug	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

REGLAN ODT

>D>		@ ALAVEN PHARM	EQ 5MG BASE	N021793	001	Jun 10, 2005	Aug	CAHN
>D>		@	EQ 10MG BASE	N021793	002	Jun 10, 2005	Aug	CAHN
>A>		@ MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005	Aug	CAHN
>A>		@	EQ 10MG BASE	N021793	002	Jun 10, 2005	Aug	CAHN

METRONIDAZOLE

GEL; TOPICAL

METROGEL

AB	+	GALDERMA LABS LP	1%	N021789	001	Jun 30, 2005	Jul	CTEC
METRONIDAZOLE								
AB		G AND W LABS INC	0.75%	A078178	001	Jan 19, 2011	Jan	NEWA
AB		TOLMAR	1%	A090903	001	Jul 22, 2011	Jul	NEWA

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+	PFIZER	500MG/100ML	N018353	002		Jun	CAHN
----	---	--------	-------------	---------	-----	--	-----	------

TABLET; ORAL

METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	250MG	A079067	001	Mar 13, 2009	May	CAHN
AB			500MG	A079067	002	Mar 13, 2009	May	CAHN

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

	@	PFIZER	EQ 500MG BASE/VIAL	N018353	001		Jun	DISC
--	---	--------	--------------------	---------	-----	--	-----	------

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+	ASTELLAS	100MG/VIAL	N021506	003	Jun 27, 2006	Jan	CRLD
---	----------	------------	---------	-----	--------------	-----	------

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

	@	ORTHO JANSSEN	2%	N017494	001		Jul	CAHN
--	---	---------------	----	---------	-----	--	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 1MG BASE/ML	A075409 002	Jun 20, 2000	Aug	DISC
>A>		@	EQ 1MG BASE/ML	A075409 002	Jun 20, 2000	Aug	DISC
		MIDOZALAM HYDROCHLORIDE					
	AP	SAGENT STRIDES	EQ 1MG BASE/ML	A090316 001	May 04, 2011	Apr	NEWA
	AP		EQ 5MG BASE/ML	A090316 002	May 04, 2011	Apr	NEWA

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

>D>		CYPRESS BIOSCIENCE	50MG	N022256 003	Jan 14, 2009	Aug	CRLD
>A>		+	50MG	N022256 003	Jan 14, 2009	Aug	CRLD
>D>		+	100MG	N022256 004	Jan 14, 2009	Aug	CRLD
>A>			100MG	N022256 004	Jan 14, 2009	Aug	CRLD

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

	@	HOSPIRA	EQ 1MG BASE/ML	A075884 001	May 28, 2002	Feb	DISC
--	---	---------	----------------	-------------	--------------	-----	------

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

>D>	AB	ACTAVIS ELIZABETH	15MG	A076308 001	Jun 20, 2003	Aug	DISC
>A>		@	15MG	A076308 001	Jun 20, 2003	Aug	DISC
>D>	AB		30MG	A076308 002	Jun 20, 2003	Aug	DISC
>A>		@	30MG	A076308 002	Jun 20, 2003	Aug	DISC
>D>	AB		45MG	A076308 003	Jun 20, 2003	Aug	DISC
>A>		@	45MG	A076308 003	Jun 20, 2003	Aug	DISC
		@ ACTAVIS TOTOWA	15MG	A076241 001	Jun 25, 2003	Jul	DISC
		@	30MG	A076241 002	Jun 25, 2003	Jul	DISC
		@	45MG	A076241 003	Jun 25, 2003	Jul	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

	AB	ACTAVIS ELIZABETH	15MG	A077959 001	Feb 14, 2011	Jan	NEWA
	AB		30MG	A077959 002	Feb 14, 2011	Jan	NEWA
	AB		45MG	A077959 003	Feb 14, 2011	Jan	NEWA
		@ ACTAVIS TOTOWA	15MG	A076689 001	Aug 31, 2005	Jul	DISC
		@	30MG	A076689 002	Aug 31, 2005	Jul	DISC
		@	45MG	A076689 003	Aug 31, 2005	Jul	DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076871 001	Apr 11, 2006	Aug	CRLD
>A>	AP	+	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076871 001	Apr 11, 2006	Aug	CRLD
>D>	AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076871 002	Apr 11, 2006	Aug	CRLD
>A>	AP	+	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076871 002	Apr 11, 2006	Aug	CRLD
>D>	AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076871 003	Apr 11, 2006	Aug	CRLD

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

>A>	AP	+	HOSPIRA	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076871 003	Apr 11, 2006	Aug	CRLD
>D>			NOVANTRONE					
>D>	AP	+	EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297 001	Dec 23, 1987	Aug	DISC
>A>		@		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297 001	Dec 23, 1987	Aug	DISC

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

	+	EKR THERAP	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CRLD
	@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	DISC

SOLUTION; ORAL

MORPHINE SULFATE

			LANNETT HOLDINGS INC	20MG/ML	N201517 001	Jun 23, 2011	Jun	NEWA
	AA		MALLINCKRODT INC	100MG/5ML	A202348 001	Jul 15, 2011	Jul	NEWA
>D>		+	ROXANE	100MG/5ML	N022195 003	Jan 25, 2010	Aug	CTEC
>A>	AA	+		100MG/5ML	N022195 003	Jan 25, 2010	Aug	CTEC

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

>D>	AB		WATSON LABS	100MG	A075656 001	Jan 30, 2001	Aug	DISC
>A>		@		100MG	A075656 001	Jan 30, 2001	Aug	DISC

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

	AB		GLENMARK PHARMS	2%	A090480 001	Jun 08, 2011	May	NEWA
--	----	--	-----------------	----	-------------	--------------	-----	------

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746 001	Dec 11, 1997	Jan	CDFR
--	---	-----------------	------------	-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

>D>	AB		ACTAVIS ELIZABETH	500MG	A079093 001	Feb 27, 2009	Aug	DISC
>A>		@		500MG	A079093 001	Feb 27, 2009	Aug	DISC
>D>	AB			750MG	A079093 002	Feb 27, 2009	Aug	DISC
>A>		@		750MG	A079093 002	Feb 27, 2009	Aug	DISC
	AB		LUPIN LTD	500MG	A090445 001	Jan 12, 2011	Jan	NEWA
	AB			750MG	A090445 002	Jan 12, 2011	Jan	NEWA
	AB		WATSON LABS	500MG	A091083 001	Jun 13, 2011	May	NEWA
	AB			750MG	A091083 002	Jun 13, 2011	May	NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

	AP		IBI	EQ 1GM BASE/VIAL	A090002 001	Jun 30, 2011	Jun	NEWA
	AP			EQ 2GM BASE/VIAL	A090002 002	Jun 30, 2011	Jun	NEWA
	AP		INSTITUTO BIOCHEMICO	EQ 10GM BASE/VIAL	A090005 001	Apr 20, 2011	Apr	NEWA
	AP	+	SANDOZ	EQ 10GM BASE/VIAL	A062527 004	Aug 02, 1984	Apr	CTEC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

>A>	AB	ACCORD HLTHCARE	50MG	A091205 001	Aug 17, 2011	Aug	NEWA
	AB	ELITE LABS	50MG	A075274 001	May 26, 1999	Feb	CAHN

NAPROXEN

TABLET; ORAL

NAPROXEN

>A>	AB	INVAGEN PHARMS	250MG	A091305 001	Aug 24, 2011	Aug	NEWA
>A>	AB		375MG	A091305 002	Aug 24, 2011	Aug	NEWA
>A>	AB		500MG	A091305 003	Aug 24, 2011	Aug	NEWA
	AB	MARKSANS PHARMA	250MG	A091416 001	Feb 14, 2011	Jan	NEWA
	AB		375MG	A091416 002	Feb 14, 2011	Jan	NEWA
	AB		500MG	A091416 003	Feb 14, 2011	Jan	NEWA

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

>D>	AB	ACTAVIS ELIZABETH	375MG	A074936 001	Feb 24, 1998	Aug	DISC
>A>		@	375MG	A074936 001	Feb 24, 1998	Aug	DISC
>D>	AB		500MG	A074936 002	Feb 24, 1998	Aug	DISC
>A>		@	500MG	A074936 002	Feb 24, 1998	Aug	DISC

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

	AB	APOTEX CORP	EQ 1MG BASE	A091373 001	Apr 22, 2011	Apr	NEWA
	AB		EQ 2.5MG BASE	A091373 002	Apr 22, 2011	Apr	NEWA
	AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552 001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

	AB	INDICUS PHARMA	EQ 1MG BASE	A200502 001	Feb 28, 2011	Feb	NEWA
	AB		EQ 2.5MG BASE	A200502 002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

	AB	WATSON LABS	60MG	A077462 001	Mar 30, 2011	Mar	NEWA
	AB		120MG	A077462 002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

VIRAMUNE XR

+		BOEHRINGER INGELHEIM	400MG	N201152 001	Mar 25, 2011	Mar	NEWA
---	--	----------------------	-------	-------------	--------------	-----	------

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

@		EKR THERAP	45MG	N020005 002	Feb 21, 1992	May	DISC
---	--	------------	------	-------------	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1		VALEANT INTL	30MG	A075269 001	Dec 04, 2000	Apr	CAHN
-----	--	--------------	------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB2	VALEANT INTL	30MG	A075289	002	Feb 06, 2001	Apr	CAHN
AB2		60MG	A075289	001	Sep 27, 2000	Apr	CAHN
AB1		60MG	A075269	002	Dec 04, 2000	Apr	CAHN
AB1		90MG	A076070	001	Aug 16, 2002	Apr	CAHN

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE; ORAL

TASIGNA

>A>	NOVARTIS	EQ 150MG BASE	N022068	002	Jun 17, 2010	Aug	NEWA
-----	----------	---------------	---------	-----	--------------	-----	------

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB	MYLAN	8.5MG	A091001	001	Jan 26, 2011	Jan	NEWA
AB		17MG	A091001	002	Jan 26, 2011	Jan	NEWA
AB		25.5MG	A091001	003	Jan 26, 2011	Jan	NEWA
AB		34MG	A091001	004	Jan 26, 2011	Jan	NEWA

SULAR

AB	+	SHIONOGI PHARMA	8.5MG	N020356	008	Jan 02, 2008	Jan	CFTG
AB	+		17MG	N020356	007	Jan 02, 2008	Jan	CFTG
AB			25.5MG	N020356	006	Jan 02, 2008	Jan	CFTG
AB	+		34MG	N020356	005	Jan 02, 2008	Jan	CFTG

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

AB	+	SHIONOGI INC	25MG/5ML	N009175	001		Apr	CFTG
----	---	--------------	----------	---------	-----	--	-----	------

NITROFURANTOIN

AB		AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011	Apr	NEWA
----	--	---------------	----------	---------	-----	--------------	-----	------

NITROGLYCERIN

OINTMENT; INTRA-ANAL

RECTIV

	+	PROSTRAKAN INC	0.4%	N021359	001	Jun 21, 2011	Jun	NEWA
--	---	----------------	------	---------	-----	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB		GLENMARK GENERICS	150MG	A090618	001	Jul 15, 2011	Jul	NEWA
AB			300MG	A090618	002	Jul 15, 2011	Jul	NEWA
AB		MYLAN	150MG	A075934	001	Jul 09, 2002	Feb	CAHN
AB			300MG	A075934	002	Jul 09, 2002	Feb	CAHN

NORGESTREL

TABLET; ORAL

OVRETTE

>A>	@	WYETH PHARMS	0.075MG	N017031	001		Aug	CAHN
>D>	@	WYETH PHARMS INC	0.075MG	N017031	001		Aug	CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

PAMELOR

>A>	AB	MALLINCKRODT LLC	EQ 10MG BASE	N018013	001		Aug	CAHN
>A>	AB		EQ 25MG BASE	N018013	002		Aug	CAHN

CAPSULE; ORAL

PAMELOR

>A>	AB	MALLINCKRODT LLC	EQ 50MG BASE	N018013 004		Aug	CAHN
>A>	AB	+	EQ 75MG BASE	N018013 003		Aug	CAHN
>D>	AB	TYCO HLTHCARE	EQ 10MG BASE	N018013 001		Aug	CAHN
>D>	AB		EQ 25MG BASE	N018013 002		Aug	CAHN
>D>	AB		EQ 50MG BASE	N018013 004		Aug	CAHN
>D>	AB	+	EQ 75MG BASE	N018013 003		Aug	CAHN

SOLUTION; ORAL

PAMELOR

AA		MALLINCKRODT INC	EQ 10MG BASE/5ML	N018012 001		Jul	CAHN
----	--	------------------	------------------	-------------	--	-----	------

NYSTATIN

CREAM; TOPICAL

MYCOSTATIN

>D>	AT	+	BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060575 001		Aug	DISC
>A>		@		100,000 UNITS/GM	A060575 001		Aug	DISC

NYSTATIN

>D>	AT		TARO	100,000 UNITS/GM	A064022 001	Jan 29, 1993	Aug	CRLD
>A>	AT			100,000 UNITS/GM	A064022 001	Jan 29, 1993	Aug	CRLD

POWDER; TOPICAL

MYCOSTATIN

>D>	AT	+	BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060578 001		Aug	DISC
>A>		@		100,000 UNITS/GM	A060578 001		Aug	DISC

NYSTATIN

>D>	AT		COASTAL PHARMS	100,000 UNITS/GM	A065203 001	Jul 15, 2004	Aug	CRLD
>A>	AT			100,000 UNITS/GM	A065203 001	Jul 15, 2004	Aug	CRLD

SUSPENSION; ORAL

NYSTATIN

>D>	AA		BAUSCH AND LOMB	100,000 UNITS/ML	A064042 001	Feb 28, 1994	Aug	CAHN
>A>	AA		HI TECH PHARMA	100,000 UNITS/ML	A064042 001	Feb 28, 1994	Aug	CAHN
	AA		VISTAPHARM	100,000 UNITS/ML	A065422 001	Mar 07, 2011	Feb	NEWA

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

>D>	AT		ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	A062367 001	May 28, 1985	Aug	DISC
>A>		@		100,000 UNITS/GM;0.1%	A062367 001	May 28, 1985	Aug	DISC

OINTMENT; TOPICAL

MYKACET

>D>	AT		ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	A062733 001	Mar 09, 1987	Aug	DISC
>A>		@		100,000 UNITS/GM;0.1%	A062733 001	Mar 09, 1987	Aug	DISC

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP		WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986 001	May 11, 2011	Apr	NEWA	
AP			EQ 1MG BASE/ML	A090986 002	May 11, 2011	Apr	NEWA	
		OCTREOTIDE ACETATE (PRESERVATIVE FREE)						
>D>	AP		BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198 001	Feb 10, 2011	Aug	CAHN
	AP			EQ 0.05MG BASE/ML	A079198 001	Feb 10, 2011	Jan	NEWA
>D>	AP			EQ 0.1MG BASE/ML	A079198 002	Feb 10, 2011	Aug	CAHN
	AP			EQ 0.1MG BASE/ML	A079198 002	Feb 10, 2011	Jan	NEWA
>D>	AP			EQ 0.5MG BASE/ML	A079198 003	Feb 10, 2011	Aug	CAHN
	AP			EQ 0.5MG BASE/ML	A079198 003	Feb 10, 2011	Jan	NEWA
>A>	AP		MYLAN INSTITUTIONAL	EQ 0.05MG BASE/ML	A079198 001	Feb 10, 2011	Aug	CAHN

INJECTABLE; INJECTIONOCTREOTIDE ACETATE (PRESERVATIVE FREE)

>A>	AP	MYLAN INSTITUTIONAL	EQ 0.1MG BASE/ML	A079198 002	Feb 10, 2011	Aug	CAHN
>A>	AP		EQ 0.5MG BASE/ML	A079198 003	Feb 10, 2011	Aug	CAHN
	AP	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985 001	May 11, 2011	Apr	NEWA
	AP		EQ 0.1MG BASE/ML	A090985 002	May 11, 2011	Apr	NEWA
	AP		EQ 0.5MG BASE/ML	A090985 003	May 11, 2011	Apr	NEWA

ONDANSETRONTABLET, ORALLY DISINTEGRATING; ORALONDANSETRON

AB	RANBAXY	4MG	A078602 001	Feb 24, 2011	Feb	NEWA
AB		8MG	A078602 002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTIONONDANSETRON HYDROCHLORIDE

AP	PFIZER	EQ 2MG BASE/ML	A078257 001	Apr 23, 2008	May	CAHN
AP	TEVA	EQ 2MG BASE/ML	A076876 001	Nov 22, 2006	Jan	CMFD

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP	+	HOSPIRA	EQ 0.64MG BASE/ML	A077348 001	Feb 01, 2007	Apr	CRLD
>D>	AP	TEVA PARENTERAL	EQ 0.64MG BASE/ML	A077480 001	Nov 22, 2006	Aug	CAHN
>A>	AP	TEVA PHARMS	EQ 0.64MG BASE/ML	A077480 001	Nov 22, 2006	Aug	CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	PFIZER	EQ 2MG BASE/ML	A078244 001	Apr 23, 2008	May	CAHN
----	--------	----------------	-------------	--------------	-----	------

SOLUTION; ORALONDANSETRON HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483 001	Jan 31, 2011	Jan	NEWA
AA	SILARX	EQ 4MG BASE/5ML	A091342 001	Jan 27, 2011	Jan	NEWA

TABLET; ORALONDANSETRON HYDROCHLORIDE

AB	TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011	Mar	NEWA
AB		EQ 8MG BASE	A077729 002	Mar 28, 2011	Mar	NEWA
AB		EQ 24MG BASE	A077729 003	Mar 28, 2011	Mar	NEWA

ORPHENADRINE CITRATEINJECTABLE; INJECTIONORPHENADRINE CITRATE

>A>	AP	SAGENT PHARMS	30MG/ML	A090585 001	Aug 30, 2011	Aug	NEWA
-----	----	---------------	---------	-------------	--------------	-----	------

OSELTAMIVIR PHOSPHATEFOR SUSPENSION; ORALTAMIFLU

	ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jun	NEWA
	@	EQ 12MG BASE/ML	N021246 001	Dec 14, 2000	Jul	DISC

OXALIPLATININJECTABLE; IV (INFUSION)OXALIPLATIN

AP	SANDOZ	50MG/10ML (5MG/ML)	A078817 001	Jan 24, 2011	Jan	NEWA
AP		50MG/VIAL	A090849 001	Apr 28, 2011	Apr	NEWA
AP		100MG/VIAL	A090849 002	Apr 28, 2011	Apr	NEWA
AP		100MG/20ML (5MG/ML)	A078817 002	Jan 24, 2011	Jan	NEWA

Oxaprozín

TABLET; ORAL

Oxaprozín

>D>	AB	ACTAVIS ELIZABETH	600MG	A075843 001	Oct 03, 2001	Aug	DISC
>A>		@	600MG	A075843 001	Oct 03, 2001	Aug	DISC
	AB	MYLAN	600MG	A075847 001	Feb 28, 2001	Feb	CAHN

Oxycodone Hydrochloride

TABLET; ORAL

Oxecta

KING PHARMS R AND D

5MG
7.5MG

N202080 001 Jun 17, 2011 Jun NEWA
N202080 002 Jun 17, 2011 Jun NEWA

Oxycodone Hydrochloride

AB COASTAL PHARMS

5MG

A091313 001 Feb 18, 2011 Feb NEWA

AB 15MG

A091313 002 Feb 18, 2011 Feb NEWA

AB 30MG

A091313 003 Feb 18, 2011 Feb NEWA

AB RHODES PHARMS

5MG

A091490 001 Mar 09, 2011 Feb NEWA

AB 10MG

A091490 002 Mar 09, 2011 Feb NEWA

AB 15MG

A091490 003 Mar 09, 2011 Feb NEWA

AB 20MG

A091490 004 Mar 09, 2011 Feb NEWA

AB 30MG

A091490 005 Mar 09, 2011 Feb NEWA

Oxymetholone

TABLET; ORAL

ANADROL-50

+ MEDA PHARMS

50MG

N016848 001 May CAHN

Oxymorphone Hydrochloride

TABLET; ORAL

Oxymorphone Hydrochloride

AB TEVA

5MG

A091443 002 Feb 15, 2011 Jan NEWA

AB 10MG

A091443 001 Feb 15, 2011 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS

7.5MG

N021610 005 Feb 29, 2008 Feb DISC

@ 15MG

N021610 006 Feb 29, 2008 Feb DISC

Paliperidone

TABLET, EXTENDED RELEASE; ORAL

INVEGA

JANSSEN PHARMS

1.5MG

N021999 006 Aug 26, 2008 Jul CAHN

3MG

N021999 001 Dec 19, 2006 Jul CAHN

+

6MG

N021999 002 Dec 19, 2006 Jul CAHN

9MG

N021999 003 Dec 19, 2006 Jul CAHN

@

12MG

N021999 004 Dec 19, 2006 Jul CAHN

Paliperidone Palmitate

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

JANSSEN PHARMS

39MG/0.25ML (39MG/0.25ML)

N022264 001 Jul 31, 2009 Jun CAHN

78MG/0.5ML (78MG/0.5ML)

N022264 002 Jul 31, 2009 Jun CAHN

>D> 117MG/0.75ML (117MG/0.75ML)

N022264 003 Jul 31, 2009 Aug CRLD

>A> + 117MG/0.75ML (117MG/0.75ML)

N022264 003 Jul 31, 2009 Aug CRLD

117MG/0.75ML (117MG/0.75ML)

N022264 003 Jul 31, 2009 Jun CAHN

156MG/ML (156MG/ML)

N022264 004 Jul 31, 2009 Jun CAHN

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

>D>	+	JANSSEN PHARMS	234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009	Aug	CRLD
>A>			234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009	Aug	CRLD
	+		234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009	Jun	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

>D>	AP	AKORN STRIDES	30MG/10ML (3MG/ML)	A078520 001	Oct 31, 2008	Aug	CAHN
>D>	AP		90MG/10ML (9MG/ML)	A078520 002	Oct 31, 2008	Aug	CAHN
	AP	MUSTAFA NEVZAT	30MG/10ML (3MG/ML)	A078373 001	Dec 23, 2008	May	CAHN
	AP		90MG/10ML (9MG/ML)	A078373 002	Dec 23, 2008	May	CAHN
>A>	AP	PFIZER	30MG/10ML (3MG/ML)	A078520 001	Oct 31, 2008	Aug	CAHN
>A>	AP		90MG/10ML (9MG/ML)	A078520 002	Oct 31, 2008	Aug	CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

		JANSSEN PHARMS	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523 001	Apr 12, 2010	Jun	CAHN
			43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523 002	Apr 12, 2010	Jun	CAHN
			70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523 004	Apr 12, 2010	Jun	CAHN
	+		61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523 003	Apr 12, 2010	Jun	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

	AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797 001	Feb 07, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A090797 002	Feb 07, 2011	Jan	NEWA
	AB	DR REDDYS LABS LTD	EQ 20MG BASE	A077619 001	Jan 19, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A077619 002	Jan 19, 2011	Jan	NEWA
>A>	AB	JUBILANT ORGANOSYS	EQ 20MG BASE	A090901 001	Aug 30, 2011	Aug	NEWA
>A>	AB		EQ 40MG BASE	A090901 002	Aug 30, 2011	Aug	NEWA
	AB	KUDCO IRELAND	EQ 20MG BASE	A078281 001	Jan 20, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A078281 002	Jan 20, 2011	Jan	NEWA
	AB	MATRIX LABS LTD	EQ 20MG BASE	A090970 001	Jan 19, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A090970 002	Jan 19, 2011	Jan	NEWA
	AB	TORRENT PHARMS	EQ 20MG BASE	A090074 001	Jan 19, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A090074 002	Jan 19, 2011	Jan	NEWA
	AB	WOCKHARDT	EQ 20MG BASE	A091231 001	Jan 19, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A091231 002	Jan 19, 2011	Jan	NEWA

PARICALCITOL

INJECTABLE; INJECTION

PARICALCITOL

	AP	SANDOZ CANADA INC	0.002MG/ML	A091108 001	Jul 27, 2011	Jul	NEWA
	AP		0.005MG/ML	A091108 002	Jul 27, 2011	Jul	NEWA
		ZEMPLAR					
	AP	+ ABBOTT	0.002MG/ML	N020819 002	Feb 01, 2000	Jul	CFTG
	AP	+	0.005MG/ML	N020819 001	Apr 17, 1998	Jul	CFTG

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

>A>	@	KING PFIZER	EQ 250MG BASE	A062310 001		Aug	CAHN
>D>	@	MONARCH PHARMS	EQ 250MG BASE	A062310 001		Aug	CAHN
	@		EQ 250MG BASE	A062310 001		May	CAHN

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Aug	DISC
>A>		@	EQ 10MG BASE	A076968 001	Jun 21, 2010	Aug	DISC
>D>	AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Aug	DISC
>A>		@	EQ 20MG BASE	A076968 002	Jun 21, 2010	Aug	DISC
>D>	AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Aug	DISC
>A>		@	EQ 30MG BASE	A076968 003	Jun 21, 2010	Aug	DISC
>D>	AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Aug	DISC
>A>		@	EQ 40MG BASE	A076968 004	Jun 21, 2010	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB		MYLAN	EQ 37.5MG BASE	A091427 001	Apr 14, 2011	Apr	NEWA
		PAXIL CR					
AB	+	GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936 003	Dec 06, 2000	Apr	CTEC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB		VALEANT INTL	400MG	A075028 001	Jul 20, 1998	Apr	CAHN
----	--	--------------	-------	-------------	--------------	-----	------

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

>D>	AA	EMCURE PHARMS USA	35MG	A040762 001	Jan 28, 2008	Aug	CAHN
	AA		35MG	A040762 001	Jan 28, 2008	Jul	CAHN
>A>	AA	MIKAH PHARMA	35MG	A040762 001	Jan 28, 2008	Aug	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

	@	ACTAVIS TOTOWA	15MG	A040460 001	Jan 14, 2003	Jul	DISC
	@		30MG	A040227 001	Jun 18, 1997	Jul	DISC
	@		30MG	A040448 001	Jan 22, 2003	Jul	DISC
	@		37.5MG	A040228 001	Jun 19, 1997	Jul	DISC
AA		LANNETT HOLDINGS INC	37.5MG	A201961 001	Jul 20, 2011	Jul	NEWA

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

	@	ACTAVIS TOTOWA	37.5MG	A040190 001	May 30, 1997	Jul	DISC
AA		ELITE LABS	37.5MG	A200272 001	Jan 31, 2011	May	CAHN
AA		EPIC PHARMA LLC	37.5MG	A200272 001	Jan 31, 2011	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

		CITIUS PHARMS	15MG	N202088 001	Jun 13, 2011	Jun	NEWA
	+		30MG	N202088 002	Jun 13, 2011	Jun	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

LANNETT HOLDINGS INC EQ 15MG BASE

A040872 001 Jul 28, 2011 Jul NEWA

EQ 30MG BASE

A040872 002 Jul 28, 2011 Jul NEWA

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

ORAVERSE

>D> + NOVALAR 0.4MG/1.7ML

N022159 001 May 09, 2008 Aug CAHN

>A> + SEPTODONT HOLDING 0.4MG/1.7ML

N022159 001 May 09, 2008 Aug CAHN

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP X-GEN PHARMS 50MG/ML

A040573 001 Sep 13, 2006 May CAHN

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

>D> @ ATON 1MG/0.5ML

N012223 002 Aug CAHN

>D> @ 10MG/ML

N012223 001 Aug CAHN

>A> @ BIOVAIL TECHNOLOGIES 1MG/0.5ML

N012223 002 Aug CAHN

>A> @ 10MG/ML

N012223 001 Aug CAHN

TABLET; ORAL

MEPHYTON

>D> + ATON 5MG

N010104 003 Aug CAHN

>A> + BIOVAIL TECHNOLOGIES 5MG

N010104 003 Aug CAHN

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

ALCON RES 1%

N200890 001 Jun 22, 2010 May CTNA

2%

N200890 002 Jun 22, 2010 May CTNA

+ 4%

N200890 003 Jun 22, 2010 May CTNA

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

+ VALEANT INTL 1%

N021302 001 Dec 13, 2001 Jul CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP AUROBINDO PHARMA LTD EQ 2GM BASE/VIAL;EQ 250MG
BASE/VIAL

A065498 001 May 23, 2011 May NEWA

AP EQ 3GM BASE/VIAL;EQ 375MG
BASE/VIAL

A065498 002 May 23, 2011 May NEWA

AP EQ 4GM BASE/VIAL;EQ 500MG
BASE/VIAL

A065498 003 May 23, 2011 May NEWA

AP HOSPIRA INC EQ 2GM BASE/VIAL;EQ 250MG
BASE/VIAL

A065386 001 Sep 15, 2009 Jan CAHN

AP EQ 3GM BASE/VIAL;EQ 375MG
BASE/VIAL

A065386 002 Sep 15, 2009 Jan CAHN

AP EQ 4GM BASE/VIAL;EQ 500MG
BASE/VIAL

A065386 003 Sep 15, 2009 Jan CAHN

AP EQ 36GM BASE/VIAL;EQ 4.5GM
BASE/VIAL

A065446 001 Sep 15, 2009 Jan CAHN

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	INSTITUTO BIOCHEMICO	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523 001	May 31, 2011	May	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523 002	May 31, 2011	May	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523 003	May 31, 2011	May	NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498 001	May 31, 2011	May	NEWA

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@ MYLAN

10MG

A074043 001 Sep 22, 1992 Feb CAHN

@

20MG

A074043 002 Sep 22, 1992 Feb CAHN

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

KOWA CO

EQ 1MG BASE

N022363 001 Aug 03, 2009 Jul CAHN

EQ 2MG BASE

N022363 002 Aug 03, 2009 Jul CAHN

+

EQ 4MG BASE

N022363 003 Aug 03, 2009 Jul CAHN

PODOFILOX

SOLUTION; TOPICAL

PODOFILOX

AT	PRECISION DERMAT	0.5%	A090184 001	Jul 21, 2010	Jun	CAHN
----	------------------	------	-------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

@ MEDA PHARMS

120GM/PACKET;1.49GM/PACKET;3.36GM
/PACKET;2.92GM/PACKET;11.36GM/PAC
KET

N018983 005 Oct 26, 1984 Jun CAHN

@

227.1GM/PACKET;2.82GM/PACKET;6.36
GM/PACKET;5.53GM/PACKET;21.5GM/PA
CKET

N018983 004 Oct 26, 1984 Jul DISC

AA	+	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT ;5.53GM/BOT;21.5GM/BOT	N018983 010	Jan 31, 1989	Jun	CAHN
----	---	---	-------------	--------------	-----	------

227.1GM/PACKET;2.82GM/PACKET;6.36
GM/PACKET;5.53GM/PACKET;21.5GM/PA
CKET

N018983 004 Oct 26, 1984 Jun CAHN

AA	+	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT	N018983 007	Jun 12, 1987	Jun	CAHN
----	---	--	-------------	--------------	-----	------

@

360GM/PACKET;4.47GM/PACKET;10.08G
M/PACKET;8.76GM/PACKET;34.08GM/PA
CKET

N018983 006 Oct 26, 1984 Jun CAHN

COLYTE WITH FLAVOR PACKS

AA	+	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT	N018983 012	Oct 08, 1998	Jun	CAHN
----	---	-------------	--	-------------	--------------	-----	------

COLYTE-FLAVORED

AA	+	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT ;5.53GM/BOT;21.5GM/BOT	N018983 008	Nov 14, 1991	Jun	CAHN
----	---	-------------	---	-------------	--------------	-----	------

AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT	N018983 009	Nov 14, 1991	Jun	CAHN
----	---	--	--	-------------	--------------	-----	------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

AP	SAGENT STRIDES	EQ 500,000 UNITS BASE/VIAL	A090110 001	Jun 29, 2011	Jun	NEWA
----	----------------	----------------------------	-------------	--------------	-----	------

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

>D>	@ PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995	Aug	CMFD
>A>		75MG/VIAL	N020451	001	Dec 27, 1995	Aug	CMFD
	@	75MG/VIAL	N020451	001	Dec 27, 1995	Jun	DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

>D>	AB	KV PHARM	8MEQ	N018238	001		Aug	CAHN
>A>	AB	NESHER PHARMS	8MEQ	N018238	001		Aug	CAHN

MICRO-K 10

>D>	AB	KV PHARM	10MEQ	N018238	002	May 14, 1984	Aug	CAHN
>A>	AB	NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Aug	CAHN

POTASSIUM CHLORIDE

	AB	PADDOCK LABS	8MEQ	A200185	001	May 18, 2011	May	NEWA
	AB		10MEQ	A200185	002	May 18, 2011	May	NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

		BOEHRINGER INGELHEIM	2.25MG	N022421	006	Jun 17, 2011	Jun	NEWA
			3.75MG	N022421	007	Jun 17, 2011	Jun	NEWA

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

	@	VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007	May	DISC
--	---	----------------	-----------------	---------	-----	--------------	-----	------

PREDNISONE

TABLET; ORAL

PREDNISONE

	AB	JUBILANT CADISTA	1MG	A040611	001	Jun 06, 2005	Jan	CAHN
	AB		5MG	A040362	002	Aug 29, 2001	Jan	CAHN
	AB		10MG	A040362	001	Aug 29, 2001	Jan	CAHN
	AB		20MG	A040362	003	Jun 29, 2005	Jan	CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

	AB	JUBILANT CADISTA	EQ 5MG BASE	A040268	001	Feb 27, 1998	Jan	CAHN
	AB		EQ 10MG BASE	A040268	002	Feb 27, 1998	Jan	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

	AP	X-GEN PHARMS	25MG/ML	A040737	001	Apr 24, 2008	May	CAHN
	AP		50MG/ML	A040737	002	Apr 24, 2008	May	CAHN

SUPPOSITORY; RECTAL

PHENERGAN

>A>	@	SHIONOGI INC	12.5MG	N010926	002		Aug	CAHN
>A>	@		25MG	N010926	001		Aug	CAHN
>A>	@		50MG	N011689	001		Aug	CAHN
>D>	@	VICTORY PHARMA	12.5MG	N010926	002		Aug	CAHN

SUPPOSITORY; RECTAL

PHENERGAN

>D>	@ VICTORY PHARMA	25MG	N010926 001	Aug	CAHN
>D>	@	50MG	N011689 001	Aug	CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB	EMCURE PHARMS USA	12.5MG	A040673 001	Mar 05, 2008	Jul	CAHN
AB		25MG	A040673 002	Mar 05, 2008	Jul	CAHN
AB		50MG	A040673 003	Mar 05, 2008	Jul	CAHN
>A>	MYLAN	12.5MG	A091054 001	Aug 30, 2011	Aug	NEWA
>A>		25MG	A091054 002	Aug 30, 2011	Aug	NEWA
>A>		50MG	A091054 003	Aug 30, 2011	Aug	NEWA

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+	ROXANE	15MG	A080927 002	Jan	CMFD
---	--------	------	-------------	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

	@ XANODYNE PHARM	65MG	N010997 003	Jan	DISC	
>D>	DOLENE					
>D>	AA HERITAGE PHARMS INC	65MG	A080530 001	Aug	DISC	
>A>	@	65MG	A080530 001	Aug	DISC	
>D>	PROPOXYPHENE HYDROCHLORIDE					
>D>	AA MYLAN	65MG	A040569 001	Dec 16, 2004	Aug	DISC
>A>	@	65MG	A040569 001	Dec 16, 2004	Aug	DISC
	@ TEVA	65MG	A088615 001	Oct 22, 1984	Mar	DISC
	@ VINTAGE PHARMS	65MG	A040908 001	Jul 17, 2009	Mar	DISC
	@ WEST WARD	65MG	A083501 001	Jan	DISC	

PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVON-N

@ XANODYNE PHARM	100MG	N016862 002	Jan	DISC
------------------	-------	-------------	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	GLAXOSMITHKLINE	60MG	A078703 001	Jul 15, 2011	Jul	NEWA
AB		80MG	A078703 002	Jul 15, 2011	Jul	NEWA
AB		120MG	A078703 003	Jul 15, 2011	Jul	NEWA
AB		160MG	A078703 004	Jul 15, 2011	Jul	NEWA
AB	ZYDUS PHARMS USA INC	60MG	A090321 001	Mar 25, 2011	Mar	NEWA
AB		80MG	A090321 002	Mar 25, 2011	Mar	NEWA
AB		120MG	A090321 003	Mar 25, 2011	Mar	NEWA
AB		160MG	A090321 004	Mar 25, 2011	Mar	NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	MYLAN	60MG	A070213 005	Apr 08, 2011	Mar	NEWA
----	-------	------	-------------	--------------	-----	------

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+	COREPHARMA	25MG	N008578 001	Jun	CAHN
---	------------	------	-------------	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@	ACTAVIS TOTOWA	EQ 5MG BASE	A076459 001	Dec 22, 2004	Jul	DISC
	@		EQ 10MG BASE	A076459 002	Dec 22, 2004	Jul	DISC
	@		EQ 20MG BASE	A076459 003	Dec 22, 2004	Jul	DISC
	@		EQ 40MG BASE	A076459 004	Dec 22, 2004	Jul	DISC
AB		MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005	Feb	CAHN
AB			EQ 10MG BASE	A076036 002	Jan 28, 2005	Feb	CAHN
AB			EQ 20MG BASE	A076036 003	Jan 28, 2005	Feb	CAHN
AB			EQ 40MG BASE	A076036 004	Jan 28, 2005	Feb	CAHN

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

>D>	AB	ACTAVIS ELIZABETH	1.25MG	A077513 001	Jun 18, 2008	Aug	DISC
>A>		@	1.25MG	A077513 001	Jun 18, 2008	Aug	DISC
>D>	AB		2.5MG	A077513 002	Jun 18, 2008	Aug	DISC
>A>		@	2.5MG	A077513 002	Jun 18, 2008	Aug	DISC
>D>	AB		5MG	A077513 003	Jun 18, 2008	Aug	DISC
>A>		@	5MG	A077513 003	Jun 18, 2008	Aug	DISC
>D>	AB		10MG	A077513 004	Jun 18, 2008	Aug	DISC
>A>		@	10MG	A077513 004	Jun 18, 2008	Aug	DISC
	AB	AUROBINDO PHARMA LTD	1.25MG	A091604 001	Jun 08, 2011	May	NEWA
	AB		2.5MG	A091604 002	Jun 08, 2011	May	NEWA
	AB		5MG	A091604 003	Jun 08, 2011	May	NEWA
	AB		10MG	A091604 004	Jun 08, 2011	May	NEWA

TABLET; ORAL

RAMIPRIL

	AB	MATRIX LABS LTD	1.25MG	A090650 001	Jun 30, 2011	Jun	NEWA
	AB		2.5MG	A090650 002	Jun 30, 2011	Jun	NEWA
	AB		5MG	A090650 003	Jun 30, 2011	Jun	NEWA
	AB		10MG	A090650 004	Jun 30, 2011	Jun	NEWA

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

	@	MYLAN	EQ 150MG BASE	A075564 001	Oct 27, 2000	Feb	CAHN
	@		EQ 300MG BASE	A075564 002	Oct 27, 2000	Feb	CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA		HI TECH PHARMA	EQ 15MG BASE/ML	A091078 001	Mar 22, 2011	Mar	NEWA
AA		TARO	EQ 15MG BASE/ML	A077476 001	Jun 13, 2011	May	NEWA

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

	AB	MYLAN	EQ 150MG BASE	A074023 001	Aug 22, 1997	Feb	CAHN
	AB		EQ 300MG BASE	A074023 002	Aug 22, 1997	Feb	CAHN

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

	@	ACTAVIS TOTOWA	300MG	N050429 001		Jul	DISC
--	---	----------------	-------	-------------	--	-----	------

INJECTABLE; INJECTION

RIFAMPIN

AP		PFIZER	600MG/VIAL	A065421 001	May 22, 2008	May	CAHN
----	--	--------	------------	-------------	--------------	-----	------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+	SALIX PHARMS	550MG	N022554	001	Mar 24, 2010	Feb	CRLD
---	--------------	-------	---------	-----	--------------	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	TIBOTEC	EQ 25MG BASE	N202022	001	May 20, 2011	May	NEWA
---	---------	--------------	---------	-----	--------------	-----	------

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

@	ACTAVIS TOTOWA	100MG	A076375	001	Jan 14, 2003	Jul	DISC
---	----------------	-------	---------	-----	--------------	-----	------

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jun	CAHN
+		25MG/VIAL	N021346	001	Oct 29, 2003	Jun	CAHN
		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jun	CAHN
		50MG/VIAL	N021346	003	Oct 29, 2003	Jun	CAHN

SOLUTION; ORAL

RISPERDAL

AA	+	JANSSEN PHARMS	1MG/ML	N020588	001	Jun 10, 1996	Jun	CAHN
----	---	----------------	--------	---------	-----	--------------	-----	------

RISPERIDONE

AA		AMNEAL PHARMS	1MG/ML	A091384	001	May 25, 2011	May	NEWA
----	--	---------------	--------	---------	-----	--------------	-----	------

AA		TARO	1MG/ML	A090347	001	Feb 07, 2011	Jan	NEWA
----	--	------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

RISPERDAL

AB		JANSSEN PHARMS	0.25MG	N020272	008	May 10, 1999	Jun	CAHN
AB			0.5MG	N020272	007	Jan 27, 1999	Jun	CAHN
AB	+		1MG	N020272	001	Dec 29, 1993	Jun	CAHN
AB			2MG	N020272	002	Dec 29, 1993	Jun	CAHN
AB			3MG	N020272	003	Dec 29, 1993	Jun	CAHN
AB			4MG	N020272	004	Dec 29, 1993	Jun	CAHN
	@		5MG	N020272	005	Dec 29, 1993	Jun	CAHN

RISPERIDONE

@	ACTAVIS TOTOWA	0.25MG	A078071	001	Jun 17, 2009	Jul	DISC
---	----------------	--------	---------	-----	--------------	-----	------

@		0.5MG	A078071	002	Jun 17, 2009	Jul	DISC
---	--	-------	---------	-----	--------------	-----	------

@		1MG	A078071	003	Jun 17, 2009	Jul	DISC
---	--	-----	---------	-----	--------------	-----	------

@		2MG	A078071	004	Jun 17, 2009	Jul	DISC
---	--	-----	---------	-----	--------------	-----	------

@		3MG	A078071	005	Jun 17, 2009	Jul	DISC
---	--	-----	---------	-----	--------------	-----	------

@		4MG	A078071	006	Jun 17, 2009	Jul	DISC
---	--	-----	---------	-----	--------------	-----	------

>A>	AB	AJANTA PHARMA LTD	0.25MG	A201003	001	Aug 24, 2011	Aug	NEWA
-----	----	-------------------	--------	---------	-----	--------------	-----	------

>A>	AB		0.5MG	A201003	002	Aug 24, 2011	Aug	NEWA
-----	----	--	-------	---------	-----	--------------	-----	------

>A>	AB		1MG	A201003	003	Aug 24, 2011	Aug	NEWA
-----	----	--	-----	---------	-----	--------------	-----	------

>A>	AB		2MG	A201003	004	Aug 24, 2011	Aug	NEWA
-----	----	--	-----	---------	-----	--------------	-----	------

>A>	AB		3MG	A201003	005	Aug 24, 2011	Aug	NEWA
-----	----	--	-----	---------	-----	--------------	-----	------

>A>	AB		4MG	A201003	006	Aug 24, 2011	Aug	NEWA
-----	----	--	-----	---------	-----	--------------	-----	------

	AB	CIPLA	0.25MG	A077543	001	May 18, 2011	May	NEWA
--	----	-------	--------	---------	-----	--------------	-----	------

	AB		0.5MG	A077543	002	May 18, 2011	May	NEWA
--	----	--	-------	---------	-----	--------------	-----	------

	AB		1MG	A077543	003	May 18, 2011	May	NEWA
--	----	--	-----	---------	-----	--------------	-----	------

	AB		2MG	A077543	004	May 18, 2011	May	NEWA
--	----	--	-----	---------	-----	--------------	-----	------

	AB		3MG	A077543	005	May 18, 2011	May	NEWA
--	----	--	-----	---------	-----	--------------	-----	------

TABLET; ORAL

RISPERIDONE

AB	CIPLA	4MG	A077543	006	May 18, 2011	May	NEWA
	@ RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010	Feb	DISC
	@	0.5MG	A077784	002	Jun 08, 2010	Feb	DISC
	@	1MG	A077784	003	Jun 08, 2010	Feb	DISC
	@	2MG	A077784	004	Jun 08, 2010	Feb	DISC
	@	3MG	A077784	005	Jun 08, 2010	Feb	DISC
	@	4MG	A077784	006	Jun 08, 2010	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

AB	JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003	Jul	CAHN
AB	+	1MG	N021444	002	Apr 02, 2003	Jul	CAHN
AB		2MG	N021444	003	Apr 02, 2003	Jul	CAHN
AB		3MG	N021444	004	Dec 23, 2004	Jul	CAHN
AB		4MG	N021444	005	Dec 23, 2004	Jul	CAHN

RISPERIDONE

AB	MYLAN	0.5MG	A091537	001	Mar 30, 2011	Mar	NEWA
AB		1MG	A091537	002	Mar 30, 2011	Mar	NEWA
AB		2MG	A091537	003	Mar 30, 2011	Mar	NEWA
AB		3MG	A091537	004	Mar 30, 2011	Mar	NEWA
AB		4MG	A091537	005	Mar 30, 2011	Mar	NEWA
AB	WATSON LABS FLORIDA	0.5MG	A076996	001	Apr 19, 2011	Apr	NEWA
AB		1MG	A076996	002	Apr 19, 2011	Apr	NEWA
AB		2MG	A076996	003	Apr 19, 2011	Apr	NEWA
AB		3MG	A076996	004	Apr 19, 2011	Apr	NEWA
AB		4MG	A076996	005	Apr 19, 2011	Apr	NEWA

RIVAROXABAN

TABLET; ORAL

XARELTO

+	JOHNSON AND JOHNSON	10MG	N022406	001	Jul 01, 2011	Jul	NEWA
---	---------------------	------	---------	-----	--------------	-----	------

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Jan	CAHN
AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Jan	CAHN

ROFLUMILAST

TABLET; ORAL

DALIRESP

+	FOREST RES INST INC	500MCG	N022522	001	Feb 28, 2011	Feb	NEWA
---	---------------------	--------	---------	-----	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

>A>	AB	PRINSTON INC	EQ 0.25MG BASE	A078110	001	May 05, 2008	Aug	CAHN
>A>	AB		EQ 0.5MG BASE	A078110	002	May 05, 2008	Aug	CAHN
>A>	AB		EQ 1MG BASE	A078110	003	May 05, 2008	Aug	CAHN
>A>	AB		EQ 2MG BASE	A078110	004	May 05, 2008	Aug	CAHN
>A>	AB		EQ 3MG BASE	A078110	005	May 05, 2008	Aug	CAHN
>A>	AB		EQ 4MG BASE	A078110	006	May 05, 2008	Aug	CAHN
>D>	AB	PRINSTON PHARM LLC	EQ 0.25MG BASE	A078110	001	May 05, 2008	Aug	CAHN
	AB		EQ 0.25MG BASE	A078110	001	May 05, 2008	May	CAHN
>D>	AB		EQ 0.5MG BASE	A078110	002	May 05, 2008	Aug	CAHN

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	PRINSTON PHARM LLC	EQ 0.5MG BASE	A078110 002	May 05, 2008	May	CAHN
>D>	AB	EQ 1MG BASE	A078110 003	May 05, 2008	Aug	CAHN
	AB	EQ 1MG BASE	A078110 003	May 05, 2008	May	CAHN
>D>	AB	EQ 2MG BASE	A078110 004	May 05, 2008	Aug	CAHN
	AB	EQ 2MG BASE	A078110 004	May 05, 2008	May	CAHN
>D>	AB	EQ 3MG BASE	A078110 005	May 05, 2008	Aug	CAHN
	AB	EQ 3MG BASE	A078110 005	May 05, 2008	May	CAHN
>D>	AB	EQ 4MG BASE	A078110 006	May 05, 2008	Aug	CAHN
	AB	EQ 4MG BASE	A078110 006	May 05, 2008	May	CAHN

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+	EISAI INC	40MG/ML	N201367 001	Mar 03, 2011	Mar	NEWA
---	-----------	---------	-------------	--------------	-----	------

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+	MARATHON PHARMS	50MG	A086101 001	Oct 03, 1983	Jan	CAHN
+		100MG	A086101 002	Oct 03, 1983	Jan	CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

>D>	AT	ACTAVIS MID ATLANTIC	2.5%	A084394 001		Aug	DISC
>A>	@		2.5%	A084394 001		Aug	DISC

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	ORTHO JANSSEN	2%	N021385 001	Dec 10, 2003	Jul	CAHN
---	---------------	----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@	ROXANE	EQ 20MG BASE/ML	A076934 001	Jun 30, 2006	Mar	DISC
---	--------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

	@	ACTAVIS TOTOWA	EQ 25MG BASE	A078175 001	Jul 21, 2010	Jul	DISC
	@		EQ 50MG BASE	A078175 002	Jul 21, 2010	Jul	DISC
	@		EQ 100MG BASE	A078175 003	Jul 21, 2010	Jul	DISC
	@	IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719 003	Jun 30, 2006	Apr	DISC
	@		EQ 50MG BASE	A075719 001	Jun 30, 2006	Apr	DISC
	@		EQ 100MG BASE	A075719 002	Jun 30, 2006	Apr	DISC
AB		MYLAN	EQ 25MG BASE	A076540 001	Mar 20, 2007	Feb	CAHN
AB			EQ 50MG BASE	A076540 002	Mar 20, 2007	Feb	CAHN
AB			EQ 100MG BASE	A076540 003	Mar 20, 2007	Feb	CAHN
	@	PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299 001	Feb 06, 2007	Jul	DISC
	@		EQ 50MG BASE	A077299 002	Feb 06, 2007	Jul	DISC
	@		EQ 100MG BASE	A077299 003	Feb 06, 2007	Jul	DISC
	@	ROXANE	EQ 25MG BASE	A076881 001	Feb 06, 2007	Mar	DISC
	@		EQ 50MG BASE	A076881 002	Feb 06, 2007	Mar	DISC
	@		EQ 100MG BASE	A076881 003	Feb 06, 2007	Mar	DISC

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

@	ACTAVIS TOTOWA	5MG	A078735 001	Aug 30, 2010	Jul	DISC
@		10MG	A078735 002	Aug 30, 2010	Jul	DISC
@		20MG	A078735 003	Aug 30, 2010	Jul	DISC
@		40MG	A078735 004	Aug 30, 2010	Jul	DISC
@		80MG	A078735 005	Aug 30, 2010	Jul	DISC

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+	MEDIGENE AG	15%	N021902 001	Oct 31, 2006	May	CAHN
---	-------------	-----	-------------	--------------	-----	------

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

>D>	@	LAFAYETTE PHARMS	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985	Aug	CAHN
>A>	@	MALLINCKRODT LLC	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985	Aug	CAHN

SODIUM CHLORIDE

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D>	AT	HOSPIRA	450MG/100ML	N018380 001		Aug	DISC
>D>	AT		450MG/100ML	N017670 001		Aug	DISC
>A>	@		450MG/100ML	N017670 001		Aug	DISC
>A>	@		450MG/100ML	N018380 001		Aug	DISC

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955 001	Feb 18, 1999	Mar	CFTG
AB		SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE					
AB		GENERAMEDIX	62.5MG/5ML	A078215 001	Mar 31, 2011	Mar	NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F 18

@	NIH NCI DCTD	10-200mCi/ML	N022494 001	Jan 26, 2011	Apr	DISC
+		10-200mCi/ML	N022494 001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5G M/50ML(250MG/ML)	N201444 001	Jan 14, 2011	Feb	CTNA
---	-------------	--	-------------	--------------	-----	------

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5G M/50ML(250MG/ML)	N201444 001	Jan 14, 2011	Jan	NEWA
---	-------------	--	-------------	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		PADDOCK LABS	15GM/60ML	A090590 001	May 13, 2011	May	NEWA
----	--	--------------	-----------	-------------	--------------	-----	------

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

@ PFIZER	EQ 2GM BASE/VIAL	N050347 001	Jun	DISC
@	EQ 4GM BASE/VIAL	N050347 002	Jun	CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+ PARAPRO PHARMS	0.9%	N022408 001	Jan 18, 2011	Jan	NEWA
------------------	------	-------------	--------------	-----	------

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

@ PFIZER	EQ 1GM BASE/2.5ML	A060111 001	Jul	DISC
----------	-------------------	-------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

>D>	+ KING PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Aug	CAHN
-----	---------------	-------------------------------------	-------------	--------------	-----	------

>A>	+ MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Aug	CAHN
-----	------------------	-------------------------------------	-------------	--------------	-----	------

IMITREX STATDOSE

AB	+ GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080 003	Dec 23, 1996	Jun	CFTG
----	-------------------	-------------------------------------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AB	SUN PHARM INDS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358 001	Jun 21, 2011	Jun	NEWA
----	--------------------	-------------------------------------	-------------	--------------	-----	------

>D>	AP	TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318 001	Feb 06, 2009	Aug	DISC
-----	----	-----------------	------------------------------------	-------------	--------------	-----	------

>A>	@	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318 001	Feb 06, 2009	Aug	DISC
-----	---	------------------------------------	-------------	--------------	-----	------

>D>	AP	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318 002	Feb 06, 2009	Aug	DISC
-----	----	-------------------------------------	-------------	--------------	-----	------

>A>	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318 002	Feb 06, 2009	Aug	DISC
-----	---	-------------------------------------	-------------	--------------	-----	------

TABLET; ORAL

SUMATRIPTAN SUCCINATE

@ ROXANE	EQ 25MG BASE	A078241 001	Aug 10, 2009	Mar	DISC
----------	--------------	-------------	--------------	-----	------

@	EQ 50MG BASE	A078241 002	Aug 10, 2009	Mar	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 100MG BASE	A078241 003	Aug 10, 2009	Mar	DISC
---	---------------	-------------	--------------	-----	------

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

@ SHIONOGI INC	EQ 10MG BASE	N020070 001	Sep 09, 1993	Jun	DISC
----------------	--------------	-------------	--------------	-----	------

@	EQ 20MG BASE	N020070 002	Sep 09, 1993	Jun	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 30MG BASE	N020070 003	Sep 09, 1993	Jun	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 40MG BASE	N020070 004	Sep 09, 1993	Jun	DISC
---	--------------	-------------	--------------	-----	------

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

>A>	AB	ACCORD HLTHCARE	0.5MG	A091195 001	Aug 31, 2011	Aug	NEWA
-----	----	-----------------	-------	-------------	--------------	-----	------

>A>	AB	1MG	A091195 002	Aug 31, 2011	Aug	NEWA
-----	----	-----	-------------	--------------	-----	------

>A>	AB	5MG	A091195 003	Aug 31, 2011	Aug	NEWA
-----	----	-----	-------------	--------------	-----	------

TAPENTADOL HYDROCHLORIDE

>A>	TABLET, EXTENDED RELEASE; ORAL						
>A>	NUCYNTA ER						
>A>	ORTHO MCNEIL JANSSEN	EQ 50MG BASE	N200533	001	Aug 25, 2011	Aug	NEWA
>A>		EQ 100MG BASE	N200533	002	Aug 25, 2011	Aug	NEWA
>A>		EQ 150MG BASE	N200533	003	Aug 25, 2011	Aug	NEWA
>A>		EQ 200MG BASE	N200533	004	Aug 25, 2011	Aug	NEWA
>A>	+	EQ 250MG BASE	N200533	005	Aug 25, 2011	Aug	NEWA

TELAPREVIR

TABLET; ORAL

INCIVEK

+	VERTEX PHARMS	375MG	N201917	001	May 23, 2011	May	NEWA
---	---------------	-------	---------	-----	--------------	-----	------

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

@	NOVARTIS	100MG/5ML	N022154	001	Apr 28, 2009	Jun	DISC
---	----------	-----------	---------	-----	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	JUBILANT CADISTA	EQ 1MG BASE	A075317	001	Dec 20, 2004	Jan	CAHN
AB		EQ 2MG BASE	A075317	002	Dec 20, 2004	Jan	CAHN
AB		EQ 5MG BASE	A075317	003	Dec 20, 2004	Jan	CAHN
AB		EQ 10MG BASE	A075317	004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

AB	MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Feb	CAHN
	@ ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL

TERBUTALINE SULFATE

AB	+	IMPAX LABS	5MG	A075877	002	Jun 26, 2001	Jan	CRLD
----	---	------------	-----	---------	-----	--------------	-----	------

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

>A>		ABBOTT LABS	1% (2.5GM/PACKET)	N021015	001	Feb 28, 2000	Aug	CAHN
>A>	BX	+	1% (5GM/PACKET)	N021015	002	Feb 28, 2000	Aug	CAHN
>D>	BX	+	ABBOTT PRODS	1% (5GM/PACKET)	N021015	002	Feb 28, 2000	Aug
>D>			1% (2.5GM/PACKET)	N021015	001	Feb 28, 2000	Aug	CAHN

GEL, METERED; TRANSDERMAL

ANDROGEL

>A>	+	ABBOTT LABS	1% (1.25GM/ACTIVATION)	N021015	003	Sep 26, 2003	Aug	CAHN
>A>	+		1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Aug	CAHN
>D>	+	ABBOTT PRODS	1% (1.25GM/ACTIVATION)	N021015	003	Sep 26, 2003	Aug	CAHN
>D>	+		1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Aug	CAHN
	+		1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Apr	NEWA
		FORTESTA						
	+	ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463	001	Dec 29, 2010	Mar	CPOT

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+	ACTIENT PHARMS	30MG	N021543	001	Jun 19, 2003	Jun	CAHN
---	----------------	------	---------	-----	--------------	-----	------

TETRABENAZINE

TABLET; ORAL

XENAZINE

	VALEANT INTL	12.5MG	N021894	001	Aug 15, 2008	Jun	CAHN
+		25MG	N021894	002	Aug 15, 2008	Jun	CAHN

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

@	SCHIFF AND CO	12.7MG/FIBER	N050653	001	Mar 25, 1994	Jun	CAHN
---	---------------	--------------	---------	-----	--------------	-----	------

SUSPENSION; ORAL

SUMYCIN

@	PAR PHARM	125MG/5ML	A060400	001		Jul	DISC
---	-----------	-----------	---------	-----	--	-----	------

TABLET; ORAL

SUMYCIN

@	PAR PHARM	250MG	A061147	001		Jul	DISC
@		500MG	A061147	004		Jul	DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

BC	ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983	Jun	CAHN
BC		200MG	A087943	001	Aug 22, 1983	Jun	CAHN
BC		300MG	A087944	001	Aug 22, 1983	Jun	CAHN
		400MG	A081034	001	Feb 28, 1992	Jun	CAHN

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	+	HOSPIRA	80MG/100ML	N019211	002	Dec 14, 1984	Aug	DISC
>A>			@	80MG/100ML	N019211	002	Dec 14, 1984	Aug	DISC
>D>	AP	+		200MG/100ML	N019211	004	Dec 14, 1984	Aug	DISC
>A>			@	200MG/100ML	N019211	004	Dec 14, 1984	Aug	DISC
>D>	AP	+		400MG/100ML	N019211	005	Dec 14, 1984	Aug	DISC
>A>			@	400MG/100ML	N019211	005	Dec 14, 1984	Aug	DISC

SOLUTION; ORAL

THEOPHYLLINE

+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011	Mar	NEWA
---	--------	-----------	---------	-----	--------------	-----	------

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

@	HOSPIRA	100MG/ML	A040079	001	May 03, 1996	May	DISC
---	---------	----------	---------	-----	--------------	-----	------

TICAGRELOR

TABLET; ORAL

BRILINTA

+	ASTRAZENECA LP	90MG	N022433	001	Jul 20, 2011	Jul	NEWA
---	----------------	------	---------	-----	--------------	-----	------

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

>D>	AB		ACTAVIS ELIZABETH	250MG	A075253	001	Aug 20, 1999	Aug	DISC
>A>			@	250MG	A075253	001	Aug 20, 1999	Aug	DISC

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

AB	MYLAN	250MG	A075161	001	Sep 13, 1999	Feb	CAHN
----	-------	-------	---------	-----	--------------	-----	------

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AT	APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000	Jun	CAHN
----	------------	---------------	---------	-----	--------------	-----	------

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A076283	001	Jul 12, 2002	Aug	DISC
>A>		@	EQ 2MG BASE	A076283	001	Jul 12, 2002	Aug	DISC
>D>	AB		EQ 4MG BASE	A076283	002	Jul 12, 2002	Aug	DISC
>A>		@	EQ 4MG BASE	A076283	002	Jul 12, 2002	Aug	DISC
		@ ACTAVIS TOTOWA	EQ 2MG BASE	A076281	001	Oct 20, 2003	Jul	DISC
		@	EQ 4MG BASE	A076281	002	Oct 20, 2003	Jul	DISC

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	FERA PHARMS	0.3%	A065026	001	Sep 11, 2001	Mar	CAHN
----	-------------	------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

>D>	AP	HOSPIRA	EQ 10MG BASE/ML	A063112	001	Apr 30, 1991	Aug	CRLD
>D>	AP	+	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991	Aug	DISC
>A>		@	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991	Aug	DISC
>A>	AP	+	EQ 10MG BASE/ML	A063112	001	Apr 30, 1991	Aug	CRLD

TOLCAPONE

TABLET; ORAL

TASMAR

	+	VALEANT PHARM INTL	100MG	N020697	001	Jan 29, 1998	Jun	CRLD
		@	200MG	N020697	002	Jan 29, 1998	Jun	DISC

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

>D>	AB	ACTAVIS ELIZABETH	EQ 400MG BASE	A073308	001	Jan 24, 1992	Aug	DISC
>A>		@	EQ 400MG BASE	A073308	001	Jan 24, 1992	Aug	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191	001	Mar 09, 2011	Feb	NEWA
AP	SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284	001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS

TOPOTECAN

AP	HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582	001	Feb 02, 2011	Feb	NEWA
	SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199	001	Feb 25, 2011	Feb	NEWA
		EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199	002	Feb 25, 2011	Feb	NEWA
AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199	003	Feb 25, 2011	Feb	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	VINTAGE PHARMS	5MG	A090613	001	Mar 22, 2011	Mar	NEWA
AB		10MG	A090613	002	Mar 22, 2011	Mar	NEWA
AB		20MG	A090613	003	Mar 22, 2011	Mar	NEWA
AB		100MG	A090613	004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

>A>							
>A>	+	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010	Aug CTNA
>A>			150MG	N022370	004	Aug 01, 2011	Aug NEWA
>A>			200MG	N022370	002	May 07, 2010	Aug CTNA
>A>			300MG	N022370	003	May 07, 2010	Aug CTNA
>D>		TRAMADOL HYDROCHLORIDE					
>D>	+	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010	Aug CTNA
>D>			200MG	N022370	002	May 07, 2010	Aug CTNA
>D>			300MG	N022370	003	May 07, 2010	Aug CTNA

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	50MG	A075960	001	Jun 19, 2002	Aug DISC
>A>		@	50MG	A075960	001	Jun 19, 2002	Aug DISC
	AB	ZYDUS PHARMS USA INC	50MG	A090404	001	Jan 31, 2011	Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB	LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Aug NEWA
>A>	AB		200MG	A200503	002	Aug 29, 2011	Aug NEWA
>A>	AB		300MG	A200503	003	Aug 29, 2011	Aug NEWA
		ULTRAM ER					
	AB	+	VALEANT INTL	100MG	N021692	001	Sep 08, 2005 Jun CAHN
	AB		200MG	N021692	002	Sep 08, 2005 Jun CAHN	
>D>	BC		300MG	N021692	003	Sep 08, 2005 Aug CTEC	
>A>	AB		300MG	N021692	003	Sep 08, 2005 Aug CTEC	
	BC		300MG	N021692	003	Sep 08, 2005 Jun CAHN	

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

>A>	+	SHIONOGI INC	50MG	N021693	001	May 05, 2005 Aug CAHN
>D>	+	VICTORY PHARMA	50MG	N021693	001	May 05, 2005 Aug CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

>D>	+	PHARMACIA AND UPJOHN	100MG/ML	N019281	001	Dec 30, 1986 Aug CFTG
>A>	AP	+	100MG/ML	N019281	001	Dec 30, 1986 Aug CFTG
>A>		TRANEXAMIC ACID				
>A>	AP	PHARMAFORCE	100MG/ML	A201885	001	Aug 10, 2011 Aug NEWA

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

	@	ALCON	0.004%	N021257	001	Mar 16, 2001 May DISC
--	---	-------	--------	---------	-----	-----------------------

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

>D>	+	ANGELINI LABOPHARM	150MG	N022411	001	Feb 02, 2010	Aug	CAHN
	+		150MG	N022411	001	Feb 02, 2010	Jun	CAHN
>D>			300MG	N022411	002	Feb 02, 2010	Aug	CAHN
			300MG	N022411	002	Feb 02, 2010	May	CAHN
>A>	+	ANGELINI LLC	150MG	N022411	001	Feb 02, 2010	Aug	CAHN
>A>			300MG	N022411	002	Feb 02, 2010	Aug	CAHN

TRETINOIN

CREAM; TOPICAL

RENOVA

	+	ORTHO JANSSEN	0.02%	N021108	001	Aug 31, 2000	Jul	CAHN
AB2	+		0.05%	N019963	001	Dec 29, 1995	Jul	CAHN

RETIN-A

AB	+	ORTHO JANSSEN	0.025%	N019049	001	Sep 16, 1988	Jul	CAHN
AB1	+		0.05%	N017522	001		Jul	CAHN
AB	+		0.1%	N017340	001		Jul	CAHN

GEL; TOPICAL

RETIN-A

AB	+	ORTHO JANSSEN	0.01%	N017955	001		Jul	CAHN
AB	+		0.025%	N017579	002		Jul	CAHN

SOLUTION; TOPICAL

RETIN-A

AT	+	ORTHO JANSSEN	0.05%	N016921	001		Jul	CAHN
----	---	---------------	-------	---------	-----	--	-----	------

SWAB; TOPICAL

RETIN-A

	@	ORTHO JANSSEN	0.05%	N016921	002		Jul	CAHN
--	---	---------------	-------	---------	-----	--	-----	------

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT	ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982	Aug	DISC
>A>		@	0.1%	A087798	001	Jun 04, 1982	Aug	DISC

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT	ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982	Aug	DISC
>A>		@	0.1%	A087799	001	Jun 07, 1982	Aug	DISC

PASTE; DENTAL

ORACORT

>D>									
>D>	AT	+	TARO	0.1%	A070730	001	Oct 01, 1986	Aug	CTNA
>A>			TRIAMCINOLONE ACETONIDE						
>A>	AT	+	TARO	0.1%	A070730	001	Oct 01, 1986	Aug	CTNA

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

>D>	AB	BARR	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Aug	CAHN
>A>	AB	TEVA BRANDED PHARM	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Aug	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP		LUITPOLD	100MG/ML	A091330	001	Mar 08, 2011	May	CAHN
AP		PHARMAFORCE	100MG/ML	A091330	001	Mar 08, 2011	Feb	NEWA

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP	LUITPOLD	100MG/ML	A091329	001	Mar 08, 2011	May	CAHN
AP	PHARMAFORCE	100MG/ML	A091329	001	Mar 08, 2011	Feb	NEWA

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB	NOVEL LABS INC	100MG	A091437	001	Jun 15, 2011	May	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361	001	Aug 02, 2006	Feb	CAHN
AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	Feb	CAHN
AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	Feb	CAHN

URSODIOL

TABLET; ORAL

URSODIOL

AB	GLENMARK GENERICS	250MG	A090801	001	Jul 12, 2011	Jul	NEWA
AB		500MG	A090801	002	Jul 12, 2011	Jul	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370	001	Mar 16, 2011	Feb	NEWA
AB		EQ 1GM BASE	A090370	002	Mar 16, 2011	Feb	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	PFIZER	EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	May	CAHN
AP		EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	May	CAHN
AP		EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008	May	CAHN
AP		EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Jun	NEWA

VANDETANIB

TABLET; ORAL

VANDETANIB

	IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Apr	NEWA
+		300MG	N022405	002	Apr 06, 2011	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	PFIZER	10MG/VIAL	A090243	001	May 11, 2010	May	CAHN
AP		20MG/VIAL	A090243	002	May 11, 2010	May	CAHN

>A> VEMURAFENIB

>A> TABLET; ORAL

>A> ZELBORAF

>A>	+	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011	Aug	NEWA
-----	---	-------------------	-------	---------	-----	--------------	-----	------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A200834 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A200834 003	Apr 14, 2011	Apr	NEWA
AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421 001	May 06, 2011	Apr	NEWA
AB		EQ 75MG BASE	A078421 002	May 06, 2011	Apr	NEWA
AB		EQ 150MG BASE	A078421 003	May 06, 2011	Apr	NEWA
AB	MYLAN	EQ 37.5MG BASE	A078789 001	Jun 01, 2011	May	NEWA
AB		EQ 75MG BASE	A078789 002	Jun 01, 2011	May	NEWA
AB		EQ 150MG BASE	A078789 003	Jun 01, 2011	May	NEWA
AB	ORCHID HLTHCARE	EQ 37.5MG BASE	A091123 001	Jul 11, 2011	Jun	NEWA
AB		EQ 75MG BASE	A091123 002	Jul 11, 2011	Jun	NEWA
AB		EQ 150MG BASE	A091123 003	Jul 11, 2011	Jun	NEWA
AB	TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899 001	Jun 01, 2011	May	NEWA
AB		EQ 75MG BASE	A090899 002	Jun 01, 2011	May	NEWA
AB		EQ 150MG BASE	A090899 003	Jun 01, 2011	May	NEWA
AB	VALEANT INTL	EQ 37.5MG BASE	A090071 001	Apr 15, 2011	Apr	NEWA
AB		EQ 75MG BASE	A090071 002	Apr 15, 2011	Apr	NEWA
AB		EQ 150MG BASE	A090071 003	Apr 15, 2011	Apr	NEWA
AB	WOCKHARDT	EQ 37.5MG BASE	A078865 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A078865 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A078865 003	Apr 14, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A090174 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A090174 003	Apr 14, 2011	Apr	NEWA

TABLET; ORAL

>D> EFFEXOR

>D>	AB	WYETH PHARMS INC	EQ 25MG BASE	N020151 002	Dec 28, 1993	Aug	DISC
>A>		@	EQ 25MG BASE	N020151 002	Dec 28, 1993	Aug	DISC
>D>	AB		EQ 37.5MG BASE	N020151 006	Dec 28, 1993	Aug	DISC
>A>		@	EQ 37.5MG BASE	N020151 006	Dec 28, 1993	Aug	DISC
>D>	AB	+	EQ 50MG BASE	N020151 003	Dec 28, 1993	Aug	DISC
>A>		@	EQ 50MG BASE	N020151 003	Dec 28, 1993	Aug	DISC
>D>	AB		EQ 75MG BASE	N020151 004	Dec 28, 1993	Aug	DISC
>A>		@	EQ 75MG BASE	N020151 004	Dec 28, 1993	Aug	DISC
>D>	AB		EQ 100MG BASE	N020151 005	Dec 28, 1993	Aug	DISC
>A>		@	EQ 100MG BASE	N020151 005	Dec 28, 1993	Aug	DISC

VENLAFAXINE HYDROCHLORIDE

	AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	A078932 001	Dec 14, 2010	Jul	CAHN
	AB		EQ 37.5MG BASE	A078932 002	Dec 14, 2010	Jul	CAHN
	AB		EQ 50MG BASE	A078932 003	Dec 14, 2010	Jul	CAHN
	AB		EQ 75MG BASE	A078932 004	Dec 14, 2010	Jul	CAHN
	AB		EQ 100MG BASE	A078932 005	Dec 14, 2010	Jul	CAHN
>D>	AB	PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517 001	Jun 13, 2008	Aug	DISC
>A>		@	EQ 25MG BASE	A078517 001	Jun 13, 2008	Aug	DISC
>D>	AB		EQ 37.5MG BASE	A078517 002	Jun 13, 2008	Aug	DISC
>A>		@	EQ 37.5MG BASE	A078517 002	Jun 13, 2008	Aug	DISC
>D>	AB		EQ 50MG BASE	A078517 003	Jun 13, 2008	Aug	DISC
>A>		@	EQ 50MG BASE	A078517 003	Jun 13, 2008	Aug	DISC
>D>	AB		EQ 75MG BASE	A078517 004	Jun 13, 2008	Aug	DISC
>A>		@	EQ 75MG BASE	A078517 004	Jun 13, 2008	Aug	DISC
>D>	AB		EQ 100MG BASE	A078517 005	Jun 13, 2008	Aug	DISC
>A>		@	EQ 100MG BASE	A078517 005	Jun 13, 2008	Aug	DISC

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

>D>	AB	TEVA	EQ 50MG BASE	A076690 003	Aug 03, 2006	Aug	CRLD
>A>	AB	+	EQ 50MG BASE	A076690 003	Aug 03, 2006	Aug	CRLD

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

>D>	AP	HOSPIRA	2.5MG/ML	A070577 001	Feb 02, 1987	Aug	DISC
>A>		@	2.5MG/ML	A070577 001	Feb 02, 1987	Aug	DISC

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	80MG	A071019 001	Sep 24, 1986	Aug	DISC
>A>		@	80MG	A071019 001	Sep 24, 1986	Aug	DISC
>D>	AB		120MG	A070468 001	Sep 24, 1986	Aug	DISC
>A>		@	120MG	A070468 001	Sep 24, 1986	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

AB		GLENMARK GENERICS	120MG	A090700 001	Aug 03, 2011	Jul	NEWA
AB			180MG	A090700 002	Aug 03, 2011	Jul	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

		FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	May	CAHN
			20MG	N022567 002	Jan 21, 2011	May	CAHN
	+		40MG	N022567 003	Jan 21, 2011	May	CAHN
		TROVIS PHARMS	10MG	N022567 001	Jan 21, 2011	Jan	NEWA
			20MG	N022567 002	Jan 21, 2011	Jan	NEWA
	+		40MG	N022567 003	Jan 21, 2011	Jan	NEWA

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

@	APP PHARMS	1MG/ML	A076401 001	Oct 28, 2003	Jan	DISC
---	------------	--------	-------------	--------------	-----	------

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB		INVAGEN PHARMS	1MG	A090935 001	May 25, 2011	May	NEWA
AB			2MG	A090935 002	May 25, 2011	May	NEWA
AB			2.5MG	A090935 003	May 25, 2011	May	NEWA
AB			3MG	A090935 004	May 25, 2011	May	NEWA
AB			4MG	A090935 005	May 25, 2011	May	NEWA
AB			5MG	A090935 006	May 25, 2011	May	NEWA
AB			6MG	A090935 007	May 25, 2011	May	NEWA
AB			7.5MG	A090935 008	May 25, 2011	May	NEWA
AB			10MG	A090935 009	May 25, 2011	May	NEWA

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

AP		LUITPOLD	10MG/ML	A091457 001	May 06, 2010	Feb	CAHN
----	--	----------	---------	-------------	--------------	-----	------

TABLET; ORAL

ZIDOVUDINE

@	MATRIX LABS LTD	100MG	N200732 001	Feb 23, 2011	Feb	NEWA
---	-----------------	-------	-------------	--------------	-----	------

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

+	NOVARTIS	EQ 4MG BASE/100ML	N021223 003	Jun 17, 2011	Jun	NEWA
---	----------	-------------------	-------------	--------------	-----	------

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	MYLAN	5MG	A078016 001	Apr 23, 2007	Feb	CAHN
----	-------	-----	-------------	--------------	-----	------

AB		10MG	A078016 002	Apr 23, 2007	Feb	CAHN
----	--	------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB	ANCHEN PHARMS	6.25MG	A078148 002	Apr 14, 2011	Apr	NEWA
----	---------------	--------	-------------	--------------	-----	------

AB	SANDOZ	6.25MG	A090107 001	Jul 01, 2011	Jun	NEWA
----	--------	--------	-------------	--------------	-----	------

AB		12.5MG	A090107 002	Jul 01, 2011	Jun	NEWA
----	--	--------	-------------	--------------	-----	------

AB	SYNTHON PHARMS	6.25MG	A078483 001	Apr 12, 2011	Apr	NEWA
----	----------------	--------	-------------	--------------	-----	------

AB		12.5MG	A078483 002	Jun 06, 2011	Jul	NEWA
----	--	--------	-------------	--------------	-----	------

OTC DRUG PRODUCT LIST - 31ST EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

2-1

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	ACTAVIS MID ATLANTIC	5MG/5ML	A090378	002	May 09, 2008	Aug	DISC
>A>	@	5MG/5ML	A090378	002	May 09, 2008	Aug	DISC
	SILARX	5MG/5ML	A091130	001	Apr 22, 2011	Apr	NEWA
	TARO	5MG/5ML	A201546	001	May 20, 2011	May	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D>	ACTAVIS MID ATLANTIC	5MG/5ML	A090378	001	May 09, 2008	Aug	DISC
>A>	@	5MG/5ML	A090378	001	May 09, 2008	Aug	DISC
	SILARX	5MG/5ML	A091130	002	Apr 22, 2011	Apr	NEWA
	TARO	5MG/5ML	A201546	002	May 20, 2011	May	NEWA

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	SUN PHARMA GLOBAL	5MG	A090142	001	Aug 30, 2011	Aug	NEWA
>A>		10MG	A090142	002	Aug 30, 2011	Aug	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A>	SUN PHARMA GLOBAL	5MG	A090142	003	Aug 30, 2011	Aug	NEWA
>A>		10MG	A090142	004	Aug 30, 2011	Aug	NEWA

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

PHARMASEAL SCRUB CARE

>A>	+ CAREFUSION	4%	N019793	001	Dec 02, 1988	Aug	CAHN
>D>	+ PHARMASEAL	4%	N019793	001	Dec 02, 1988	Aug	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN
---	---------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+	CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN
---	---------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+	CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Apr	NEWA
---	---------------	-----------------	---------	-----	--------------	-----	------

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

>D>	ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001	Aug	DISC
>A>	@	5.2MG/SPRAY	A074800	001	Jul 26, 2001	Aug	DISC

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

	MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN
--	-------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA
---	-------------------	----------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA
---	-------------------	----------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA
---	-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA
---	-------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

ALLEGRA ALLERGY

	SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
--	-------------------	------	---------	-----	--------------	-----	------

+		180MG	N020872	010	Jan 24, 2011	Jan	NEWA
---	--	-------	---------	-----	--------------	-----	------

ALLEGRA HIVES

	SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
--	-------------------	------	---------	-----	--------------	-----	------

+		180MG	N020872	009	Jan 24, 2011	Jan	NEWA
---	--	-------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA ALLERGY

	SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA
--	-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

	SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA
--	-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011	Mar	NEWA
--	--------------------	------	---------	-----	--------------	-----	------

	MYLAN	30MG	A077081	004	Jul 21, 2011	Jul	NEWA
--	-------	------	---------	-----	--------------	-----	------

	TEVA	30MG	A076447	004	Apr 13, 2011	Mar	NEWA
--	------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011	Mar	NEWA
--	--------------------	------	---------	-----	--------------	-----	------

	MYLAN	30MG	A077081	005	Jul 21, 2011	Jul	NEWA
--	-------	------	---------	-----	--------------	-----	------

	TEVA	30MG	A076447	005	Apr 13, 2011	Mar	NEWA
--	------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011	Mar	NEWA
--	--------------------	------	---------	-----	--------------	-----	------

		180MG	A076502	008	Apr 12, 2011	Mar	NEWA
--	--	-------	---------	-----	--------------	-----	------

	MYLAN	60MG	A077081	006	Jul 21, 2011	Jul	NEWA
--	-------	------	---------	-----	--------------	-----	------

		180MG	A077081	008	Jul 21, 2011	Jul	NEWA
--	--	-------	---------	-----	--------------	-----	------

	TEVA	60MG	A076447	006	Apr 13, 2011	Mar	NEWA
--	------	------	---------	-----	--------------	-----	------

		180MG	A076447	008	Apr 13, 2011	Mar	NEWA
--	--	-------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011	Mar	NEWA
--	--------------------	------	---------	-----	--------------	-----	------

		180MG	A076502	009	Apr 12, 2011	Mar	NEWA
--	--	-------	---------	-----	--------------	-----	------

	MYLAN	60MG	A077081	007	Jul 21, 2011	Jul	NEWA
--	-------	------	---------	-----	--------------	-----	------

		180MG	A077081	009	Jul 21, 2011	Jul	NEWA
--	--	-------	---------	-----	--------------	-----	------

	TEVA	60MG	A076447	007	Apr 13, 2011	Mar	NEWA
--	------	------	---------	-----	--------------	-----	------

		180MG	A076447	009	Apr 13, 2011	Mar	NEWA
--	--	-------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011	Jan	NEWA
---	-------------------	------------	---------	-----	--------------	-----	------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011	Jan	NEWA
---	-------------------	-------------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS LTD	180MG;240MG	A079043	002	Jun 22, 2011	Jun	NEWA
--	--------------------	-------------	---------	-----	--------------	-----	------

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

>A>	AMNEAL PHARMS	100MG/5ML	A200457	001	Aug 18, 2011	Aug	NEWA
-----	---------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

IBUPROFEN

>D>	ADVENT PHARMS	200MG	A076460	001	Nov 26, 2003	Aug	CAHN
-----	---------------	-------	---------	-----	--------------	-----	------

		200MG	A076460	001	Nov 26, 2003	Jul	CAHN
--	--	-------	---------	-----	--------------	-----	------

TABLET; ORAL

IBUPROFEN

>A>	AVEMA PHARMA	200MG	A076460 001	Nov 26, 2003	Aug	CAHN
		200MG	A076460 001	Nov 26, 2003	May	CAHN
	MARKSANS PHARMA	200MG	A091237 001	Feb 08, 2011	Jan	NEWA
		200MG	A091239 001	Feb 01, 2011	Jan	NEWA
	MERRO PHARM	200MG	A070985 001	Oct 02, 1987	Jan	CAHN
	SVADS HOLDINGS SA	200MG	A079129 001	Mar 28, 2011	Mar	NEWA
		200MG	A091355 001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN N

+	NOVO NORDISK INC	100 UNITS/ML	N019959 001	Jul 01, 1991	Jan	CRLD
---	------------------	--------------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

+	TEVA WOMENS	0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN
---	-------------	--------	-------------	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL

LOPERAMIDE HYDROCHLORIDE

	PERRIGO R AND D	1MG/7.5ML	A091292 001	May 20, 2011	May	NEWA
--	-----------------	-----------	-------------	--------------	-----	------

LORATADINE

TABLET; ORAL

LORATADINE

>A>	MYLAN	10MG	A078447 001	Aug 12, 2011	Aug	NEWA
-----	-------	------	-------------	--------------	-----	------

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

>D>	ACTAVIS MID ATLANTIC	2%,100MG	A074586 001	Jul 17, 1997	Aug	DISC
-----	----------------------	----------	-------------	--------------	-----	------

>A>	@	2%,100MG	A074586 001	Jul 17, 1997	Aug	DISC
-----	---	----------	-------------	--------------	-----	------

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MINOXIDIL

	PERRIGO ISRAEL	5%	A091344 001	Apr 28, 2011	Apr	NEWA
--	----------------	----	-------------	--------------	-----	------

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

	MARKSANS PHARMA	EQ 200MG BASE	A090545 001	Mar 16, 2011	Feb	NEWA
--	-----------------	---------------	-------------	--------------	-----	------

	RANBAXY LABS LTD	EQ 200MG BASE	A091183 001	May 20, 2011	May	NEWA
--	------------------	---------------	-------------	--------------	-----	------

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

	PERRIGO R AND D	EQ 2MG BASE	A091349 001	Jul 20, 2011	Jul	NEWA
--	-----------------	-------------	-------------	--------------	-----	------

		EQ 4MG BASE	A091354 001	Jul 20, 2011	Jul	NEWA
--	--	-------------	-------------	--------------	-----	------

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

>A>	+	BAYER HLTHCARE	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000	Aug	CAHN
>D>	+	PFIZER	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000	Aug	CAHN

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

ANBEX

65MG

N018664 002 May 12, 2011 Apr NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN

EQ 75MG BASE

A075497 001 Jan 14, 2000 Feb CAHN

PERRIGO R AND D

EQ 150MG BASE

A091429 002 May 11, 2011 Apr NEWA

EQ 150MG BASE

A091429 001 May 11, 2011 Apr NEWA

SVADS HOLDINGS SA

EQ 150MG BASE

A200536 001 Jun 28, 2011 Jun NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2011

NO AUGUST 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N202379 001	5604213	Feb 18, 2014	DS DP U-1126		NCE	Apr 28, 2016
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	7868044	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N022502 001	>A> 7998467	May 31, 2028	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	7964202	Sep 01, 2024	DP U-1078			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 001					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 002					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 003					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 004					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	5250542	Mar 29, 2016	DS DP U-878			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	RE42462	Oct 07, 2015	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	RE42462	Oct 07, 2015	DS			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 005					PC	Jul 02, 2011
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 006					PC	Jul 02, 2011
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303 001	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303 006	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N022434 001	7589106	Sep 27, 2026	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 001					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 002					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 003					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 004					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 005					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 006					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021713 001					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 002					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 003					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021866 001					I-633	Feb 16, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002					D-130	Feb 04, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567	003				D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567	004				D-130	Feb 04, 2014
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796	001	5583141	Dec 10, 2013	DS DP U-3	NCE	Feb 25, 2016
		5736555	Jun 25, 2012	DS DP U-3		
		5958961	Jun 06, 2014	DP U-3		
		7157584	May 22, 2025	DS		
		7572920	Jan 07, 2025	DP U-3		
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796	002	5583141	Dec 10, 2013	DS DP U-3	NCE	Feb 25, 2016
		5736555	Jun 25, 2012	DS DP U-3		
		5958961	Jun 06, 2014	DP U-3		
		7157584	May 22, 2025	DS		
		7572920	Jan 07, 2025	DP U-3		
<u>AZITHROMYCIN - ZMAX</u>						
N050797	001	7887844	Feb 14, 2024	DP		
<u>AZTREONAM - CAYSTON</u>						
N050814	001				>A> ODE	Feb 22, 2017
<u>BIMATOPROST - LATISSE</u>						
N022369	001	>A> 8017655	Nov 27, 2012	DS DP		
<u>BIMATOPROST - LUMIGAN</u>						
N021275	001	>A> 8017655	Nov 27, 2012	DS DP		
<u>BIMATOPROST - LUMIGAN</u>						
N022184	001	>A> 8017655	Nov 27, 2012	DS DP		
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873	001	>A> 5196404	Aug 13, 2012	DS DP U-1040		
		>A> 5196404*PED	Feb 13, 2013			
<u>BOCEPREVIR - VICTRELIS</u>						
N202258	001	7012066	Feb 22, 2022	DS DP U-1128	NCE	May 13, 2016
		7772178	Nov 11, 2027	DP U-1128		
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929	001	7967011	Aug 11, 2021	DP		
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929	002	7897646	Sep 09, 2018	U-1118		
		7967011	Aug 11, 2021	DP		
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712	001	5326570	Jul 23, 2011	U-215		
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712	002	5326570	Jul 23, 2011	U-215		
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712	003	5326570	Jul 23, 2011	U-215		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5760068	Jun 02, 2015	U-672			
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7935093	Oct 02, 2027	DP U-1022			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N021441 001	7863287	Feb 28, 2027	DP			
<u>CICLOPIROX - LOPROX</u>						
N021159 001	7981909	Sep 16, 2017	U-1162			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 001	4847265	Nov 17, 2011	DS DP		M-61 PED	May 06, 2014 Nov 06, 2014
	4847265*PED	May 17, 2012				
	5576328	Jan 31, 2014	U-432	Y		
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 002	4847265	Nov 17, 2011	DS DP		M-61 PED	May 06, 2014 Nov 06, 2014
	4847265*PED	May 17, 2012				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Feb 17, 2029	U-1161			
	7981938	Oct 06, 2028	U-1166			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRIZOTINIB - XALKORI</u>						
N202570 001	>A> 7230098	Feb 01, 2025	DS		>A> NCE	Aug 26, 2016
	>A> 7825137	May 12, 2027	U-1179			
	>A> 7858643	Oct 08, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	>A> 7230098	Feb 01, 2025	DS		>A> NCE	Aug 26, 2016
	>A> 7825137	May 12, 2027	U-1179			
	>A> 7858643	Oct 08, 2029	DS DP			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N021642 001	7879349	Jun 01, 2024	DP U-1152			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 001	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 002	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-744		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-935		D-118	Oct 21, 2011
	5843946*PED	Jun 01, 2016			I-578	Oct 21, 2011
	6037157	Jun 26, 2016	U-935		NCE	Jun 23, 2011
	6037157*PED	Dec 26, 2016			PED	Jun 13, 2014
	6248775	Aug 13, 2014	DS		PED	Jun 18, 2012
	6248775*PED	Feb 13, 2015			PED	Apr 21, 2012
	6335460	Aug 25, 2012	DS DP U-903		PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-935			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DASATINIB - SPRYCEL</u>						
N021986 005	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
<u>DASATINIB - SPRYCEL</u>						
N021986 006	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 007	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 008	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N021005 001	5929048	Jun 17, 2014	U-402			
	5985850	Aug 11, 2015	DP			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	6133251	Oct 25, 2016	DP U-828	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-1	Y		
	6884793	Oct 25, 2016	DP	Y		
<u>DORIPENEM - DORIBAX</u>						
N022106 001	5317016	Jun 05, 2015	DS DP U-282			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	7915307	Aug 24, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	7915307	Aug 24, 2027	U-620			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2012	DS DP U-992			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	>A> 5922695	Jul 25, 2017	DS U-750			
	>A> 5922695*PED	Jan 25, 2018				
	>A> 5935946	Jul 25, 2017	DS DP U-750			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-750			
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-750			
	>A> 6043230*PED	Jan 25, 2018				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	7547719	Jul 13, 2025	DS DP U-930			
<u>EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	>A> 5814639	Sep 29, 2015	DS DP			
	>A> 5814639*PED	Mar 29, 2016				
	>A> 5914331	Jul 02, 2017	DS			
	>A> 5914331*PED	Jan 02, 2018				
	>A> 5922695	Jul 25, 2017	DS U-257			
	>A> 5922695*PED	Jan 25, 2018				
	>A> 5935946	Jul 25, 2017	DS DP U-257			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP			
	>A> 5977089*PED	Jan 25, 2018	U-257			
	>A> 6043230	Jul 25, 2017	U-257			
	>A> 6043230*PED	Jan 25, 2018				
	>A> 6642245	Nov 04, 2020	U-257			
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 6703396*PED	Sep 09, 2021				
	>A> 6838464	Feb 26, 2021	DS DP			
	>A> 7067522	Dec 20, 2019	DS DP			
	>A> 7125879	Apr 14, 2023	DS DP U-257			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	>A> 5922695	Jul 25, 2017	DS			U-248
	>A> 5922695	Jul 25, 2017	DS			U-541
	>A> 5922695	Jul 25, 2017	DS			U-1170
	>A> 5922695*PED	Jan 25, 2018				
	>A> 5935946	Jul 25, 2017	DS DP			U-1170
	>A> 5935946	Jul 25, 2017	DS DP			U-248
	>A> 5935946	Jul 25, 2017	DS DP			U-541
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP			U-541
	>A> 5977089	Jul 25, 2017	DS DP			U-248
	>A> 5977089	Jul 25, 2017	DS DP			U-1170
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	DP			U-1170
	>A> 6043230	Jul 25, 2017	DP			U-248
	>A> 6043230	Jul 25, 2017	DP			U-541
	>A> 6043230*PED	Jan 25, 2018				
	>A> 6642245	Nov 04, 2020				U-541
	>A> 6642245	Nov 04, 2020				U-1170
	>A> 6642245	Nov 04, 2020				U-248
<u>EPINASTINE HYDROCHLORIDE - EPINASTINE HYDROCHLORIDE</u>						
A090870 001					PC	Oct 29, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001					NPP PED	Feb 27, 2011 Aug 27, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002					NPP PED	Feb 27, 2011 Aug 27, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N022101 001					M-86 PED	Jun 18, 2012 Dec 18, 2012
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	5714504	Feb 03, 2015	DP			U-1053
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS			U-1053
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP			U-1053
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			U-1053
	7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N022262 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	>A> 7037917	Dec 13, 2020	DS DP U-256			
	>A> 7037917	Dec 13, 2020	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	>A> 7037917	Dec 13, 2020	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		I-638 ODE	May 05, 2014 Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2019	DS DP		I-638 ODE	May 05, 2014 Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	5665772	Sep 09, 2019			I-638 NCE ODE	May 05, 2014 Mar 30, 2014 Oct 29, 2017
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
<u>EZETIMIBE - ZETIA</u>						
N021445 001	>A> 5846966	Sep 21, 2013	U-474			
	>A> 5846966	Sep 21, 2013	U-473			
	>A> 5846966	Sep 21, 2013	U-1172			
	>A> 7612058	Jan 25, 2022	U-1173			
	>A> 7612058	Jan 25, 2022	U-1027			
	>A> RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461	Oct 25, 2016	DS DP U-1173			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZOGABINE - POTIGA</u>						
N022345 001					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 002					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 003					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 004					NCE	Jun 10, 2016
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-98	Jan 31, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519	001				NC	Apr 23, 2014
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695	001	7863331	Aug 08, 2020	U-1107		
		7863331	Aug 08, 2020	U-1106		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695	003	7863331	Aug 08, 2020	U-1107		
		7863331	Aug 08, 2020	U-1106		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418	001	7915247	Aug 20, 2027	U-1061		
		7915247	Aug 20, 2027	U-1059		
		7915247	Aug 20, 2027	U-1000		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418	002	7915247	Aug 20, 2027	U-1061		
		7915247	Aug 20, 2027	U-1059		
		7915247	Aug 20, 2027	U-1000		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	001	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	002	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	003	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	004	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	005	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	006	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	001	7862832	Jun 15, 2028	DP		
		7862833	Jun 15, 2028	DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002					NDF	Jun 30, 2014
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	7871597	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			
	>A> 7985772	May 11, 2019	DS DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			
	>A> 7985772	May 11, 2019	DS DP U-913			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N020872 007	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N020872 010	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 008	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 009	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N020872 005	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N021909 002	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6187791	May 11, 2012	U-1158			
	6399632	May 11, 2012	U-1158			
	7138524	May 18, 2014	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N201373 001	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1157			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1157			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1157			
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N020872 006	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N021909 003	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6187791	May 11, 2012	U-1158			
	6399632	May 11, 2012	U-1158			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N201373 002	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1157			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1157			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1157			
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N020786 002	5578610	Nov 26, 2013	DS DP U-1159			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1159			
	6037353*PED	Sep 14, 2017	U-138			
	6039974	Jul 31, 2018	DP			
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1159			
	6187791*PED	Nov 11, 2012	U-138			
	6399632	May 11, 2012	U-1159			
	6399632*PED	Nov 11, 2012	U-468			
	7135571	May 18, 2014	DS U-1159			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N021704 002	5578610	Nov 26, 2013	DS DP U-1159			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1159			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1159			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1159			
	6399632*PED	Nov 11, 2012				
	6613357	Dec 25, 2020	DP U-1159			
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
	RE39069	May 29, 2018	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N201699 001	>A> 7378508	Jul 31, 2027	DS DP		NCE	May 27, 2016
	>A> 7863249	Jul 31, 2027	DS DP			
	>A> 7906489	Mar 04, 2027	U-319			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 001					>A> D-133	Aug 22, 2014
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 002					>A> D-133	Aug 22, 2014
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 003					>A> D-133	Aug 22, 2014
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 004					>A> D-133	Aug 22, 2014
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 001	>A> 5691336	Mar 04, 2019	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	>A> 5691336	Mar 04, 2019	DS DP			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			M-103	May 17, 2014
	7456160	Jan 09, 2021	U-596		PED	Nov 17, 2014
	7456160*PED	Jul 09, 2021			PED	Mar 09, 2014
<u>GABAPENTIN - GABAPENTIN</u>						
A078974 001					PC	Aug 22, 2011
<u>GABAPENTIN - GRALISE</u>						
N022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	6818787	Nov 06, 2022	DS DP		NCE	Apr 06, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 001	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 002	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 003	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 004	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 005	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 001					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 002					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A079183 001					PC	May 14, 2011
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 001					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 002					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 003					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 004					M-102	Apr 29, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 001					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 002					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 003					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 004					I-635	Feb 25, 2014
<u>HYDROCORTISONE BUTYRATE - LOCOID</u>						
N022076 001	>A> 7981877	Jan 23, 2025	DP			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041 001	5834448	Nov 14, 2016	DP		ODE	Dec 15, 2013
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N021945 001					ODE	Feb 03, 2018
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N022150 001					>A> NCE	Aug 25, 2016
<u>ILOPERIDONE - FANAPT</u>						
N022192 001	>A> RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 002	>A> RE39198	Nov 15, 2016	DS DP U-971			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N022192 003	>A> RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 004	>A> RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 005	>A> RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 006	>A> RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 007	>A> RE39198	Nov 15, 2016	DS DP U-971			
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001					I-636	Mar 24, 2014
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002					NS	Jul 15, 2014
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N022383 001	6878721	Oct 10, 2020	DS DP U-1168		NCE	Jul 01, 2016
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N020314 001	5384113	Jan 24, 2012	DP			
	5753627	May 19, 2015	U-1125			
	5776894	Jul 07, 2015	DS DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081 001	7918833	Sep 23, 2027	DP			
	7918833*PED	Mar 23, 2028				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629 003	7918833	Sep 23, 2027	DP			
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R</u>						
N018780 001					NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R PEN</u>						
N018780 005					NR	Mar 25, 2014
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001					NCE	Jan 14, 2016
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 001	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 002	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 003	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 004	7919115	Jan 04, 2029	DS DP			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	7968569	Oct 07, 2023	U-1165			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLMID</u>						
N021880 004	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 003	6036976	Dec 13, 2016	DP		D-132	Jun 17, 2014
	7429559	Dec 13, 2016	DP		NS	Jun 17, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 007	>A> 5575987	Sep 02, 2013	DP		>A> NP	Aug 15, 2014
	>A> 5631020	May 20, 2014	DP			
	>A> 5716640	Sep 02, 2013	DP			
	>A> 6036976	Dec 13, 2016	DP			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 008	>A> 5480656	Jan 02, 2013	DP		>A> NP	Aug 15, 2014
	>A> 5575987	Sep 02, 2013	DP			
	>A> 5631020	May 20, 2014	DP			
	>A> 5643607	Jul 01, 2013	DP			
	>A> 5716640	Sep 02, 2013	DP			
	>A> 6036976	Dec 13, 2016	DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001					I-637	Apr 29, 2014
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	6500829	Dec 31, 2019	DS DP		I-637 ODE	Apr 29, 2014 Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	6500829	Dec 31, 2019	DS DP		I-637 ODE	Apr 29, 2014 Mar 07, 2015
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	6303661	Apr 24, 2017	U-774		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-493			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-493			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N200738 001					NDF PED	Apr 15, 2014 Oct 15, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 001	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	>A> 7998506	Sep 20, 2013	U-1137			
	>A> 7998506	Sep 20, 2013	U-1135			
	>A> 7998506	Sep 20, 2013	U-1136			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 002	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	>A> 7998506	Sep 20, 2013	U-1137			
	>A> 7998506	Sep 20, 2013	U-1135			
	>A> 7998506	Sep 20, 2013	U-1136			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 003	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	>A> 7998506	Sep 20, 2013	U-1137			
	>A> 7998506	Sep 20, 2013	U-1135			
	>A> 7998506	Sep 20, 2013	U-1136			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 004	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	>A> 7998506	Sep 20, 2013	U-1137			
	>A> 7998506	Sep 20, 2013	U-1135			
	>A> 7998506	Sep 20, 2013	U-1136			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MALATHION - OVIDE</u>						
N018613 001	7977324	Aug 14, 2026	DP			
<u>MESALAMINE - LIALDA</u>						
N022000 001					I-640	Jul 14, 2014
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 001	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 002	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
<u>METRONIDAZOLE - VANDAZOLE</u>						
N021806 001	7456207	Sep 22, 2024	DP			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	7888342	Nov 05, 2021	U-882			
	>A> 7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	7888342	Nov 05, 2021	U-882			
	>A> 7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	7888342	Nov 05, 2021	U-882			
	>A> 7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	7888342	Nov 05, 2021	U-882			
	>A> 7994220	Sep 19, 2029	U-819			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	7919483	Feb 28, 2027	U-1078			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	7919483	Feb 28, 2027	U-1078			
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001					M-99	Jan 19, 2014
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428 001	7671070*PED	Mar 29, 2020				
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050746 001	6025389	Oct 20, 2014	DP U-1122			
<u>NALTREXONE - VIVITROL</u>						
N021897 001	7919499	Oct 15, 2029	U-1124			
	7919499	Oct 15, 2029	U-1123			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				
<u>NIACIN - NIASPAN</u>						
N020381 002	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	>A> 7998506	Sep 20, 2013	U-1141			
	>A> 7998506	Sep 20, 2013	U-1138			
	>A> 7998506	Sep 20, 2013	U-1139			
	>A> 7998506	Sep 20, 2013	U-1140			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 003	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	>A> 7998506	Sep 20, 2013	U-1141			
	>A> 7998506	Sep 20, 2013	U-1138			
	>A> 7998506	Sep 20, 2013	U-1139			
	>A> 7998506	Sep 20, 2013	U-1140			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 004	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	>A> 7998506	Sep 20, 2013	U-1141			
	>A> 7998506	Sep 20, 2013	U-1138			
	>A> 7998506	Sep 20, 2013	U-1139			
	>A> 7998506	Sep 20, 2013	U-1140			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 001	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	>A> 7998506	Sep 20, 2013	U-1151			
	>A> 7998506	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 002	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	>A> 7998506	Sep 20, 2013	U-1151			
	>A> 7998506	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 003	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	>A> 7998506	Sep 20, 2013	U-1151			
	>A> 7998506	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 004	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
	>A> 7998506	Sep 20, 2013	U-1151			
	>A> 7998506	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 005	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
	>A> 7998506	Sep 20, 2013	U-1151			
	>A> 7998506	Sep 20, 2013	U-1150			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002					>A> I-627	Jun 17, 2014
					>A> NCE	Oct 29, 2012
					>A> ODE	Oct 29, 2014
<u>NITROGLYCERIN - RECTIV</u>						
N021359 001					NP	Jun 21, 2014
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 001					NPP	Dec 04, 2012
					PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 002					NPP	Dec 04, 2012
					PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 003					NPP	Dec 04, 2012
					PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 004					NPP	Dec 04, 2012
					PED	Jun 04, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N021861 001	7977376	Feb 02, 2023	DP			
	7977376*PED	Aug 02, 2023	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001	5763483	Dec 27, 2016	DS	U-376		
	5763483	Dec 27, 2016	DS	U-1113		
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	>A> 7981439	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	>A> 7981439	Nov 26, 2023	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	7923536	Dec 09, 2023	U-1117			
	RE41884	Aug 14, 2016	U-1117			
<u>PALIPERIDONE - INVEGA</u>						
N021999 001					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 002					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 003					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 004					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 006					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 001	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	7960424	Jan 30, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 002	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	7960424	Jan 30, 2024	DP			
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>						
A091427 001					PC	Nov 01, 2011
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PERFLUTREN - DEFINITY</u>						
N021064 001	5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 001	6149938	Jul 23, 2018	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 002	6149938	Jul 23, 2018	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	6207661	Feb 22, 2019	DP			
	>A> 6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	6207661	Feb 22, 2019	DP			
	>A> 6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	6207661	Feb 22, 2019	DP			
	>A> 6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2013	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 001					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 002					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 003					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 005					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 006					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 007					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 006	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 007	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 03, 2023	DS DP			
<u>RANOLAZINE - RANEXA</u>						
N021526 001	6369062	May 27, 2019	DP	Y		
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
<u>RIBAVIRIN - COPEGUS</u>						
N021511 001					>A> NPP	Aug 09, 2014
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-1153			
	7638522	Apr 14, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N022406 001	7157456	Feb 08, 2021	DS DP		>A> NCE	Jul 01, 2016
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Feb 11, 2014		Y		
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Feb 11, 2014		Y		
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Feb 11, 2014	U-240	Y		
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Feb 11, 2014	U-240	Y		
<u>ROFLUMILAST - DALIRESP</u>						
N022522 001	5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Jul 06, 2012	DS DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 001	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 002	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 003	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 004	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 005	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 006	7927624	Dec 02, 2021	DP U-20			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 002	7030152	Apr 02, 2018	U-1032			
	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 003	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 004	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
ROSUVASTATIN CALCIUM - CRESTOR								
N021366 005	7030152*PED	Oct	02, 2018	U-1032				
	7964614	Apr	02, 2018					
	7964614*PED	Oct	02, 2018					
ROTIGOTINE - NEUPRO								
N021829 001	6699498	Nov	27, 2020	DP				
ROTIGOTINE - NEUPRO								
N021829 002	6699498	Nov	27, 2020	DP				
ROTIGOTINE - NEUPRO								
N021829 003	6699498	Nov	27, 2020	DP				
RUFINAMIDE - BANZEL								
N021911 001	6740669	Nov	14, 2022	DS DP				
RUFINAMIDE - BANZEL								
N021911 002	6740669	Nov	14, 2022	DS DP				
RUFINAMIDE - BANZEL								
N021911 003	6740669	Nov	14, 2022	DS DP				
RUFINAMIDE - BANZEL								
N201367 001	6740669	Aug	17, 2020	DS DP		NCE ODE	Nov 14, 2013 Nov 14, 2015	
SAPROPTERIN DIHYDROCHLORIDE - KUVAN								
N022181 001	7947681	Nov	17, 2024	U-1156				
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA								
N022350 001	7951400	Nov	30, 2028	DP				
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA								
N022350 002	7951400	Nov	30, 2028	DP				
SEVELAMER CARBONATE - RENVELA								
N022127 001	>A> 7985418	Oct	27, 2025	DP				
SINECATECHINS - VEREGEN								
N021902 001	7858662	Oct	02, 2026	DP U-172				
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE								
N201444 001						ODE	Jan 14, 2018	
SODIUM OXYBATE - XYREM								
N021196 001	7668730	Jun	16, 2024	U-1110				
	7895059	Dec	17, 2022	U-1110				
SORAFENIB TOSYLATE - NEXAVAR								
N021923 001	7897623	Jan	12, 2020	DP				
SPINOSAD - NATROBA								
N022408 001	5496931	Mar	05, 2013	DS U-1105		NCE	Jan 18, 2016	
	6063771	Jun	22, 2019	DP U-1105				
	6342482	Jun	22, 2019	DP U-1105				
	7030095	Jul	02, 2021	DP U-1105				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Nov 28, 2026	DP			
	7901385	Jul 31, 2026	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 003	7125905	Feb 15, 2021	DS DP		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 001	>A> 7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 002	>A> 7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 003	>A> 7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	>A> 7994364	Jun 27, 2025	DS DP U-1178		>A> NDF >A> NCE	Aug 25, 2014 Nov 20, 2013
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	>A> 7994364	Jun 27, 2025	DS DP U-1178		>A> NDF >A> NCE	Aug 25, 2014 Nov 20, 2013
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	>A> 7994364	Jun 27, 2025	DS DP U-1178		>A> NDF >A> NCE	Aug 25, 2014 Nov 20, 2013
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	>A> 7994364	Jun 27, 2025	DS DP U-1178		>A> NDF >A> NCE	Aug 25, 2014 Nov 20, 2013
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	>A> 7994364	Jun 27, 2025	DS DP U-1178		>A> NDF >A> NCE	Aug 25, 2014 Nov 20, 2013
<u>TECHNETIUM TC-99M MERTIATIDE KIT - TECHNESCAN MAG3</u>						
N019882 001	5573748	Nov 12, 2013	DP			
<u>TELAPREVIR - INCIVEK</u>						
N201917 001					NCE	May 23, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TELMISARTAN - MICARDIS</u>						
N020850 002	>A> 7998953	Jun 06, 2020	U-1177			
	>A> 8003679	Oct 06, 2022	U-1176			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	>A> 5922695	Jul 25, 2017	DS U-250		>A> I-569	Aug 11, 2011
	>A> 5922695	Jul 25, 2017	DS U-256		>A> M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-999		>A> NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-248		>A> ODE	Mar 24, 2017
	>A> 5922695*PED	Jan 25, 2018			>A> PED	Sep 24, 2017
	>A> 5935946	Jul 25, 2017	DS DP U-999		>A> PED	Apr 01, 2014
	>A> 5935946	Jul 25, 2017	DS DP U-248		>A> PED	Sep 24, 2013
	>A> 5935946	Jul 25, 2017	DS DP U-250		>A> PED	Feb 11, 2012
	>A> 5935946	Jul 25, 2017	DS DP U-256			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	>A> 6043230*PED	Jan 25, 2018				
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 001	6503894	Aug 30, 2020	U-1103		NP	Apr 29, 2014
<u>TESTOSTERONE - FORTESTA</u>						
N021463 001	6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	7935690	Apr 21, 2023	U-1009			
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>TICAGRELOR - BRILINTA</u>						
N022433 001	>A> 6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	>A> 6525060	Dec 02, 2019	DS DP U-1171			
	>A> 7250419	Dec 02, 2019	DS DP U-1171			
	>A> 7265124	Jul 09, 2021	DS DP U-1171			
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	7879828	Feb 05, 2029	DP			
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	6908928	Sep 24, 2021	DS DP U-762			
	6908928	Sep 24, 2021	DS DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 001	>A> 7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 002	>A> 7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 003	>A> 7988998	Oct 27, 2023	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	7947739	Mar 04, 2025	DP			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 001	>A> 7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 002	>A> 7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 003	>A> 7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 004	>A> 7999007	Mar 29, 2029	DP U-1174			
<u>TRIAMCINOLONE ACETONIDE - NASACORT AQ</u>						
N020468 001	>A> 7977045	Jul 03, 2016	DP U-896			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANDETANIB - VANDETANIB</u>						
N022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
<u>VANDETANIB - VANDETANIB</u>						
N022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 001					M-105	Jul 22, 2014
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 002					M-105	Jul 22, 2014
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	>A> 7504509	Oct 22, 2026	DS DP		>A> NCE	Aug 17, 2016
	>A> 7863288	Jun 20, 2029	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817 001	7932241	Feb 05, 2028	DP			
	7932241*PED	Aug 05, 2028				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 003	>A> 4939130	Sep 02, 2012	DS DP U-53			
	>A> 4939130*PED	Mar 02, 2013				
	7932241	Feb 05, 2028	DP			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor.
They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>